• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The invention relates to substituted 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridines of formula (I), their use as medicament, and pharmaceutical preparations comprising them. The compounds of formula (I) act on the TASK-1 potassium channel. The compounds are particularly suitable for the treatment or prevention of atrial arrhythmias, for example atrial fibrillation (AF) or atrial flutter.
    公开号:AU2011376721A1
    申请号:U2011376721
    申请日:2011-09-16
    公开日:2014-04-03
    发明作者:Laurent Bialy；Joachim Brendel；Gerhard Hessler；Katrin Lorenz；Josef Pernerstorfer；Klaus Steinmeyer；Klaus Wirth
    申请人:Sanofi SA；
    IPC主号:C07D471-04
    专利说明:
    WO 2013/037415 PCT/EP2011/066061 1 Description Substituted 4,5,6,7-tetrahydro-1 H-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them 5 The invention relates to 4,5,6,7-tetrahydro-1 H-pyrazolo[4,3-c]pyridine compounds of the formula I, R2 X R3 N R1 1 ~
    -
    R4 A 10 The compounds of formula I act on the TASK-1 (KCNK3) potassium channel. The compounds are suitable for the treatment of several pathologies and particularly suitable as antiarrhythmic active ingredients, in particular for the treatment and prophylaxis of atrial arrhythmias, for example atrial fibrillation (AF) or atrial flutter. 15 Potassium channels are widespread membrane proteins which, owing to their influences on cell membrane potentials, play an important role in many physiological processes. Within the various classes of the potassium channels, a distinction is drawn on the basis of their molecular structure between three large groups which 20 are characterized by the number of transmembrane domains (2, 4 or 6). The group of the potassium channels with four transmembrane segments is delimited from the two others in that their representatives each have two pore domains, which is why these channels are also referred to as K 2 P channels (Coetzee W.J. et al; Molecular diversity of K+ channels; Ann. New York Acad. Sci. 1999 (868), 233-285). In 25 functional terms, K 2 P channels are characterized in that the "leak" or "background" currents flow through them, which play an important role for the resting membrane potential and hence the excitability of nerve or muscle cells.
    WO 2013/037415 PCT/EP2011/066061 2 A family which is of particular interest among the K 2 P channels is that of the TASK channels (tandem of P domains in a weak inwardly rectifying K* channel, [TWIK] related acid-sensitive K* channels), which include TASK-1, TASK-3, and TASK-5 5 subtype (D.A. Bayliss, P. Barrett, Trends in Pharmacological Sciences, 2008, 29(11), 566-575). Other terms used in the literature for the underlying genes are KCNK3 or K2P3.1 (TASK-1), KCNK9 or K2P9.1 (TASK-3) and KCNK15 or K2P15.1 (TASK-5). The greatest homology within this family is possessed by the TASK-1 and TASK-3 channels with an amino acid identity of more than 50%. Dimerization of K 2 P 10 channels forms functional potassium channels with a total of four pore units. The streams which flow through these channels are referred to in the literature as IKso stream. In addition to a homodimerization of, for example, two TASK-1 or two TASK-3 proteins, heterodimerization of TASK-1 and TASK-3 is also possible in this context (Berg A.P., Talley E.M., Manger J.P., Bayliss D.A.; Motoneurons express 15 Heteromeric TWIK-related acid-sensitive K+ (TASK) Channels containing TASK-1 (KCNK3) and TASK-3 (KCNK9) subunits; J. Neuroscience 2004 (24), 6693 - 6702). The TASK channels are notable in particular for their very strong dependence upon the extracellular pH in the physiological range (pK ca. 6,5-7,5). The channels are 20 inhibited at acidic pH and activated at alkaline pH. Owing to this pH dependence, the physiological function of a sensor which translates small changes in the extracellular pH to corresponding cellular signals is ascribed to the TASK channels (Duprat F., Lesage F., Fink M., Reyes R., Heurteaux C., Lazdunski M.; TASK, a human background K+ channel to sense external pH variations near physiological 25 pH; EMBO J. 1997 (16), 5464 - 5471; Patel A.J., Honore E.; Properties and modulation of mammalian 2P domain K+ channels; Trends Neurosci. 2001 (24), 339 - 346). TASK-1 knock-out mice show a mild phenotype and have been described and 30 appear generally in good health and show normal breeding behaviour (Journal of Neuroscience (2005), 25(49), 11455-11467).
    WO 2013/037415 PCT/EP2011/066061 3 TASK-1 is expressed in the brain and also in spinal ganglia and some peripheral tissues, for example pancreas, placenta, uterus, lung, heart, kidney, small intestine and stomach. In addition, TASK-1 has been detected in the chemosensitive cells of the brainstem and of the carotid bodies, and also the motor neurons of the 5 hypoglossal nerve (Medhurst A.D., Rennie G., Chapman C.G., Meadows H., Duckworth M.D., Kelsell R.E., Glober 1.1., Pangalos M.N.; Distribution analysis of human two pore domain potassium channels in tissues of the central nervous system and periphery; Mol. Brain Res. 2001 (86), 101 - 114). 10 Electrical currents which are caused by TASK-1 potassium channels have been detected in motor neurons of the hypoglossal nerve, a motor cranial nerve which possesses the most important function for the maintenance and patency of the upper respiratory pathways, and locus coeruleus. It has been found that TASK-1 channels are involved in respiratory regulation in respiratory neurons of the 15 brainstem, in carotid bodies and in motor neurons of the hypoglossal nerve, and also in neuroepithelial cells of the lung. In the event of inadequate respiration (hypoxia, hindered breathing) and in the event of physical stress, either via a rise in the C02 concentration and the resulting acidosis or via acidic metabolites, there is a lowering of the pH and hence a blockage of the pH-dependent TASK-1 channels. 20 This depolarizes the cells, which leads to the activation of the neurons involved in the respiratory regulation (Buckler K.J., Williams B.A., Honore E.; An oxygen-, acid and anaesthetic-sensitive TASK-like background potassium channel in rat arterial chemoreceptor cells; J. Physiol. 2000 (525), 135 - 142; Bayliss D.A., Talley E.M., Sirois J.E., Lei Q.; TASK-1 is a highly modulated pH-sensitive 'leak' K+ channel 25 expressed in brainstem respiratory neurons; Respiration Physiology 2001 (129), 159 - 174). An increase in the activity of chemosensitive neurons in conjunction with an activation of the motor neurons of the hypoglossal nerve through blockage of the 30 TASK-1 channel can stimulate respiration and simultaneously stabilize the upper airways to protect them from collapse and occlusion. Moreover, snoring can be inhibited by stabilizing the upper airway via an increase in pharyngeal muscle WO 2013/037415 PCT/EP2011/066061 4 activity. The blockage of the TASK-1 ion channels is therefore useful in the treatment of respiratory disorders, for example of sleep apnea (Brendel, J.; Goegelein, H.; Wirth, K.; Kamm, W., WO 2007/124849). 5 In cultivated granulosa cells of the cerebellum, it has been shown that genetic inactivation of TASK channels brings about neuroprotective action (Lauritzen I., Zanzouri M., Honor6 E., Duprat F., Ehrengruber M.U., Lazdunski M., Patel A.J.; K* dependent cerebellar granule neuron apoptosis - Role of Task leak K* channels; J. Biol. Chem. 2003 (278), 32068-32076). It has also been shown that TASK-1 10 channels are responsible for programmed cell death (apoptosis) in granulosa cells, and that the cell death can be prevented by blocking the TASK-3. Thus, the development of specific inhibitors of the TASK-1/3 channels can be useful for the treatment of neurodegenerative disorders (Patel A.J., Lazdunski M., The 2P-domain K* channels: role in apoptosis and tumorigenesis, Pflugers Arch. 2004 (448), 261 15 273). It has been stated that TASK-1 is relevant for setting the resting membrane potential and balancing neuronal excitability that is expressed on T cells and neurons, and is a key modulator of T cell immunity and neurodegeneration in autoimmune central 20 nervous system inflammation. After induction of experimental autoimmune encephalomyelitis, an experimental model mimicking multiple sclerosis, TASK1(-/-) mice showed a significantly reduced clinical severity and markedly reduced axonal degeneration compared with wild-type controls. T cells from TASK1 (-/-) mice displayed impaired T cell proliferation and cytokine production, while the immune 25 repertoire is otherwise normal. In addition to these effects on systemic T cell responses, TASK1 exhibits an independent neuroprotective effect which was demonstrated using both a model of acutely prepared brain slices cocultured with activated T cells as well as in vitro cultivation experiments with isolated optic nerves. Preventive blockade of TASK1 significantly ameliorated experimental autoimmune 30 encephalomyelitis after immunization and significantly reduced disease severity and was capable of lowering progressive loss of brain parenchymal volume as assessed by magnetic resonance imaging. Thus TASK-1 blockers are potent compounds WO 2013/037415 PCT/EP2011/066061 5 useful for the therapy of inflammatory and degenerative central nervous system disorders (Bittner Stefan; Meuth Sven G; Gobel Kerstin; Melzer Nico; Herrmann Alexander M; Simon Ole J; Weishaupt Andreas; Budde Thomas; Bayliss Douglas A; Bendszus Martin; Wiendl Heinz , Brain : a journal of neurology (2009), 132(Pt 9), 5 2501-16). TASK-1, a member of two-pore-domain (K2P) potassium channel family, has emerged as a target for the pharmacological treatment of atrial fibrillation recently. Two-pore-domain (K2P) potassium channels mediate background potassium 10 currents, stabilizing resting membrane potential and expediting action potential repolarization. In the heart, TASK-1 channels have been shown to play a role in cardiac repolarization, (Basic Res Cardiol. 2011 Jan;106(1):75-87, Putzke C, Wemhbner K, Sachse FB, Rinn6 S, Schlichthbrl G, Li XT, Ja6 L, Eckhardt I, Wischmeyer E, Wulf H, Preisig-MCiller R, Daut J, Decher N (2007), Cardiovascular 15 Research, 75: 59-68). Atrial fibrillation (AF) and atrial flutter are extremely common cardiac rhythm disorder that causes substantial morbidity and contributes to mortality (Journal of Clinical Invest. 2011;121(8):2955-2968). Presently available therapeutic approaches 20 have major limitations, including limited efficacy and potentially serious side effects such as malignant ventricular arrhythmia induction or negative inotropic effects. The occurrence of AF increases with age and frequently leads to fatal sequelae such as stroke. The class I and III antiarrhythmics in use at present reduce the rate of recurrence of AF but are used to only a limited extent because of their potential 25 proarrhythmic side effects and limited efficacy. The growing incidence of AF emphasizes the importance of identifying appropriate treatments, particularly drugs, that are safe, effective, and associated with improved clinical outcomes. It has been shown that in atrial fibrillation and flutter re-entrant mechanism play an important role in the induction and maintenance of the arrhythmia. Such reentries or 30 re-entrant waves occur when the cardiac tissue has a low conduction velocity and, at the same time, short refractory periods. Increasing the myocardial refractory period by prolonging the action potential is an acknowledged mechanism for WO 2013/037415 PCT/EP2011/066061 6 terminating arrhythmias or for preventing them to develop (T. J. Colatsky et al., Drug Dev. Res. 19, 1990, 129 - 140; "Potassium channels as targets for antiarrhythmic drug action"). The length of the action potential is essentially determined by the extent of repolarizing K+ currents which flow out of the cells through various K+ 5 channels. TASK-1 constitutes one of those repolarizing potassium currents. Its inhibition prolong the action potential and thereby refractoriness. Most of the known class III antiarrhythmics (e.g. dofetilide, E4031 and d-sotalol) block predominantly or exclusively the rapidly activating potassium channel IKr, 10 which can be detected both in cells of the human ventricle and in the atrium. It has emerged that these compounds have an increased proarrhythmic risk at heart rates which are low or normal, and arrhythmias referred to as torsades de pointes have been observed in particular (D. M. Roden, Am. J. Cardiol. 72, 1993, 44B - 49B; "Current status of class III antiarrhythmic drug therapy"). Apart from this 15 proarrhythmic risk, the therapeutic efficacy of the IKr blockers has been found to decline under the conditions of tachycardia (electrical tachycardic atrial remodelling). TASK-1 expression in the human heart has been shown to be restricted to the atria 20 with no or very little expression in the ventricles. A further advantage is that TASK-1 expression is not decreased but even slightly increased in atrial fibrillation patients compared with sinus rhythm patients, by contrast a decreased expression of other atrial K* channels has been reported in atrial fibrillation patients compared with sinus rhythm patients: see for example Basic. Res. Cardiol. 2003, 98, 137-148, 25 JACC Vol. 37, No. 3, 2001). Thus, TASK-1 is still expressed in the target patient population (Journal of Molecular Medicine 2004, 308-316; European Journal of Physiology 2005, 450, 201-208, WO 2005/016965; Journal of Thoracic and Cardiovascular Surgery 2005). 30 In spite of the great physiological significance of the TASK channels, only very few pharmacological modulators of these channels are known to date in the literature.
    WO 2013/037415 PCT/EP2011/066061 7 It has been stated that an activation of the TASK-1 channel can be achieved by therapeutic concentrations of the inhalative anesthetics halothane and isoflurane (Patel A.J., Honor6 E., Lesage F., Fink M., Romey G., Lazdunski M.; Inhalational anesthetics activate two-pore-domain background K+ channels; Nature Neurosci. 5 1999 (2), 422-426). Furthermore, some Kv1.5 blockers which also inhibit the TASK 1 channel are described in the state of the art (Brendel, J.; Goegelein, H.; Wirth, K.; Kamm, W., WO 2007/124849, Brendel, J.; Englert, H. C.; Wirth, K.; Wagner, M.; Ruxer, J.-M.; Pilorge, F., WO 2006/136304). A1899, a previously described Kv1.5 blocker (Peukert, S., Brendel, J., Pirard, B., Brueggemann, A., Below, P., Kleemann, 10 H.-W., Hemmerle, H., Schmidt, W.; Identification, Synthesis, and Activity of Novel Blockers of the Voltage-Gated Potassium Channel Kv1.5.; Journal of Medicinal Chemistry (2003), 46(4), 486-498) has been stated to be a TASK-1 blocker (Streit, A. K.; Netter, M. F., Kempf, F., Walecki, M., Rinne, S., Bollepalli, M. K.; Preisig Mueller, R.; Renigunta, V.; Daut, J.; Baukrowitz, T.; Sansom, M. S. P.; Stansfeld, P. 15 J.; Decher, N.. A Specific Two-pore Domain Potassium Channel Blocker Defines the Structure of the TASK-1 Open Pore; Journal of Biological Chemistry (2011), 286(16), 13977-13984). Also arachidonamide anandamide (an endogenous ligand of the cannabinoid receptor) and its methanandamide homolog have been described as TASK-1 blockers (Maingret F., Patel A.J., Lazdunski M., Honor6 E.; 20 The endocannabinoid anandamide is a direct and selective blocker of the background K+ channel TASK-1; EMBO J. 2001 (20), 47-54). Doxapram, which is used for the treatment of respiratory disorders has been stated to be a TASK-1 blocker (Cotten J.F., Keshavaprasad B., Laster M.J., Eger E.I., Yost C.S.; The Ventilatory Stimulant Doxapram Inhibits TASK Tandem Pore (K 2 p) Potassium 25 Channel Function but Does Not Affect Minimum Alveolar Anesthetic Concentration; Anesth. Analg. 2006 (102) 779-785). EP 0 086 422 A2 describes some N-acetylated tetrahydro-1 H-pyrazolo[4,3 c]pyridine compounds. However no biological activity has been described for these 30 compounds therein. Thus, a goal of the present invention is to provide efficient TASK-1 inhibitors WO 2013/037415 PCT/EP2011/066061 8 suitable for the treatment and prevention of TASK-1 related conditions. The present invention relates to TASK-1 blockers of the formula I R2 X R3 N N N R1 1 R4 A 5 wherein A = (C 6
    -C
    1 o)-aryl or a five- or six-membered heteroaryl, comprising 1-3 heteroatoms selected from the group N, 0 and S, wherein aryl and heteroaryl are optionally substituted with 1-3 rests selected independently from F, Cl, Br, CN, (C1-C 6 )-alkyl-, (C1-C 6 )-alkyl-0 10 and (C1-C 6 )-alkyl-S-, wherein one or more hydrogen atoms of the alkyl moieties may be replaced by fluorine; X = (C 6 -C1o)-aryl or a five- or six-membered heteroaryl, comprising 1-3 heteroatoms selected from the group N, 0 and S, 15 wherein aryl and heteroaryl are optionally substituted with 1-3 rests selected independently from F, Cl, Br, CN, (C1-C 6 )-alkyl-, (C1-C 6 )-alkyl-O-, (C1-C 6 )-alkyl-S-, (C1-C 6 )-alkyl-O-C(O)- and (C 1
    -C
    6 )-alkyl-SO 2 -, wherein one or more hydrogen atoms of the alkyl moieties may be replaced by fluorine; 20 R1 = R5-C(=0)- or (C 1
    -C
    6 )-alkyl-SO 2 -; R2 = H, (C 1
    -C
    6 )-alkyl-, (C 3
    -C
    6 )-cycloalkyl-; R3 = H, (C 1
    -C
    4 )-alkyl-; R4 = H, (C 1
    -C
    4 )-alkyl-; or wherein R3 and R4 together form a (C 2
    -C
    3 )-alkylene bridge; 25 R5 = H, (C 1
    -C
    6 )-alkyl-, (C 3
    -C
    6 )-cycloalkyl-, (C 1
    -C
    6 )-alkyl-O-, (C 1
    -C
    6 )-alkyl-S-, (C1
    C
    6 )-alkyl-O-(C 1
    -C
    6 )-alkyl-, HO-(C 1
    -C
    6 )-alkyl-, (C 3
    -C
    6 )-cycloalkyl-(C 1
    -C
    6 )-alkyl-, WO 2013/037415 PCT/EP2011/066061 9
    (C
    6
    -C
    1 o)-aryl-, (C 6
    -C
    1 o)-aryl-(C 1
    -C
    6 )-alkyl-, R7R6N-, heteroaryl, heteroaryl (C1-C 6 )-alkyl-, aliphatic heterocycle, wherein one or more hydrogen atoms of the alkyl moieties may be replaced by fluorine, and 5 wherein the aliphatic heterocycle is selected from the group of morpholinyl, piperidinyl, pyrrolidinyl and 4 to 7 membered aliphatic heterocycles comprising an oxygen atom, and wherein the aliphatic heterocycle may be optionally substituted with 1 to 3 substituents independently selected from the group of F, OH, (C1-C6) 10 alkyl-O- and (C1-C 6 )-alkyl-, and wherein the heteroaryl residues are five- or six-membered ring systems, comprising 1-3 heteroatoms selected from the group N, 0 and S, and wherein aryl and heteroaryl are optionally substituted with 1-3 rests 15 selected independently from F, Cl, Br, CF 3 , (C 1
    -C
    6 )-alkyl-, (C 1
    -C
    6 )-alkyl-O-, CN, (C 1
    -C
    2 )-alkyl-SO 2 -; R6 = H, (C 1
    -C
    6 )-alkyl-, (C 3
    -C
    6 )-cycloalkyl-, wherein one hydrogen atom of the alkyl group may be replaced by an OH or (C 1
    -C
    6 )-alkyl-0- residue, and 20 wherein one or more hydrogen atoms of the alkyl group may be replaced by fluorine; R7 = H, (C 1
    -C
    6 )-alkyl-; wherein one or more hydrogen atoms of the alkyl group may be replaced by fluorine, 25 and/or of a stereoisomeric form of the compound of the formula I and/or mixtures of these forms, and/or their pharmaceutically acceptable salts, and with the proviso if R5 is methyl and R2, R3 and R4 are equal to H and A is equal to 4-fluoro-phenyl, the residue X is not phenyl, 4-fluoro-phenyl, 4-chloro-phenyl, 4 methyl-phenyl, 4-methoxy-phenyl, 4-acetoxyphenyl, 2-chloro-phenyl, 3,4 30 dichlorophenyl, and with the proviso if R5 is methyl and R2, R3 and R4 are equal to H and X is a phenyl residue, the residue A is not phenyl, 4-fluoro-phenyl, 4-chloro-phenyl, 4-methyl- WO 2013/037415 PCT/EP2011/066061 10 phenyl, 4-ethyloxy-phenyl, 3-trifluoromethyl-phenyl, 2-thiophenyl or 4 methylthiophenyl, and with the proviso if R5 is methyl and R2 is methyl and R3 and R4 are equal to H and A is equal to 4-fluoro-phenyl, the residue X is not phenyl. 5 A preferred embodiment of the present invention relates to compounds, wherein A = phenyl or a five- or six-membered heteroaryl selected from the group consisting of pyridine-2-yl, pyridine-3-yl, pyridine-4-yl, thiophen-2-yl or 10 thiophen-3-yl, wherein phenyl and heteroaryl are optionally substituted with 1-3 rests selected independently from F, Cl, Br, CN, (C1-C 6 )-alkyl-, (C1-C 6 )-alkyl-0 and (C1-C 6 )-alkyl-S-, wherein one or more hydrogen atoms of the alkyl moieties may be 15 replaced by fluorine; X = a five- or six-membered heteroaryl, comprising 1-3 heteroatoms selected from the group N, 0 and S, wherein the heteroaryl group is optionally substituted with 1-3 residues selected independently from F, Cl, Br, CN, (C1-C 6 )-alkyl-, (C1-C 6 )-alkyl-0 20 and (C1-C 6 )-alkyl-S-, (C1-C 6 )-alkyl-O-C(O)- and (C 1
    -C
    6 )-alkyl-SO 2 -, wherein one or more hydrogen atoms of the alkyl moieties may be replaced by fluorine; R1 = R5-C(=0)- or (C 1
    -C
    6 )-alkyl-SO 2 -; R2 = H, (C 1
    -C
    4 )-alkyl-, (C 3
    -C
    6 )-cycloalkyl-; 25 R3 = H, (C 1
    -C
    2 )-alkyl-; R4 = H, (C 1
    -C
    2 )-alkyl-; or wherein R3 and R4 together form a (C 2
    -C
    3 )-alkylene bridge; R5 = H, (C 1
    -C
    6 )-alkyl-, (C 3
    -C
    6 )-cycloalkyl-, (C 1
    -C
    6 )-alkyl-O-, (C 1
    -C
    6 )-alkyl-S-, (C1
    C
    6 )-alkyl-O-(C 1
    -C
    6 )-alkyl-, HO-(C 1
    -C
    6 )-alkyl-, (C 3
    -C
    6 )-cycloalkyl-(C 1
    -C
    6 )-alkyl-, 30 (C 6
    -C
    1 o)-aryl-, (C 6
    -C
    1 o)-aryl-(C 1
    -C
    6 )-alkyl-, R7R6N-, heteroaryl, heteroaryl
    (C
    1
    -C
    6 )-alkyl-, aliphatic heterocycle, WO 2013/037415 PCT/EP2011/066061 11 wherein one or more hydrogen atoms of the alkyl moieties may be replaced by fluorine, and wherein the aliphatic heterocycle is selected from the group of morpholinyl, piperidinyl, pyrrolidinyl and 4 to 7 membered aliphatic 5 heterocycles comprising an oxygen atom, and wherein the aliphatic heterocycle may be optionally substituted with 1 to 3 substituents independently selected from the group of F, OH, (C1-C6) alkyl-O- and (C1-C 6 )-alkyl-, and wherein the heteroaryl residues are five- or six-membered ring 10 systems, comprising 1-3 heteroatoms selected from the group N, 0 and S, and wherein aryl and heteroaryl are optionally substituted with 1-3 rests selected independently from F, Cl, Br, CF 3 , (C 1
    -C
    6 )-alkyl-, (C 1
    -C
    6 )-alkyl-O-, CN, (C 1
    -C
    2 )-alkyl-SO 2 -; 15 R6 = H, (C 1
    -C
    6 )-alkyl-, (C 3
    -C
    6 )-cycloalkyl-, wherein one hydrogen atom of the alkyl group may be replaced by an OH- or (C 1
    -C
    6 )-alkyl-0- residue, and wherein one or more hydrogen atoms of the alkyl group may be replaced by fluorine; 20 R7 = H, (C 1
    -C
    6 )-alkyl-; wherein one or more hydrogen atoms of the alkyl group may be replaced by fluorine, and/or of a stereoisomeric form of the compound of the formula I and/or mixtures of these forms, and/or their pharmaceutically acceptable salts. 25 Preferred compounds are, wherein A= phenyl, wherein the phenyl residue is optionally substituted with 1-3 rests selected independently from F, CI, Br, CN, (C 1
    -C
    4 )-alkyl-, (C 1
    -C
    4 )-alkyl-O- and (C1 30
    C
    4 )-alkyl-S-, wherein one or more hydrogen atoms of the alkyl moieties may be replaced by fluorine; WO 2013/037415 PCT/EP2011/066061 12 X = a five- or six-membered heteroaryl, selected from the group consisting of pyridine-2-yl, pyridine-3-yl, pyridine-4-yl, thiophen-2-yl, thiophen-3-yl, thiazol 2-yl, thiazol-4-yl, thiazol-5-yl, wherein the heteroaryl group is optionally substituted with 1-3 residues 5 selected independently from F, Cl, Br, CN, (C1-C 6 )-alkyl-, (C1-C 6 )-alkyl-0 and (C1-C 6 )-alkyl-S-, (C1-C 6 )-alkyl-O-C(O)- and (C 1
    -C
    6 )-alkyl-SO 2 -, wherein one or more hydrogen atoms of the alkyl moieties may be replaced by fluorine; R1 = R5-C(=O)- or (C 1
    -C
    2 )-alkyl-SO 2 -, 10 R2 = H, (C1-C 2 )-alkyl-, cyclopropyl-; R3 = H, methyl-; R4 = H, methyl-; or wherein R3 and R4 together form an ethylene bridge; and wherein 15 R5 = H, (C1-C 4 )-alkyl-, (C 3
    -C
    6 )-cycloalkyl-, (C1-C 2 )-alkyl-O-, (C1-C 2 )-alkyl-S-, (C1
    C
    4 )-alkyl-0-methyl-, HO-(C1-C 2 )-alkyl-, (C 3
    -C
    6 )-cycloalkyl-(C 1
    -C
    2 )-alkyl-, phenyl, phenyl-(C1-C 2 )-alkyl-, R7R6N-, heteroaryl, heteroaryl-(C 1
    -C
    4 )-alkyl-, aliphatic heterocycle, wherein one or more hydrogen atoms of the alkyl moieties may be 20 replaced by fluorine, and wherein the aliphatic heterocycle is selected from the group of morpholinyl, piperidinyl, pyrrolidinyl, oxetanyl, tetrahydrofuranyl, and tetrahydropyranyl, and wherein the aliphatic heterocycle may be optionally substituted with 1 25 or 2 substituents independently selected from the group of F, OH, (C1-C2) alkyl-O- and (C1-C 4 )-alkyl-, and wherein the phenyl residue is optionally substituted with 1-3 rests selected independently from F, Cl, Br, CF 3 , (C 1
    -C
    4 )-alkyl-, (C 1
    -C
    4 )-alkyl-O-, CN, (C 1
    -C
    2 )-alkyl-SO 2 30 wherein the heteroaryl residues are selected from the group consisting of pyridine-2-yl, pyridine-3-yl, pyridine-4-yl, thiophen-2-yl, thiophen-3-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol- WO 2013/037415 PCT/EP2011/066061 13 5-yl, pyrazol-3-yl, pyrazol-4-yl, imidazol-2-yl, imidazol-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyridazin-3-yl, pyridazin-4-yl, pyrazin-2-yl and pyrazin-3-yl, and wherein the heteroaryl residues are optionally substituted with 1 or 2 5 rests selected independently from F, Cl, Br, CF 3 , (C 1
    -C
    4 )-alkyl-, (C 1
    -C
    4 )-alkyl 0-, CN, (C 1
    -C
    2 )-alkyl-SO 2 -, R6 = H, (C 1
    -C
    4 )-alkyl-, cyclopropyl, wherein one hydrogen atom of the alkyl group may be replaced by an OH, methoxy or ethoxy residue; and 10 R7 = H, methyl-, ethyl; and/or of a stereoisomeric form of the compound of the formula I and/or mixtures of these forms, and/or their pharmaceutically acceptable salts. Particularly preferred compounds are, wherein 15 A = phenyl, wherein the phenyl residue is optionally substituted with 1 or 2 rests selected independently from F, CI, Br, CN, (C 1
    -C
    4 )-alkyl-, CF 3 , CF 2 H,
    CFH
    2 , methoxy, ethoxy, OCF 3 , and (C 1
    -C
    2 )-alkyl-S-; X = a five- or six-membered heteroaryl, selected from the group consisting of 20 pyridine-2-yl, pyridine-3-yl, pyridine-4-yl, thiophen-2-yl, thiophen-3-yl, thiazol 2-yl, thiazol-4-yl, thiazol-5-yl, wherein these residues are optionally substituted with 1 or 2 residues selected independently from F, CI, Br, CN, (C 1
    -C
    4 )-alkyl-, CF 3 , CF 2 H,
    CFH
    2 , methoxy, ethoxy, OCF 3 , (C 1
    -C
    2 )-alkyl-S-, (C 1
    -C
    2 )-alkyl-O-C(O)- and 25 methyl-SO 2 -; R1 = R5-C(=O)- or (C 1
    -C
    2 )-alkyl-SO 2 -; R2 = H, methyl, ethyl, cyclopropyl; R3 and R4 = H, and R5 = methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert.-butyl, cyclopropyl or 30 cyclobutyl; WO 2013/037415 PCT/EP2011/066061 14 and/or of a stereoisomeric form of the compound of the formula I and/or mixtures of these forms, and/or their pharmaceutically acceptable salts. A further preferred embodiment of the present invention relates to compounds, 5 wherein A = a five- or six-membered heteroaryl, comprising 1-3 heteroatoms selected from the group N, 0 and S, wherein the heteroaryl is substituted with 1-3 residues selected 10 independently from F, Cl, Br, CN, (C1-C 6 )-alkyl-, (C1-C 6 )-alkyl-0- and (C1 Cs)-alkyl-S-, wherein one or more hydrogen atoms of the alkyl moieties may be replaced by fluorine; X = phenyl, thiophen-2-yl or thiophen-3-yl, 15 wherein these residues are optionally substituted with 1-3 rests selected independently from F, Cl, Br, CN, (C1-C 6 )-alkyl-, (C1-C 6 )-alkyl-0- and (C1
    C
    6 )-alkyl-S-, (C1-C 6 )-alkyl-O-C(O)- and (C 1
    -C
    6 )-alkyl-SO 2 -, wherein one or more hydrogen atoms of the alkyl moieties may be replaced by fluorine; 20 R1 = R5-C(=0)- or (C 1
    -C
    6 )-alkyl-SO 2 -; R2 = H, (C1-C 6 )-alkyl-, (C 3
    -C
    6 )-cycloalkyl-; R3 = H, (C1-C 4 )-alkyl-; R4 = H, (C1-C 4 )-alkyl-; or wherein R3 and R4 together form a (C 2
    -C
    3 )-alkylene bridge; 25 R5 = H, (C 1
    -C
    6 )-alkyl-, (C 3
    -C
    6 )-cycloalkyl-, (C 1
    -C
    6 )-alkyl-O-, (C 1
    -C
    6 )-alkyl-S-, (C1
    C
    6 )-alkyl-O-(C 1
    -C
    6 )-alkyl-, HO-(C 1
    -C
    6 )-alkyl-, (C 3
    -C
    6 )-cycloalkyl-(C 1
    -C
    6 )-alkyl-,
    (C
    6
    -C
    1 o)-aryl-, (C 6
    -C
    1 o)-aryl-(C 1
    -C
    6 )-alkyl-, R7R6N-, heteroaryl, heteroaryl
    (C
    1
    -C
    6 )-alkyl-, aliphatic heterocycle, wherein one or more hydrogen atoms of the alkyl moieties may be 30 replaced by fluorine, and WO 2013/037415 PCT/EP2011/066061 15 wherein the aliphatic heterocycle is selected from the group of morpholinyl, piperidinyl, pyrrolidinyl and 4 to 7 membered aliphatic heterocycles comprising an oxygen atom, and wherein the aliphatic heterocycle may be optionally substituted with 1 5 to 3 substituents selected from the group of F, OH, (C1-C 6 )-alkyl-0- and (C1
    C
    6 )-alkyl-, and wherein the heteroaryl residues are five- or six-membered ring systems, comprising 1-3 heteroatoms selected from the group N, 0 and S, and 10 wherein aryl and heteroaryl are optionally substituted with 1-3 rests selected independently from F, Cl, Br, CF 3 , (C 1
    -C
    6 )-alkyl-, (C 1
    -C
    6 )-alkyl-O-, CN, (C 1
    -C
    2 )-alkyl-SO 2 -; R6 = H, (C 1
    -C
    6 )-alkyl-, (C 3
    -C
    6 )-cycloalkyl-, wherein one hydrogen atom of the alkyl group may be replaced by an 15 OH- or (C 1
    -C
    6 )-alkyl-0- residue, and wherein one or more hydrogen atoms of the alkyl group may be replaced by fluorine; R7 = H, (C 1
    -C
    6 )-alkyl-; wherein one or more hydrogen atoms of the alkyl group may be 20 replaced by fluorine, and/or of a stereoisomeric form of the compound of the formula I and/or mixtures of these forms, and/or their pharmaceutically acceptable salts, with the proviso that A is not 4-methylthiophenyl if in compounds of formula I R5 is methyl and R2, R3 and R4 are hydrogen and X is phenyl. 25 Preferred compounds are, wherein A = 2-pyridyl, 3-pyridyl or 4-pyridyl, wherein the pyridyl residues are substituted with 1 or 2 residues selected independently from F, CI, Br, CN, (C 1
    -C
    4 )-alkyl-, CF 3 , CF 2 H, CFH 2 , 30 methoxy, ethoxy, OCF 3 , and (C 1
    -C
    2 )-alkyl-S-; X = phenyl, thiophen-2-yl or thiophen-3-yl, WO 2013/037415 PCT/EP2011/066061 16 wherein these residues are substituted with 1 or 2 residues selected independently from F, Cl, Br, CN, (C1-C 4 )-alkyl-, CF 3 , CF 2 H, CFH 2 , methoxy, ethoxy, OCF 3 , (C 1
    -C
    2 )-alkyl-S-, (C 1
    -C
    2 )-alkyl-O-C(O)- and methyl-SO 2 -; 5 R1 = R5-C(=O)- or (C 1
    -C
    2 )-alkyl-SO 2 -; R2 = H, methyl, ethyl, cyclopropyl; R3 and R4 = H; and R5 = H, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert.-butyl or wherein 10 R5 = cyclopropyl, cyclobutyl, cyclopentyl or (C 3
    -C
    6 )-cycloalkyl-(C 1
    -C
    2 )-alkyl-; or wherein R5 = (C 1
    -C
    2 )-alkyl-O-, (C 1
    -C
    2 )-alkyl-S-, or OCF 3 , or wherein R5 = (C 1
    -C
    4 )-alkyl-0-methyl-, HO-(C 1
    -C
    2 )-alkyl-, 15 or wherein R5 = phenyl or phenylmethyl-, wherein the phenyl residues are optionally substituted with 1-3 rests selected independently from F, CI, Br, CF 3 , (C 1
    -C
    2 )-alkyl-, (C 1
    -C
    2 )-alkyl-O-, CN, methyl-SO 2 -; 20 or wherein, R5 = R7R6N-, wherein R6 = H, (C 1
    -C
    4 )-alkyl-, cyclopropyl, wherein one hydrogen atom of the alkyl group may be replaced by an OH, methoxy or ethoxy residue; and 25 R7 = H, methyl-, ethyl; or wherein R5 = heteroaryl, heteroaryl-(C 1
    -C
    6 )-alkyl-, wherein the heteroaryl residues are selected from the group consisting of pyridine-2-yl, pyridine-3-yl, pyridine-4-yl, thiophen-2-yl, thiophen-3-yl, 30 thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol 5-yl, pyrazol-3-yl, pyrazol-4-yl, imidazol-2-yl, imidazol-4-yl, pyrimidin-2-yl, WO 2013/037415 PCT/EP2011/066061 17 pyrimidin-4-yl, pyrimidin-5-yl, pyridazin-3-yl, pyridazin-4-yl, pyrazin-2-yl and payrazin-3-yl, and wherein the heteroaryl residues are optionally substituted with 1 or 2 rests selected independently from F, Cl, Br, CF 3 , (C 1
    -C
    4 )-alkyl-, (C 1
    -C
    4 )-alkyl 5 0-, CN, (C 1
    -C
    2 )-alkyl-SO 2 -, or wherein R5 = an aliphatic heterocycle, wherein the aliphatic heterocycle is selected from the group of morpholinyl, piperidinyl, pyrrolidinyl, oxetanyl and tetrahydrofuranyl, 10 tetrahydropyranyl, and wherein the aliphatic heterocycle may be optionally substituted with 1 or 2 substituents independently selected from the group of F, OH, (C1-C2) alkyl-O- and (C 1
    -C
    4 )-alkyl-; and/or of a stereoisomeric form of the compound of the formula I and/or mixtures of 15 these forms, and/or their pharmaceutically acceptable salts. A further preferred embodiment of the present invention relates to compounds, wherein 20 A is equal to phenyl, wherein the phenyl residue is optionally substituted with 1-3 residues selected independently from F, CI, Br, CN, (C 1
    -C
    4 )-alkyl-, (C 1
    -C
    4 )-alkyl-O and (C 1
    -C
    4 )-alkyl-S-, wherein one or more hydrogen atoms of the alkyl moieties may be 25 replaced by fluorine, and X is equal to phenyl, wherein the phenyl group is optionally substituted with 1, 2 or 3 residues selected independently from F, CI, Br, CN, (C 1
    -C
    4 )-alkyl-, (C 1
    -C
    4 )-alkyl-O-,
    (C
    1
    -C
    4 )-alkyl-S-, (C 1
    -C
    4 )-alkyl-O-C(O)- and (C 1
    -C
    4 )-alkyl-SO 2 -, 30 wherein one or more hydrogen atoms of the alkyl moieties may be replaced by fluorine, and R1 = R5-C(=O)- or (C 1
    -C
    6 )-alkyl-SO 2
    -;
    WO 2013/037415 PCT/EP2011/066061 18 R2 = H, (C 1
    -C
    6 )-alkyl-, (C 3
    -C
    6 )-cycloalkyl-; R3 = H, (C 1
    -C
    4 )-alkyl-; R4 = H, (C1-C 4 )-alkyl-; or wherein R3 and R4 together form a (C 2
    -C
    3 )-alkylene bridge; 5 R5 = H, (C1-C 6 )-alkyl-, (C 3
    -C
    6 )-cycloalkyl-, (C1-C 6 )-alkyl-O-, (C1-C 6 )-alkyl-S-, (C1
    C
    6 )-alkyl-O-(C 1
    -C
    6 )-alkyl-, HO-(C1-C 6 )-alkyl-, (C 3
    -C
    6 )-cycloalkyl-(C 1
    -C
    6 )-alkyl-,
    (C
    6
    -C
    1 o)-aryl-, (C 6 -C1o)-aryl-(C1-C 6 )-alkyl-, R7R6N-, heteroaryl, heteroaryl (C1-C 6 )-alkyl-, aliphatic heterocycle, wherein one or more hydrogen atoms of the alkyl moieties may be 10 replaced by fluorine, and wherein the aliphatic heterocycle is selected from the group of morpholinyl, piperidinyl, pyrrolidinyl and 4 to 7 membered aliphatic heterocycles comprising an oxygen atom, and wherein the aliphatic heterocycle may be optionally substituted with 1 15 to 3 substituents selected from the group of F, OH, (C1-C 6 )-alkyl-0- and (C1
    C
    6 )-alkyl-, and wherein the heteroaryl residues are five- or six-membered ring systems, comprising 1-3 heteroatoms selected from the group N, 0 and S, and 20 wherein aryl and heteroaryl are optionally substituted with 1-3 rests selected independently from F, Cl, Br, CF 3 , (C 1
    -C
    6 )-alkyl-, (C 1
    -C
    6 )-alkyl-O-, CN, (C 1
    -C
    2 )-alkyl-SO 2 -; R6 = H, (C 1
    -C
    6 )-alkyl-, (C 3
    -C
    6 )-cycloalkyl-, wherein one hydrogen atom of the alkyl group may be replaced by an 25 OH- or (C 1
    -C
    6 )-alkyl-0- residue, and wherein one or more hydrogen atoms of the alkyl group may be replaced by fluorine; R7 = H, (C 1
    -C
    6 )-alkyl-; wherein one or more hydrogen atoms of the alkyl group may be 30 replaced by fluorine, with the proviso if R5 is methyl and R2, R3 and R4 are equal to H and A is equal to 4-fluoro-phenyl, the residue X is not phenyl, 4-fluoro-phenyl, 4-chloro-phenyl, 4- WO 2013/037415 PCT/EP2011/066061 19 methyl-phenyl, 4-methoxy-phenyl, 4-acetoxyphenyl, 2-chloro-phenyl, 3,4 dichlorophenyl, and with the proviso if R5 is methyl and R2, R3 and R4 are equal to H and X is a phenyl residue, the residue A is not phenyl, 4-fluoro-phenyl, 4-chloro-phenyl, 4-methyl 5 phenyl, 4-ethyloxy-phenyl or 3-trifluoromethyl-phenyl, and with the proviso if R5 is methyl and R2 is methyl and R3 and R4 are equal to H and A is equal to 4-fluoro-phenyl, the residue X is not phenyl. Preferred compounds are, wherein 10 A = phenyl, wherein the phenyl residue is substituted with 1 or 2 residues selected independently from F, Cl, Br, CN, (C1-C 4 )-alkyl-, CF 3 , CF 2 H, CFH 2 , methoxy, ethoxy, OCF 3 and (C 1
    -C
    2 )-alkyl-S-; 15 X = phenyl, wherein the phenyl residue is substituted with 1 or 2 residues selected independently from F, Cl, Br, CN, (C 1
    -C
    4 )-alkyl-, CF 3 , CF 2 H, CFH 2 , methoxy, ethoxy, OCF 3 , (C 1
    -C
    2 )-alkyl-S-, (C 1
    -C
    2 )-alkyl-O-C(O)- and methyl-SO 2 -, 20 R1 = R5-C(=O)- or methyl-SO 2 -, R2 = H, (C 1
    -C
    2 )-alkyl-, cyclopropyl-; R3 = H, methyl-; R4 = H, methyl-; or wherein R3 and R4 together form an ethylene bridge; 25 and wherein R5 is equal to a heteroaryl or heteroaryl-(C 1
    -C
    6 )-alkyl-, wherein the heteroaryl residues are selected from the group consisting of pyridine-2-yl, pyridine-3-yl, pyridine-4-yl, thiophen-2-yl, thiophen-3-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, pyrazol-3-yl, pyrazol-4-yl, imidazol 30 2-yl, imidazol-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyridazin-3-yl, pyridazin-4-yl, pyrazin-2-yl and payrazin-3-yl, and WO 2013/037415 PCT/EP2011/066061 20 wherein these residues are optionally substituted with 1 or 2 residues selected independently from F, Cl, Br, CF 3 , methyl, ethyl, methoxy, ethoxy, CN, methyl-SO 2 -, or wherein 5 R5 is equal to H; or wherein R5 is equal to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or (C 3
    -C
    6 )-cycloalkyl (C1-C 2 )-alkyl-, or wherein 10 R5 is equal to (C 1
    -C
    2 )-alkyl-O-, (C 1
    -C
    2 )-alkyl-S-, or wherein R5 is equal to (C 1
    -C
    4 )-alkyl-0-methyl-, HO-(C 1
    -C
    2 )-alkyl-, or wherein R5 is equal to phenyl- or phenylmethyl-, 15 wherein the phenyl residues are optionally substituted with 1-3 residues selected independently from F, CI, Br, CF 3 , (C 1
    -C
    2 )-alkyl-, (C1-C2) alkyl-O-, CN, methyl-SO 2 -, and wherein one or more hydrogen atoms of the alkyl moieties may be replaced by fluorine; 20 or wherein R5 is equal to R7R6N-, wherein R6 = H, (C 1
    -C
    4 )-alkyl-, cyclopropyl-, wherein one hydrogen atom of the alkyl group may be replaced by a hydroxy, methoxy or ethoxy residue and R7 = H, methyl-, ethyl 25 or wherein R5 is equal to an aliphatic heterocycle, wherein the aliphatic heterocycle is selected from the group of oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, morpholinyl, piperidinyl, pyrrolidinyl, and 30 wherein the aliphatic heterocycle may be optionally substituted with 1 or 2 substituents selected from the group of F, OH, (C 1
    -C
    2 )-alkyl-O- and (C1- WO 2013/037415 PCT/EP2011/066061 21
    C
    4 )-alkyl-, and wherein one or more hydrogen atoms of the alkyl groups may be replaced by fluorine; and/or of a stereoisomeric form of the compound of the formula I and/or mixtures of these forms, and/or their pharmaceutically acceptable salts. 5 Particularly preferred compounds are, wherein A = phenyl, wherein the phenyl residue is substituted with 1 or 2 residues selected 10 independently from F, Cl, Br, CN, (C1-C 4 )-alkyl-, CF 3 , CF 2 H, CFH 2 , methoxy, ethoxy, OCF 3 and (C 1
    -C
    2 )-alkyl-S-; X = phenyl, wherein the phenyl residue is substituted with 1 or 2 residues selected independently from F, Cl, Br, CN, (C 1
    -C
    4 )-alkyl-, CF 3 , CF 2 H, CFH 2 , 15 methoxy, ethoxy, OCF 3 , (C 1
    -C
    2 )-alkyl-S-, (C 1
    -C
    2 )-alkyl-O-C(O)- and methyl-SO 2 -, R1 = R5-C(=O)-; R2 = H, (C 1
    -C
    2 )-alkyl-, cyclopropyl-; R3 = H, methyl-; 20 R4 = H, methyl-; or wherein R3 and R4 together form an ethylene bridge; and wherein R5 is equal to (C 2
    -C
    4 )-alkyl, and/or of a stereoisomeric form of the compound of the formula I and/or mixtures of 25 these forms, and/or their pharmaceutically acceptable salts. A further embodiment of the present invention are compounds of formula I, wherein A = (C 6
    -C
    1 o)-aryl or a five- or six-membered heteroaryl, comprising 1-3 30 heteroatoms selected from the group N, 0 and S, WO 2013/037415 PCT/EP2011/066061 22 wherein aryl and heteroaryl are optionally substituted with 1-3 rests selected independently from F, Cl, Br, CN, (C1-C 6 )-alkyl-, (C1-C 6 )-alkyl-0 and (C1-C 6 )-alkyl-S-, wherein one or more hydrogen atoms of the alkyl moieties may be 5 replaced by fluorine; X = (C 6
    -C
    1 o)-aryl or a five- or six-membered heteroaryl, comprising 1-3 heteroatoms selected from the group N, 0 and S, wherein aryl and heteroaryl are optionally substituted with 1-3 rests selected independently from F, Cl, Br, CN, (C1-C 6 )-alkyl-, (C1-C 6 )-alkyl-0 10 and (C1-C 6 )-alkyl-S-, (C1-C 6 )-alkyl-O-C(O)- and (C 1
    -C
    6 )-alkyl-SO 2 -, wherein one or more hydrogen atoms of the alkyl moieties may be replaced by fluorine; R1 = R5-C(=0)- or (C 1
    -C
    6 )-alkyl-SO 2 -; R2 = H, (C1-C 6 )-alkyl-, (C 3
    -C
    6 )-cycloalkyl-; 15 R3 = H, (C1-C 4 )-alkyl-; R4 = H, (C1-C 4 )-alkyl-; or R3,R4 together form a (C 2
    -C
    3 )-alkylene bridge; and wherein R5 is equal to a heteroaryl or heteroaryl-(C1-C 6 )-alkyl-, wherein the heteroaryl 20 residues are five- or six-membered ring systems, comprising 1-3 heteroatoms selected from the group N, 0 and S, and wherein the heteroaryl residues are optionally substituted with 1-3 residues selected independently from F, Cl, Br, CF 3 , (C 1
    -C
    6 )-alkyl-, (C 1
    -C
    6 )-alkyl-O-, CN, (C 1
    -C
    2 )-alkyl-SO 2 -, 25 wherein one or more hydrogen atoms of the alkyl moieties may be replaced by fluorine, with the proviso if in compounds of formula I A is a 3-cyanophenyl residue and X a 2,4-difluorophenyl residue R5 is not pyrimidin-4-yl, pyridine-2-yl, 1 methyl-pyrazol-3-yl or 1-methyl-imidazol-2-yl, 30 or wherein R5 is methyl, with the proviso if in compounds of formula I R2, R3 and R4 are hydrogen and X is a 2,4-difluorophenyl residue A is not pyridine-3-yl, 2-fluoro-phenyl, 3- WO 2013/037415 PCT/EP2011/066061 23 fluoro-phenyl, 4-fluorophenyl, 3-cyano-phenyl, 3-methoxy-phenyl, 3 trifluormethoxy-phenyl, 2-fluoro-5-methoxy-phenyl, and with the proviso if in compounds of formula I R2, R3 and R4 are hydrogen and X is a 3-cyanophenyl residue A is not a 4-fluorophenyl residue, and 5 with the proviso if in compounds of formula I R3 is methyl, R2 and R4 are hydrogen and X is a 2,4-difluoro-phenyl residue A is not a 4-fluoro-phenyl, and with the proviso if in compounds of formula I R2, R3 and R4 are hydrogen and X is phenyl A is not phenyl, 3-trifluoromethyl-phenyl, 4-fluoro-phenyl, 4 10 chloro-phenyl, 4-methyl-phenyl, 4-ethyloxy-phenyl, 4-methyl-thiophenyl, 2 thiophenyl, and with the proviso if in compounds of formula I R2, R3 and R4 are hydrogen and A is 4-fluoro-phenyl X is not phenyl, 2-chloro-phenyl, 3,4-dichloro-phenyl, 4-chloro-phenyl, 4-fluoro-phenyl, 4-methyl-phenyl, 4-methoxy-phenyl, 4 15 ethyloxy-phenyl, or 4-acetoxyphenyl, and with the proviso if R5 is methyl and R2 is methyl and R3 and R4 are equal to H and A is equal to 4-fluoro-phenyl, the residue X is not phenyl, and or wherein R5 is equal to H, (C 2
    -C
    6 )-alkyl, CF 3 , CF 2 H, CFH 2 , 20 wherein one or more hydrogen atoms of the alkyl residue may be replaced by fluorine; or wherein R5 is equal to (C 3
    -C
    6 )-cycloalkyl or (C 3
    -C
    6 )-cycloalkyl-(C 1
    -C
    4 )-alkyl-, with the proviso if in compounds of formula I A is a 3-cyanophenyl residue 25 and X a 2,4-difluorophenyl residue R5 is not cyclopropyl, or wherein R5 is equal to (C1-C 4 )-alkyl-O- or (C1-C 4 )-alkyl-S-, wherein one or more hydrogen atoms of the alkyl moieties may be replaced by fluorine; 30 or wherein R5 is equal to (C 1
    -C
    4 )-alkyl-O-(C 1
    -C
    2 )-alkyl-, HO-(C1-C 4 )-alkyl-, or wherein WO 2013/037415 PCT/EP2011/066061 24 R5 is equal to phenyl-, phenyl-(C1-C 4 )-alkyl-, wherein the phenyl residues are optionally substituted with 1-3 residues selected independently from F, Cl, Br, CF 3 , (C 1
    -C
    6 )-alkyl-, (C1-C6) alkyl-O-, CN, (C 1
    -C
    2 )-alkyl-SO 2 -, and 5 wherein one or more hydrogen atoms of the alkyl moieties may be replaced by fluorine, with the proviso if in compounds of formula I A is a 3-cyanophenyl residue and X a 2,4-difluorophenyl residue R5 is not 3-methylsulfonyl-phenyl, 4 methylsulfonyl-phenyl, 10 or wherein R5 is equal to R7R6N-, wherein R6 = H, (C 1
    -C
    4 )-alkyl-, cyclopropyl-, wherein one hydrogen atom of the alkyl group may be replaced by an OH, methoxy or ethoxy residue and R7 = H, (C 1
    -C
    2 )-alkyl-, 15 or wherein R5 is equal to an aliphatic heterocycle, wherein the aliphatic heterocycle is selected from the group of oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, morpholinyl, piperidinyl, pyrrolidinyl, and 20 wherein the aliphatic heterocycle may be optionally substituted with 1 or 2 substituents selected from the group of F, OH, (C 1
    -C
    4 )-alkyl-O- and (C1
    C
    4 )-alkyl-, and wherein one or more hydrogen atoms of the alkyl groups may be replaced by fluorine, 25 with the proviso if in compounds of formula I A is a 3-cyanophenyl residue and X a 2,4-difluorophenyl residue R5 is not 3-methyl-oxetan-3-yl, tetrahydrofuran-3-yl, tetrahydropyran-4-yl or 1-methyl-piperidin-4-yl. Preferred compounds are, wherein 30 A = phenyl, pyridine-2-yl, pyridine-3-yl, pyridine-4-yl, thiophen-2-yl or thiophen-3 yl, WO 2013/037415 PCT/EP2011/066061 25 wherein these residues are optionally substituted with 1 or 2 residues selected independently from F, Cl, Br, CN, (C1-C 4 )-alkyl-, CF 3 , CF 2 H,
    CFH
    2 , methoxy, ethoxy, OCF 3 and (C 1
    -C
    2 )-alkyl-S-; X= phenyl, 5 wherein the phenyl residue is substituted with 1 or 2 residues selected independently from F, Cl, Br, CN, (C 1
    -C
    4 )-alkyl-, CF 3 , CF 2 H, CFH 2 , methoxy, ethoxy, OCF 3 , (C 1
    -C
    2 )-alkyl-S-, (C 1
    -C
    2 )-alkyl-O-C(O)- and methyl-SO 2 -, or 10 pyridine-2-yl, pyridine-3-yl, pyridine-4-yl, thiophen-2-yl, thiophen-3-yl, thiazol 2-yl, thiazol-4-yl, thiazol-5-yl, wherein these residues are optionally substituted with 1 or 2 residues selected independently from F, CI, Br, CN, (C 1
    -C
    4 )-alkyl-, CF 3 , CF 2 H,
    CFH
    2 , methoxy, ethoxy, OCF 3 , (C 1
    -C
    2 )-alkyl-S-, (C 1
    -C
    2 )-alkyl-O-C(O)- and 15 methyl-SO 2 -; R1 = R5-C(=O)- or (C1-C 2 )-alkyl-SO 2 -; R2 = H, (C1-C 2 )-alkyl-, cyclopropyl-; R3 = H, (C1-C 2 )-alkyl-; R4 = H, (C1-C 2 )-alkyl-; 20 or wherein R3 and R4 together form an ethylene bridge; and wherein R5 is equal to a heteroaryl or heteroaryl-(C 1
    -C
    6 )-alkyl-, wherein the heteroaryl residues are selected from the group consisting of pyridine-2-yl, pyridine-3-yl, pyridine-4-yl, thiophen-2-yl, thiophen-3-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, 25 isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, pyrazol-3-yl, pyrazol-4-yl, imidazol 2-yl, imidazol-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyridazin-3-yl, pyridazin-4-yl, pyrazin-2-yl and payrazin-3-yl, and wherein these residues are optionally substituted with 1 or 2 residues selected independently from F, CI, Br, CF 3 , methyl, ethyl, methoxy, ethoxy, 30 CN, methyl-SO 2
    -,
    WO 2013/037415 PCT/EP2011/066061 26 with the proviso if in compounds of formula I A is a 3-cyanophenyl residue and X a 2,4-difluorophenyl residue R5 is not pyrimidin-4-yl, pyridine-2-yl, 1-methyl pyrazol-3-yl or 1 -methyl-imidazol-2-yl, or wherein R5 is methyl, 5 with the proviso if in compounds of formula I R2, R3 and R4 are hydrogen and X is a 2,4-difluorophenyl residue A is not pyridine-3-yl, 2-fluoro-phenyl, 3-fluoro phenyl, 4-fluorophenyl, 3-cyano-phenyl, 3-methoxy-phenyl, 3-trifluormethoxy phenyl, 2-fluoro-5-methoxy-phenyl, and with the proviso if in compounds of formula I R2, R3 and R4 are hydrogen and X 10 is a 3-cyanophenyl residue A is not a 4-fluorophenyl residue, and with the proviso if in compounds of formula I R3 is methyl, R2 and R4 are hydrogen and X is a 2,4-difluoro-phenyl residue A is not a 4-fluoro-phenyl, and with the proviso if in compounds of formula I R2, R3 and R4 are hydrogen and X is phenyl A is not phenyl, 3-trifluoromethyl-phenyl, 4-fluoro-phenyl, 4-chloro 15 phenyl, 4-methyl-phenyl, 4-ethoxy-phenyl, 2-thiophenyl, 4-methylthiophenyl, and with the proviso if in compounds of formula I R2, R3 and R4 are hydrogen and A is 4-fluoro-phenyl X is not 2-chloro-phenyl, 3,4-dichloro-phenyl, 4-chloro-phenyl, 4-fluoro-phenyl, 4-methyl-phenyl, 4-methoxy-phenyl, 4-acetoxyphenyl or 4 ethoxy-phenyl, and 20 or wherein R5 is equal to H, (C 2
    -C
    4 )-alkyl, CF 3 ; or wherein R5 is equal to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or (C 3
    -C
    6 )-cycloalkyl (C1-C 2 )-alkyl-, 25 with the proviso if in compounds of formula I A is a 3-cyanophenyl residue and X a 2,4-difluorophenyl residue R5 is not cyclopropyl, or wherein R5 is equal to (C 1
    -C
    2 )-alkyl-O- or (C 1
    -C
    2 )-alkyl-S-, wherein one or more hydrogen atoms of the alkyl moieties may be 30 replaced by fluorine; or wherein R5 is equal to (C 1
    -C
    4 )-alkyl-0-methyl-, HO-(C 1
    -C
    2 )-alkyl-, WO 2013/037415 PCT/EP2011/066061 27 wherein one or more hydrogen atoms of the alkyl moieties may be replaced by fluorine; or wherein R5 is equal to phenyl-, phenyl-(C1-C 2 )-alkyl-, 5 wherein the phenyl residues are optionally substituted with 1-3 residues selected independently from F, Cl, Br, CF 3 , (C 1
    -C
    2 )-alkyl-, (C1-C2) alkyl-O-, CN, methyl-SO 2 -, and wherein one or more hydrogen atoms of the alkyl moieties may be replaced by fluorine, 10 with the proviso if in compounds of formula I A is a 3-cyanophenyl residue and X a 2,4-difluorophenyl residue R5 is not 3-methylsulfonyl-phenyl, 4-methylsulfonyl phenyl; or wherein R5 is equal to R7R6N-, wherein 15 R6 = H, (C 1
    -C
    4 )-alkyl-, cyclopropyl-, wherein one hydrogen atom of the alkyl group may be replaced by a hydroxy, methoxy or ethoxy residue and R7 = H, methyl-, ethyl or wherein R5 is equal to an aliphatic heterocycle, 20 wherein the aliphatic heterocycle is selected from the group of oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, morpholinyl, piperidinyl, pyrrolidinyl, and wherein the aliphatic heterocycle may be optionally substituted with 1 or 2 substituents selected from the group of F, OH, (C 1
    -C
    2 )-alkyl-O- and (C1 25 C 4 )-alkyl-, and wherein one or more hydrogen atoms of the alkyl groups may be replaced by fluorine, with the proviso if in compounds of formula I A is a 3-cyanophenyl residue and X a 2,4-difluorophenyl residue R5 is not 3-methyl-oxetan-3-yl, 30 tetrahydrofuran-3-yl, tetrahydropyran-4-yl or 1-methyl-piperidin-4-yl. and/or of a stereoisomeric form of the compound of the formula I and/or mixtures of these forms, and/or their pharmaceutically acceptable salts.
    WO 2013/037415 PCT/EP2011/066061 28 Further preferred compounds are, wherein A is equal to phenyl, 5 wherein the phenyl residue is optionally substituted with 1-3 residues selected independently from F, Cl, Br, CN, (C1-C 4 )-alkyl-, (C1-C 4 )-alkyl-O and (C1-C 4 )-alkyl-S-, wherein one or more hydrogen atoms of the alkyl moieties may be replaced by fluorine, and 10 X is equal to phenyl, wherein the phenyl group is optionally substituted with 1, 2 or 3 residues selected independently from F, Cl, Br, CN, (C1-C 4 )-alkyl-, (C1-C 4 )-alkyl-O-, (C1-C 4 )-alkyl-S-, (C1-C 4 )-alkyl-O-C(O)- and (C 1
    -C
    4 )-alkyl-SO 2 -, wherein one or more hydrogen atoms of the alkyl moieties may be 15 replaced by fluorine, and R1 = R5-C(=O)- or (C 1
    -C
    6 )-alkyl-SO 2 -; R2 = H, (C1-C 6 )-alkyl-, (C 3
    -C
    6 )-cycloalkyl-; R3 = H, (C1-C 4 )-alkyl-; R4 = H, (C1-C 4 )-alkyl-; 20 or wherein R3 and R4 together form a (C 2
    -C
    3 )-alkylene bridge; and wherein R5 is equal to a heteroaryl or heteroaryl-(C1-C 6 )-alkyl-, wherein the heteroaryl residues are five- or six-membered ring systems, comprising 1-3 heteroatoms selected from the group N, 0 and S, and 25 wherein the heteroaryl residues are optionally substituted with 1-3 residues selected independently from F, Cl, Br, CF 3 , (C 1
    -C
    6 )-alkyl-, (C 1
    -C
    6 )-alkyl-O-, CN, (C 1
    -C
    2 )-alkyl-SO 2 -, wherein one or more hydrogen atoms of the alkyl moieties may be replaced by fluorine, 30 with the proviso if in compounds of formula I A is a 3-cyanophenyl residue and X a 2,4-difluorophenyl residue R5 is not pyrimidin-4-yl, pyridine-2-yl, 1 methyl-pyrazol-3-yl or 1-methyl-imidazol-2-yl, WO 2013/037415 PCT/EP2011/066061 29 or wherein R5 is methyl, with the proviso if in compounds of formula I R2, R3 and R4 are hydrogen and X is a 2,4-difluorophenyl residue A is not pyridine-3-yl, 2-fluoro-phenyl, 3 fluoro-phenyl, 4-fluorophenyl, 3-cyano-phenyl, 3-methoxy-phenyl, 3 5 trifluormethoxy-phenyl, 2-fluoro-5-methoxy-phenyl, and with the proviso if in compounds of formula I R2, R3 and R4 are hydrogen and X is a 3-cyanophenyl residue A is not a 4-fluorophenyl residue, and with the proviso if in compounds of formula I R3 is methyl, R2 and R4 are hydrogen and X is a 2,4-difluoro-phenyl residue A is not a 4-fluoro-phenyl, 10 and with the proviso if in compounds of formula I R2, R3 and R4 are hydrogen and X is phenyl A is not phenyl, 3-trifluoromethyl-phenyl, 4-fluoro-phenyl, 4 chloro-phenyl, 4-methyl-phenyl, 4-ethyloxy-phenyl, 4-methyl-thiophenyl, 2 thiophenyl, and 15 with the proviso if in compounds of formula I R2, R3 and R4 are hydrogen and A is 4-fluoro-phenyl X is not phenyl, 2-chloro-phenyl, 3,4-dichloro-phenyl, 4-chloro-phenyl, 4-fluoro-phenyl, 4-methyl-phenyl, 4-methoxy-phenyl, 4 ethyloxy-phenyl, or 4-acetoxyphenyl, and with the proviso if in compounds of formula I R2 is methyl, R3 and R4 are 20 hydrogen and A is 4-fluoro-phenyl, the residue X is not phenyl, and or wherein R5 is equal to H, (C 2
    -C
    6 )-alkyl, CF 3 , CF 2 H, CFH 2 , wherein one or more hydrogen atoms of the alkyl residue may be 25 replaced by fluorine, or wherein R5 is equal to (C 3
    -C
    6 )-cycloalkyl or (C 3
    -C
    6 )-cycloalkyl-(C 1
    -C
    4 )-alkyl-, with the proviso if in compounds of formula I A is a 3-cyanophenyl residue and X a 2,4-difluorophenyl residue R5 is not cyclopropyl, 30 or wherein R5 is equal to (C1-C 4 )-alkyl-O- or (C1-C 4 )-alkyl-S-, WO 2013/037415 PCT/EP2011/066061 30 wherein one or more hydrogen atoms of the alkyl moieties may be replaced by fluorine; or wherein R5 is equal to (C 1
    -C
    4 )-alkyl-O-(C 1
    -C
    2 )-alkyl-, HO-(C1-C 4 )-alkyl-, 5 or wherein R5 is equal to phenyl-, phenyl-(C1-C 4 )-alkyl-, wherein the phenyl residues are optionally substituted with 1-3 residues selected independently from F, Cl, Br, CF 3 , (C 1
    -C
    6 )-alkyl-, (C1-C) alkyl-O-, CN, (C 1
    -C
    2 )-alkyl-SO 2 -, and 10 wherein one or more hydrogen atoms of the alkyl moieties may be replaced by fluorine, with the proviso if in compounds of formula I A is a 3-cyanophenyl residue and X a 2,4-difluorophenyl residue R5 is not 3-methylsulfonyl-phenyl, 4 methylsulfonyl-phenyl; 15 or wherein R5 is equal to R7R6N-, wherein R6 = H, (C 1
    -C
    4 )-alkyl-, cyclopropyl-, wherein one hydrogen atom of the alkyl group may be replaced by an OH, methoxy or ethoxy residue and R7 = H, (C 1
    -C
    2 )-alkyl-, 20 or wherein R5 is equal to an aliphatic heterocycle, wherein the aliphatic heterocycle is selected from the group of oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, morpholinyl, piperidinyl, pyrrolidinyl, and 25 wherein the aliphatic heterocycle may be optionally substituted with 1 or 2 substituents selected from the group of F, OH, (C 1
    -C
    4 )-alkyl-O- and (C1
    C
    4 )-alkyl-, and wherein one or more hydrogen atoms of the alkyl groups may be replaced by fluorine, 30 with the proviso if in compounds of formula I A is a 3-cyanophenyl residue and X a 2,4-difluorophenyl residue R5 is not 3-methyl-oxetan-3-yl, tetrahydrofuran-3-yl, tetrahydropyran-4-yl or 1-methyl-piperidin-4-yl.
    WO 2013/037415 PCT/EP2011/066061 31 R6 = H, (C1-C 6 )-alkyl-, (C 3
    -C
    6 )-cycloalkyl-, wherein one hydrogen atom of the alkyl group may be replaced by an OH- or (C1-C 6 )-alkyl-0- residue, and wherein one or more hydrogen atoms of the alkyl group may be 5 replaced by fluorine; R7 = H, (C1-C 6 )-alkyl-; wherein one or more hydrogen atoms of the alkyl group may be replaced by fluorine. 10 Particularly preferred compounds are compounds of formula I, wherein A = phenyl, wherein the phenyl residue is substituted with 1 or 2 residues selected independently from F, Cl, Br, CN, (C1-C 4 )-alkyl-, CF 3 , CF 2 H, CFH 2 , 15 methoxy, ethoxy, OCF 3 and (C 1
    -C
    2 )-alkyl-S-; X = phenyl, wherein the phenyl residue is substituted with 1 or 2 residues selected independently from F, Cl, Br, CN, (C 1
    -C
    4 )-alkyl-, CF 3 , CF 2 H, CFH 2 , methoxy, ethoxy, OCF 3 , (C 1
    -C
    2 )-alkyl-S-, (C 1
    -C
    2 )-alkyl-O-C(O)- and 20 methyl-SO 2 -, R1 = R5-C(=O)- or methyl-SO 2 -, R2 = H, (C1-C 2 )-alkyl-, cyclopropyl-; R3 = H, methyl-; R4 = H, methyl-; 25 or wherein R3 and R4 together form an ethylene bridge; and wherein R5 is equal to a heteroaryl or heteroaryl-(C 1
    -C
    6 )-alkyl-, wherein the heteroaryl residues are selected from the group consisting of pyridine-2-yl, pyridine-3-yl, pyridine-4-yl, thiophen-2-yl, thiophen-3-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, 30 isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, pyrazol-3-yl, pyrazol-4-yl, imidazol 2-yl, imidazol-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyridazin-3-yl, pyridazin-4-yl, pyrazin-2-yl and payrazin-3-yl, and WO 2013/037415 PCT/EP2011/066061 32 wherein these residues are optionally substituted with 1 or 2 residues selected independently from F, Cl, Br, CF 3 , methyl, ethyl, methoxy, ethoxy, CN, methyl-SO 2 -, with the proviso if in compounds of formula I A is a 3-cyanophenyl residue and X 5 a 2,4-difluorophenyl residue R5 is not pyrimidin-4-yl, pyridine-2-yl, 1-methyl pyrazol-3-yl or 1 -methyl-imidazol-2-yl, or wherein R5 is methyl, with the proviso if in compounds of formula I R2, R3 and R4 are hydrogen and X is a 2,4-difluorophenyl residue A is not pyridine-3-yl, 2-fluoro-phenyl, 3-fluoro 10 phenyl, 4-fluorophenyl, 3-cyano-phenyl, 3-methoxy-phenyl, 3-trifluormethoxy phenyl, 2-fluoro-5-methoxy-phenyl, and with the proviso if in compounds of formula I R2, R3 and R4 are hydrogen and X is a 3-cyanophenyl residue A is not a 4-fluorophenyl residue, and with the proviso if in compounds of formula I R3 is methyl, R2 and R4 are 15 hydrogen and X is a 2,4-difluoro-phenyl residue A is not a 4-fluoro-phenyl, and with the proviso if in compounds of formula I R2, R3 and R4 are hydrogen and X is phenyl A is not phenyl, 3-trifluoromethyl-phenyl, 4-fluoro-phenyl, 4-chloro phenyl, 4-methyl-phenyl, 4-ethoxy-phenyl, 2-thiophenyl, 4-methylthiophenyl, and with the proviso if in compounds of formula I R2, R3 and R4 are hydrogen and A 20 is 4-fluoro-phenyl X is not 2-chloro-phenyl, 3,4-dichloro-phenyl, 4-chloro-phenyl, 4-fluoro-phenyl, 4-methyl-phenyl, 4-methoxy-phenyl, 4-ethoxy-phenyl or 4 acetoxyphenyl, and with the proviso if in compounds of formula I R2 is methyl, R3 and R4 are hydrogen and A is 4-fluoro-phenyl, the residue X is not phenyl, and 25 or wherein R5 is equal to H, (C 2
    -C
    4 )-alkyl, CF 3 , or wherein R5 is equal to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or (C 3
    -C
    6 )-cycloalkyl (C1-C 2 )-alkyl-, 30 with the proviso if in compounds of formula I A is a 3-cyanophenyl residue and X a 2,4-difluorophenyl residue R5 is not cyclopropyl, or wherein WO 2013/037415 PCT/EP2011/066061 33 R5 is equal to (C1-C 2 )-alkyl-O- or (C1-C 2 )-alkyl-S-, wherein one or more hydrogen atoms of the alkyl moieties may be replaced by fluorine; or wherein 5 R5 is equal to (C1-C 4 )-alkyl-0-methyl-, HO-(C1-C 2 )-alkyl-, wherein one or more hydrogen atoms of the alkyl moieties may be replaced by fluorine; or wherein R5 is equal to phenyl-, phenyl-(C1-C 2 )-alkyl-, 10 wherein the phenyl residues are optionally substituted with 1-3 residues selected independently from F, Cl, Br, CF 3 , (C 1
    -C
    2 )-alkyl-, (C1-C2) alkyl-O-, CN, methyl-SO 2 -, and wherein one or more hydrogen atoms of the alkyl moieties may be replaced by fluorine, 15 with the proviso if in compounds of formula I A is a 3-cyanophenyl residue and X a 2,4-difluorophenyl residue R5 is not 3-methylsulfonyl-phenyl, 4-methylsulfonyl phenyl; or wherein R5 is equal to R7R6N-, wherein 20 R6 = H, (C 1
    -C
    4 )-alkyl-, cyclopropyl-, wherein one hydrogen atom of the alkyl group may be replaced by a hydroxy, methoxy or ethoxy residue and R7 = H, methyl-, ethyl or wherein R5 is equal to an aliphatic heterocycle, 25 wherein the aliphatic heterocycle is selected from the group of oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, morpholinyl, piperidinyl, pyrrolidinyl, and wherein the aliphatic heterocycle may be optionally substituted with 1 or 2 substituents selected from the group of F, OH, (C1-C 2 )-alkyl-O- and (C1 30 C 4 )-alkyl-, and wherein one or more hydrogen atoms of the alkyl groups may be replaced by fluorine, WO 2013/037415 PCT/EP2011/066061 34 with the proviso if in compounds of formula I A is a 3-cyanophenyl residue and X a 2,4-difluorophenyl residue R5 is not 3-methyl-oxetan-3-yl, tetrahydrofuran-3-yl, tetrahydropyran-4-yl or 1-methyl-piperidin-4-yl, and/or of a stereoisomeric form of the compound of the formula I and/or mixtures of 5 these forms, and/or their pharmaceutically acceptable salts. Further preferred compounds suitable as TASK-1 inhibitors are compounds of formula I, wherein 10 A = phenyl, wherein the phenyl residue is substituted with 1 or 2 residues selected independently from F, Cl, Br, CN, (C1-C 4 )-alkyl-, CF 3 , CF 2 H, CFH 2 , methoxy, ethoxy, OCF 3 and (C 1
    -C
    2 )-alkyl-S-; X = phenyl, 15 wherein the phenyl residue is substituted with 1 or 2 residues selected independently from F, Cl, Br, CN, (C 1
    -C
    4 )-alkyl-, CF 3 , CF 2 H, CFH 2 , methoxy, ethoxy, OCF 3 , (C 1
    -C
    2 )-alkyl-S-, (C 1
    -C
    2 )-alkyl-O-C(O)- and methyl-SO 2 -, R1 = R5-C(=O)-; 20 R2 = H, (C 1
    -C
    2 )-alkyl-, cyclopropyl-; R3 = H, methyl-; R4 = H, methyl-; or wherein R3 and R4 together form an ethylene bridge; and wherein 25 R5 is equal to (C 2
    -C
    4 )-alkyl; and/or of a stereoisomeric form of the compound of the formula I and/or mixtures of these forms, and/or their pharmaceutically acceptable salts. Alkyl radicals have between 1 and 6, preferably between 1 and 4 carbon atoms and 30 may be straight-chain or branched. Alkyl radicals may also be straight-chain or branched if they are substituted or are present in other radicals, for example in an alkyloxy radical (alkoxy radical) or in a fluorinated alkyl radical. Examples of alkyl WO 2013/037415 PCT/EP2011/066061 35 radicals are methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert butyl. One or more, for example 1, 2, 3, 4, 5, 6, 7, 8, or 9 hydrogen atoms in alkyl radicals may be replaced by fluorine atoms. Preferred fluorinated alkyl radicals are
    CF
    3 , CF 2 H and CFH 2 . Substituted alkyl radicals may be substituted in any positions. 5 Preferred alkyloxy radicals are methoxy and ethoxy. These explanations with respect to alkyl radicals apply correspondingly to alkyl radicals which in the definition of a group in the compounds of the formula I are bonded to two adjacent groups, or linked to two groups, and may be regarded as divalent alkyl radicals (alkanediyl radicals, alkylene radicals), like in the case of the alkyl part of a 10 substituted alkyl group, for example the group (C 1
    -C
    6 )-alkyloxy-(C 1
    -C
    6 )-alkyl- or the group heteroaryl-(C 1
    -C
    6 )-alkyl-, in which groups and likewise in other groups the terminal hyphen denotes the free bond via which the group is bonded, and thus indicates via which subgroup a group composed of subgroups is bonded. Thus, such radicals can also be straight-chain or branched, the bonds to the adjacent 15 groups can be located in any positions and can start from the same carbon atom or from different carbon atoms, and they can be unsubstituted or substituted by fluorine substituents independently of any other substituents. Examples of such divalent alkyl radicals are methylene, 1,1-ethylene, 1,2-ethylene, 1,1-propylene, 1,2 propylene, 2,2-propylene, 1,3-propylene, 1,1-butylene, 1,4-butylene, etc. 20 Examples of cycloalkyl radicals having 3 to 6 C atoms are cyclopropyl, cyclobutyl, 1 methylcyclopropyl-, 2-methylcyclopropyl-, cyclobutyl, 2-methylcyclobutyl-, 3 methylcyclobutyl-, cyclopentyl, 2-methylcyclopentyl-, 3-methylcyclopentyl-, cyclohexyl etc. 25 Preferred heteroaryl residues are five or six-membered rings, comprising 1 to 3 heteroatoms selected from the group N, 0 and S, wherein a heteroaryl ring preferably comprise only one 0 or S atom. Preferred heteroaryl groups are 2 thiophenyl, 3-thiophenyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 2-pyrazinyl, 3 30 pyridazinyl, 4-pyridazinyl, 3-pyrazolyl, 4-pyrazolyl, 2-imidazolyl, 4-imidazolyl, 2 thiazolyl, 4-thiazolyl, 5-thiazolyl, 3-isothiazolyl, 4-isothiazolyl, 5-isothiazolyl, wherein particularly preferred are 2-pyridyl, 3-pyridyl and 4-pyridyl.
    WO 2013/037415 PCT/EP2011/066061 36 Preferred heteroaryl residues for the group A are unsubstituted or substituted pyridine-2-yl, pyridine-3-yl, pyridine-4-yl, thiophen-2-yl and thiophen-3-yl, particularly preferred are substituted heteroaryl residues. 5 Preferred heteroaryl residues for the group X are unsubstituted or substituted pyridine-2-yl, pyridine-3-yl, pyridine-4-yl, thiophen-2-yl, thiophen-3-yl, thiazol-2-yl, thiazol-4-yl and thiazol-5-yl, particularly preferred are substituted heteroaryl residues. 10 Preferred heteroaryl residues for R5 are unsubstituted or substituted pyridine-2-yl, pyridine-3-yl, pyridine-4-yl, thiophen-2-yl, thiophen-3-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, pyrazol-3-yl, pyrazol-4-yl, imidazol-2-yl, imidazol-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyridazin-3 15 yl, pyridazin-4-yl, pyrazin-2-yl and payrazin-3-yl. The heteroaryl residues may unsubstituted or substituted with one or two substituents. Preferred substituents of the heteroaryl residues are F, Cl, Br, methoxy, ethoxy, methyl, ethyl, NC-, CF 3 0-, CF 3 . 20 A preferred aryl residue is phenyl, wherein one or two hydrogen may be replaced by substituents, preferably selected from the group F, Cl, methoxy, ethoxy, methyl, ethyl, NC-, CF 3 0-, CF 3 , CH 3
    -SO
    2 25 Preferred aliphatic heterocycle are selected from the group of morpholinyl, piperidinyl, pyrrolidinyl, oxetanyl and tetrahydrofuranyl and tetrahydropyranyl, wherein these aliphatic heterocycle may be optionally substituted with 1 or 2 substituents preferably selected independently from the group of F, OH, methoxy, ethoxy, methyl and ethyl. 30 If a radical is disubstituted or trisubstituted, the substituents may be identical or different.
    WO 2013/037415 PCT/EP2011/066061 37 If the compounds of the formula I comprise one or more basic groups or one or more basic heterocycles, the invention also includes the corresponding physiologically acceptable salts including trifluoroacetates, in particular the 5 pharmaceutically acceptable salts. Thus, the compounds of the formula I which have one or more basic, i.e. protonatable, groups or comprise one or more basic heterocyclic rings, can also be used in the form of their physiologically tolerated acid addition salts with inorganic or organic acids, for example as hydrochlorides, phosphates, sulfates, methanesulfonates, acetates, lactates, maleates, fumarates, 10 malates, gluconates etc. Salts can be obtained from compounds of the formula I by conventional processes, for example by combining with an acid in a solvent or dispersant or else by anion exchange from other salts. The compounds of the formula I may also be deprotonated on an acidic group and be used for example as alkali metal salts, preferably sodium or potassium salts, or as ammonium salts, for 15 example as salts with ammonia or organic amines or amino acids. The compounds of the formula I may exist in stereoisomeric forms. The centers of asymmetry which are present may independently of one another have the S configuration or the R configuration. The invention includes all possible 20 stereoisomers, for example enantiomers or diastereomers, and mixtures of two or more stereoisomeric forms, for example enantiomers and/or diastereomers, in any ratios. The invention thus includes for example enantiomers in enantiopure form, both as levorotatory and as dextrorotatory antipodes, and in the form of mixtures of the two enantiomers in various ratios or in the form of racemates. Individual 25 stereoisomers can be prepared as desired by fractionating a mixture by conventional methods or for example by stereoselective synthesis. For the preparation of the compounds of formula I the following methods can be used. 30 WO 2013/037415 PCT/EP2011/066061 38 In the described various chemical processes, the residues A, X, R1, R2, R3, R4, R5, R6 and R7 have the same meaning as in compounds of the formula I, provided that no specific definition of the respective residue is mentioned. 5 The preparation of diverse 4,5,6,7-Tetrahydro-1 H-pyrazolo[4,3-c]pyridine intermediates can be done according to Scheme 1 (method A) following a previously described synthesis (EP 0 086 422 A2). The synthesis is applicable to a large variety of different groups A. Thus, starting from commercially available 1 -acetyl-4 piperidone 1-(4-Morpholin-4-yl-3,6-dihydro-2H-pyridin-1-yl)-ethanone (enamine 1) is 10 obtained. Thus, morpholine is added to a solution of 1-acetyl-4-piperidone in the presence of p-toluenesulfonic acid monohydrate (catalytic PTSA). After acylation with commercially available acyl chlorides, followed by acidic aqueous hydrolysis the diketones 2 are obtained and can be subjected to ring-closure with hydrazine hydrate to give the corresponding diverse 4,5,6,7-Tetrahydro-1 H-pyrazolo[4,3 15 c]pyridine intermediates 3.
    WO 2013/037415 PCT/EP2011/066061 39 Method A 0 0 0 HN N N N 0 01 CI 0 A
    HCI/H
    2 0 H 0 NN N
    N
    2
    H
    4 N 0 - N / -a o A 0 A 3 2 Method B 0 1) LiHMDS 0 N 00 N 0 2) ), Y 4 ,J AOO 0 2 A 0 N 2
    H
    4 A-COOH H N N /N 0 A 3 Scheme 1 WO 2013/037415 PCT/EP2011/066061 40 The acyl chlorides can alternatively be prepared by standard procedures from the corresponding acids e.g. by reaction with thionyl chloride in the presence of catalytic amounts of DMF (see for example Dalisay, D. S.; Quach, T.; Nicholas, G. N.; 5 Molinski, T. F., Angewandte Chemie, International Edition, 2009, vol. 48, 4367 4371). If A is a heteroaryl than sometimes an alternative synthesis is preferable and can be used as shown in Scheme 1 (method B). Thus starting from commercially available acids the mixed anhydrides are formed by reaction with isobutylchloroformate. 1-Acetyl-4-piperidone 1-(4-Morpholin-4-yl-3,6-dihydro-2H 10 pyridin-1-yl)-ethanone can be deprotonated with strong bases like lithium hexamethyldisilazide and reacted with the mixed anhydride described above. The diketones 2 are obtained and can be subjected to ring-closure with hydrazine hydrate to give the corresponding diverse 4,5,6,7-Tetrahydro-1 H-pyrazolo[4,3 c]pyridine intermediates 3. 15 R3 0 R3 0 AcCI HN N R4 04 R4 HO H LDA, c I o R3 N R3 0 NN
    N
    2
    H
    4 , C 2
    H
    5 OH N N O 0 R4 A 0 R4 A 5 Scheme 2 WO 2013/037415 PCT/EP2011/066061 41 R3,R4 substituted intermediates 5 can be accorded similarly as shown in Scheme 2. Thus after acetylation of commercially available or known piperidones N-Acetyl piperidones 4 are obtained. They can be deprotonated with strong bases like lithium 5 diisopropylamide (LDA) and reacted with mixed anhydrides formed by reaction of aryl or heteroarylcarbonic acids and isobutylchloroformate as described above. The diketones obtained can be subjected to ring-closure with hydrazine hydrate to give the corresponding R3, R4 substituted 4,5,6,7-Tetrahydro-1 H-pyrazolo[4,3-c]pyridine intermediates 5. 10 4,5,6,7-Tetrahydro-1 H-pyrazolo[4,3-c]pyridine intermediates can be successfully alkylated with a range of different aryl- and heteroaryl halogenides by heating in the presence of an excess amount of a base like K 2 C0 3 in an inert solvent like CH 3 CN as shown in Scheme 3. The corresponding substituted 4,5,6,7-Tetrahydro-1 H 15 pyrazolo[4,3-c]pyridine intermediates 6 were found to be TASK-1 blockers. H R2 N 3X R N N X+K2CO 3 , CH 3 CN 3 N + Hal R2 N o R4 A o R4 A 3/ 5 6 Scheme 3 WO 2013/037415 PCT/EP2011/066061 42 R3 LiHMDS R3 0 0 N 0 , N 0 0 R4 A-COOH r o cl 0 R4 A R2 X HN EtOH
    NH
    2 R2 X R2 R3 N HCI R3 N HN N _ __ _ _ 0 N / R4 A 0 R4 A 7 Scheme 4 In a different approach (Scheme 4), starting from Boc-protected piperidones, the 5 diketones obtained after deprotonation by a strong base like lithium diisopropylamide and reaction with diverse acyl chlorides can be reacted with substituted benzylhydrazines and subsequently deprotected to give compounds 7 which are intermediates in the synthesis of TASK-1 blockers. 10 The group R1 of compounds of formula I can be varied synthetically as shown in Scheme 5. The N-acetyl group can be cleaved by heating an acidic aqueous solution of compounds 6, for example in a mixture of ethanol and 2N aqueous HCI. The corresponding amines 7 can be modified in a variety of ways, for example by acylation as shown in Scheme 6. This can be done by several methods: for example 15 by reaction with carboxylic acids in the presence of 1 -hydroxybenzotriazole and EDC (1 -ethyl-3-(3-dimethylaminopropyl)carbodiim ide hydrochloride) (Nozaki, S. J. Peptide Res. 1999, 54, 162) (method A) or TOTU (0-[(Ethoxycarbonyl) cyanomethylenamino]-N, N, N', N'-tetramethyluronium tetrafluoroborate) (Knorr, R. et al. Tetrahedron Lett. 1989, 30, 1927) (method D), by reaction with acyl chlorides or WO 2013/037415 PCT/EP2011/066061 43 alkyl chloroformates in the presence of K 2 C0 3 in CH 3 CN (method B), in a "Schotten Baumann" reaction type by reaction with acyl chlorides in a water-ethyl acetate mixture in the presence of NaHCO 3 (method C), by reaction with acyl chlorides in the presence of triethylamine in CH 2
    CI
    2 (method E), or by reaction with acetic 5 anhydride in pyridine (method F). The group R5 may carry protecting groups which can be cleaved off by methods known in the prior art. For example a hydroxyl group in R5 can be protected as a tert-butylether which can be cleaved off by an acid like HCI to give deprotected compounds 14 (Scheme 11). Of course the reaction is broadly applicable and not limited to the exact structure shown in Scheme 11. 10 R2 R2 R3 N R3 N N -N HN N o R4 A R4 A 6 7 Scheme 5 WO 2013/037415 PCT/EP2011/066061 44 R2 R2 X R5 OH x R3 N A: EDAC, HOBt R3 N HN N R5 CI ,5__ _N R5 N R4 A B: K 2 C0 3 0 R4 A 0 7 R5 CI 8 C: R5 NaHCO 3 0 R5 OH D: TOTU 0 E: R5 Cl N(C2H5)3 0 F: R5 0 R5 N(C 2
    H
    5
    )
    3 (R5 = CH 3 ) o 0 Scheme 6 R2 R2 x ,0 R3 N R3 N H NN alkyl Cl alkyl N -- S Q0 \ R4 A O R4 A 5 7 9 Scheme 7 Alternatively TASK-1 blockers 8 can be obtained by sulfonylation with alkylsulfonyl halogenides ((C 1
    -C
    6 )-alkyl-SO 2 -) in inert solvents like CH 2
    CI
    2 in the presence of a 10 base like triethylamine as shown in Scheme 7.
    WO 2013/037415 PCT/EP2011/066061 45 R2 x R2 R3 N R6-NCO R3 N H NN N R4 A 0 R4 A 7 11 Scheme 8 In another reaction (Scheme 8), reaction of intermediates 7 with diverse isocyanates 5 in an inert solvent for example CH 2
    CI
    2 leads to formation of ureas 11 which have been found to be TASK-1 blockers. R2 R2 0 ciR X 0+ 0 R3 N R3 N N N H N I
    --
    4 0, ~a 0R4 A R4 A N I I 0 7 R6R7NH R2 X R3 N R7 R6 N 0 R4 A 12 Scheme 9 10 In another reaction (Scheme 9), reaction of intermediates 7 with 4 nitrophenylchloroformate leads to intermediates with can be reacted with diverse WO 2013/037415 PCT/EP2011/066061 46 amines to give ureas 12 which have been found to be TASK-1 blockers and are novel compounds not described before. R2 R2 R3 N R3 N Zn(CN) 2 N -N __ _ _ _ _ _ _NN cat. Pd(0) O R4 0 R4 N 6 Br 13 CN 5 Scheme 10 The aryl or heteroaryl ring A can be modified when substituted by a bromide to give the corresponding nitriles as shown in Scheme 10 by reaction with Zn(CN) 2 in the presence of a catalytic amount of tetrakis(triphenylphosphine)palladium (0) (in 10 analogy to Alterman, M.; Anders, H. Journal of Organic Chemistry, 2000, vol. 65, 23 p. 7984 - 7989). The reaction is not limited to pyridines as drawn in Scheme 10 but is applicable to a range of aryl and heteroaryl systems. The novel compounds 13 which have not been previously described have been found to be TASK-1 blockers. R2 R2 R3 N HCI R3 N 0 N HO N 0 R4 A 0 R4 A 15 8 14 Scheme 11 WO 2013/037415 PCT/EP2011/066061 47 A tert-butylether 8 can be cleaved off by an acid like HCI to give deprotected compounds 14 (Scheme 11). The reaction is broadly applicable and not limited to the exact structure shown in Scheme 11. 5 The working up and, if desired, the purification of the products and/or intermediates takes place by conventional methods such as extraction, chromatography or crystallization and conventional dryings. Owing to the TASK-1 -inhibitory properties, the compounds of the formula I and/or 10 their pharmaceutically compatible salts are suitable for the prevention and treatment of disorders which are caused by activation or by an activated TASK-1, and also of disorders in which have TASK-1 - related damages appear secondary to another, primary cause. 15 The compounds of the formula I, and/or physiologically compatible salts thereof can also be used for the treatment and prevention of disorders where TASK-1 requires only partial inhibition, for example by using a lower dosage, wherein for the treatment and prevention of disorders described below the compounds of formula I includes 20 compounds wherein R5 is methyl and R2, R3 and R4 are equal to H and A is equal to 4-fluoro-phenyl, and the residue X is phenyl, 4-fluoro-phenyl, 4-chloro phenyl, 4-methyl-phenyl, 4-methoxy-phenyl, 4-acetoxyphenyl, 2-chloro-phenyl, 3,4 dichlorophenyl, and compounds wherein R5 is methyl and R2, R3 and R4 are equal to H and X is 25 a phenyl residue, and the residue A is phenyl, 4-fluoro-phenyl, 4-chloro-phenyl, 4 methyl-phenyl, 4-ethyloxy-phenyl, 3-trifluoromethyl-phenyl, 2-thiophenyl or 4 methylthiophenyl, and compounds wherein R5 is methyl and R2 is methyl and R3 and R4 are equal to H and A is equal to 4-fluoro-phenyl and the residue X is phenyl. 30 These compounds can be employed to produce medicaments with a TASK-1 channel-blocking effect for the therapy and prophylaxis of TASK-1 channel- WO 2013/037415 PCT/EP2011/066061 48 mediated diseases. The compounds of the formula I and/or their pharmaceutically acceptable salts can further be used for the therapy or prophylaxis of cardiac arrhythmias, e.g. of arrhythmias that respond to the changes in the shape of the action potential, mainly a prolongation of the action potential, which is induced by 5 TASK-1 blockade. The compounds of the formula I and/or their pharmaceutically acceptable salts can be employed for terminating existent atrial fibrillation or flutter to restore the sinus rhythm (cardioversion). In addition, the compounds reduce the susceptibility for a 10 new development of atrial fibrillation events, thus the compounds are suitable for prophylactic treatment by maintenance of sinus rhythm (rhythm control). The substances are devoid of a ventricular proarrhythmic risk (prolongation of the QT interval and Torsades de pointe arrhythmias). 15 The compounds of the formula I and/or their pharmaceutically acceptable salts can be employed for producing a medicament for the treatment and/or prevention of arrhythmias, particularly atrial trachyarrhythmias, atrial fibrillation and atrial flutter The compounds of the formula I and/or their pharmaceutically acceptable salts are 20 further suitable for producing a medicament for the therapy or prophylaxis of sleep related respiratory disorders, central and obstructive sleep apneas, upper airway resistance syndrome, Cheyne-Stokes respiration, snoring, disrupted central respiratory drive, sudden child death, postoperative hypoxia and apnea, muscle related respiratory disorders, respiratory disorders after long-term mechanical 25 ventilation (weaning), respiratory disorders during adaptation in high mountains, acute and for respiratory disorders, chronic lung disorders with hypoxia and hypercapnia, chronic obstructive pulmonary disease (COPD) and obesity hypoventilation syndrome. 30 The compounds of the formula I and/or their pharmaceutically acceptable salts are WO 2013/037415 PCT/EP2011/066061 49 further suitable as a respiratory stimulant for the prevention and treatment of respiratory depression associated with anesthesia or procedural sedations for small interventions or for diagnostic purposes, for the treatment and prevention of respiratory depression by opioids in chronic pain treatment e.g. in cancer or 5 palliative care or procedural sedations and/or for weaning from longterm mechanical ventilation. The compounds of the formula I and/or their pharmaceutically acceptable salts are further suitable for the treatment and/or prevention of multiple sclerosis and 10 inflammatory and degenerative disorders of the central nervous system. The compounds of the invention of the formula I and their pharmaceutically acceptable salts can thus be used on animals, preferably on mammals, and in particular on humans, as pharmaceuticals on their own, in mixtures with one another 15 or in the form of pharmaceutical preparations (pharmaceutical compositions). Thus, a further embodiment of the present invention is a pharmaceutical preparation comprising an effective amount of a compound of the formula I and/or of its pharmaceutically acceptable salts, together with pharmaceutically acceptable 20 carriers and additives, alone or in combination with other pharmacological active ingredients or pharmaceuticals. The pharmaceutical preparations usually comprise from 0.1 to 90 percent by weight of the compounds of the formula I and/or their pharmaceutically acceptable salts. The pharmaceutical preparations can be produced in a manner known per se. For this purpose, the compounds of the 25 formula I and/or their pharmaceutically acceptable salts are converted together with one or more solid or liquid pharmaceutical vehicles and/or excipients and, if desired, in combination with other pharmaceutical active ingredients into a suitable dosage form, which can then be used as pharmaceutical in human medicine or veterinary medicine. 30 Pharmaceuticals which comprise a compound of the formula I and/or its pharmaceutically acceptable salts can moreover be administered for example orally, WO 2013/037415 PCT/EP2011/066061 50 intravenously, intramuscular, subcutaneously, nasally, topically, pharyngeally or by inhalation, and the preferred administration depends on the individual case, for example on the particular manifestation of the disorder. The compounds of the formula I can moreover be used alone or together with pharmaceutical excipients, in 5 particular both in veterinary and in human medicine. The pharmaceuticals comprise active ingredients of the formula I and/or their pharmaceutically acceptable salts generally in an amount of from 0.01 mg to 1 g per dose unit. The skilled worker is familiar on the basis of his expert knowledge with which 10 excipients are suitable for the desired pharmaceutical formulation. Besides solvents, gel formers, suppository bases, tablet excipients and other active substance carriers it is possible to use for example antioxidants, dispersants, emulsifiers, antifoams, masking flavors, preservatives, solubilizers, agents for achieving a depot effect, buffer substances or colorants. 15 For a form for oral use, the active compounds are mixed with the additives suitable for this purpose, such as carriers, stabilizers or inert diluents, and converted by conventional methods into suitable presentations such as tablets, coated tablets, two-piece capsules, aqueous, alcoholic or oily solutions. Examples of inert carriers 20 which can be used are gum arabic, magnesia, magnesium carbonate, potassium phosphate, lactose, glucose or starch, especially corn starch. Preparation can take place both as dry and as wet granules. Suitable as oily carriers or as solvents are, for example, vegetable or animal oils such as sunflower oil or fish liver oil. Suitable solvents for aqueous or alcoholic solutions are, for example, water, ethanol or sugar 25 solutions or mixtures thereof. Examples of further excipients, also for other administration forms, are polyethylene glycols and polypropylene glycols. For subcutaneous, intramuscular or intravenous administration, the active compounds are converted if desired with the substances usual for this purpose, 30 such as solubilizers, emulsifiers or further excipients, into a solution, suspension or emulsion. The compounds of the formula I and/or their pharmaceutically acceptable WO 2013/037415 PCT/EP2011/066061 51 salts may also be lyophilized and the resulting lyophilizates be used, for example, for producing products for injection or infusion. Examples of suitable solvents are: water, physiological saline or alcohols, for example ethanol, propanol, glycerol, as well as sugar solutions such as glucose or mannitol solutions, or else mixtures of 5 the various solvents mentioned. Suitable as pharmaceutical formulation for administration in the form of aerosols or sprays are, for example, solutions, suspensions or emulsions of the active ingredient of the formula I or their pharmaceutically acceptable salts in a 10 pharmaceutically acceptable solvent, such as in particular ethanol or water, or a mixture of such solvents. The formulation may if required also comprise other pharmaceutical excipients such as surfactants, emulsifiers and stabilizers, and a propellant gas. Such a preparation comprises the active ingredient normally in a concentration of about 0.1 to 10, in particular of about 0.3 to 3 percent by weight. 15 The dosage of the active ingredient to be administered or of the pharmaceutically acceptable salts thereof depends on the individual case and should be adapted to the circumstances of the individual case as usual for an optimal effect. Thus, it naturally depends on the frequency of administration and on the potency and 20 duration of action of the particular compounds employed for therapy or prophylaxis, but also on the type and severity of the disease to be treated, and on the gender, age, weight and individual response of the human or animal to be treated, and on whether therapy is acute or prophylactic. 25 The daily dose of a compound of the formula I and/or its pharmaceutically acceptable salts for a patient weighing about 75 kg is normally at least 0.001 mg/kg to 100 mg/kg of body weight, preferably 0.01 mg/kg to 20 mg/kg. Even higher dosages may also be necessary for acute episodes of the disease, for example in an intensive care unit. Up to 800 mg per day may be necessary. The dose may be 30 in the form of a single dose or be divided into a plurality, for example two, three or four, single doses. Parenteral administration by injection or infusion, for example a continuous intravenous infusion, may also be advantageous, especially in the WO 2013/037415 PCT/EP2011/066061 52 treatment of acute cases of cardiac arrhythmias, for example in an intensive care unit. 5 Examples The following examples illustrate the various embodiments of the present invention and are part of the present invention. 10 1-(4-Morpholin-4-yl-3,6-dihydro-2H-pyridin-1 -yl)-ethanone (1) 0 N N 0 According to Scheme 1, step 1: a mixture of morpholine (67.85 g, 0.779 mol), 1 acetyl-4-piperidone (99.95 g, 0.708 mol) and para-toluenesulfonic acid (0.366 g, 2.1 15 mmol) in toluene (300 ml) was heated in a Dean-Stark trap apparatus for 16 h at reflux. Solvents were evaporated in vacuo to give 149 g of 1-(4-Morpholin-4-yl-3,6 dihydro-2H-pyridin-1 -yl)-ethanone (1) which was used in the next step without any further purification. 20 3-(5-Acetyl-4,5,6,7-tetrahydro-1 H-pyrazolo[4,3-c]pyridin-3-yl)-benzonitrile (3a) H N N / N 0
    -N
    WO 2013/037415 PCT/EP2011/066061 53 According to Scheme 1, method A: steps 2-3: to a solution of 1-(4-Morpholin-4-yl 3,6-dihydro-2H-pyridin-1-yl)-ethanone (1) (6.35 g, 30.2 mmol) in dry dichloromethane (30 ml) at 0 C was added triethylamine (3.056 g, 30.2 mmol) and after stirring the solution at 0C for 10 min, 3-cyanobenzoyl chloride (5 g, 30.2 5 mmol) was added. The mixture was stirred for 45 min at 0C then the mixture was allowed to warm to room temeperature and stirred overnight. 5% aqueous HCI was added and the mixture was stirred for 2 h. The mixture was extracted with dichloromethane and the organic layer was washed with water, filtered over a short pad of silica gel and evaporated to dryness to give 8 g of 3-(1 -Acetyl-4-oxo 10 piperidine-3-carbonyl)-benzonitrile (2a) which was used immediately in the next step without purification. To a mixture of 3-(1-Acetyl-4-oxo-piperidine-3-carbonyl)-benzonitrile (2a) (8 g, 29.6 mmol) in ethanol (26 ml) at 10 C hydrazine hydrate (4.44 g, 88.8 mmol) was added slowly within 5 min. The mixture was stirred 3 h and allowed to warm to room 15 temperature overnight. The mixture was concentrated to % of its volume until a precipitate formed. The suspension was stirred for 2 h, cooled down and filtrated. The solid was washed with a small amount of ethanol. A second portion of product precipitated overnight from the filtrate and was pooled with the first portion of solid to give 4.02 g of 3-(5-Acetyl-4,5,6,7-tetrahydro-1 H-pyrazolo[4,3-c]pyridin-3-yl) 20 benzonitrile (3a) as a solid. Ri = 1.20 min (LC-method 7). Detected mass: 267.15 [M+H*] 1 -[3-(4-Trifluorom ethyl-pyrid in-2-yl)-1, 4,6,7-tetrahydro-pyrazolo[4,3-c]pyrid in-5-yl] ethanone (3m) 25 H N N /N O N F 0 N IF F
    F
    WO 2013/037415 PCT/EP2011/066061 54 According to Scheme 1, method B: to a solution of 4-(trifluoromethyl)-2 pyridinecarboxylic acid (0.42 g, 1.54 mmol) in dry tetrahydrofuran was added N methylmorpholine (163 mg, 1.62 mmol) and isobutylchloroformate (221 mg, 1.62 mmol) and the mixture was stirred for 30 min at room temperature and the solid was 5 filtered off. The filtrate was used in the subsequent reaction. To a solution of 1-acetyl-4-piperidone (0.207g, 1.466 mmol) in tetrahydrofuran at 0 C was added dropwise 1 M lithium bis(trimethyldisilazide) in tetrahydrofuran (1.54 mmol, 1.54 ml) and the mixture was stirred for 15 min at 0C, then the mixture was cooled down to -780C. The mixed anhydride solution generated above was added to 10 this mixture at -780C, the mixture was allowed to warm to room temperature and stirred for 90 min. To this mixture at 10 C was added ethanol (5 ml) and hydrazine hydrate (0.603 g, 7.72 mmol) and the mixture was stirred 16 h at room temperature. The mixture was concentrated and after addition of CH 2 Cl 2 and aqueous NaHCO 3 the mixture was extracted 3 times with CH 2 Cl 2 , the combined organic layers were 15 washed with brine, dried over NaCI, filtrated and the filtrate was evaporated to dryness to give 323 mg of 1 -[3-(4-Trifluoromethyl-pyridin-2-yl)-1, 4,6,7-tetrahydro pyrazolo[4,3-c]pyridin-5-yl]-ethanone (3m). The product was used crude in the next reaction steps without further purification. Ri = 1.61 min (LC-method 1). Detected mass: 311.18 [M+H*] 20 The examples in the following table were obtained according to Scheme 1, Method A or Method B as specified, from the specified starting compound (SC) (by following a similar procedure as used for the synthesis of (3a); in part the compounds were purified by reverse phase HPLC (CH 3 CN / water gradient with 0,1 % trifluoroacetic 25 acid).
    WO 2013/037415 PCT/EP2011/066061 55 Ri/ [min] Cm.Starting (C No. Product Chemical Name (LC (Mth' Comp. Meth.) [M+H*] H N 1-[3-(4-Fluoro 4-fluoro- N N phenyl)-1,4,6,7 2.32 3b (A) benzoyl tetrahydro- (8) chloride pyrazolo[4,3- 260.12 c]pyridin-5-yl] F ethanone 6-(tri- 1-[3-(6-Trifluoro H fluoro- N methyl-pyridin methyl)- N /N 2-yl)-1,4,6,7- 1.10 3c (A) pyridine N tetrahydro- (4) -2- ONpyrazolo[4,3- 311.2 carbonyl CF 3 c]pyridin-5-yl] chloride ethanone H 1-[3-(3-Trifluoro 3- N methyl-phenyl) Trifluoro N 1.12 N N 1,4,6,7-tetra 3d (A) methyl- (4) benzoyl 0 hydro-pyrazolo 310.11 [4,3-c]pyridin-5 yl]-ethanone 1-[3-(3 H Trifluoromethox N y-phenyl) 3 N Trifluoro N 3.60 3e (A) methoxy- 1,4,6,7- (2) benzoyl tetrahydro- 326.16 0 pyrazolo[4,3 chlorideI
    CF
    3 c]pyridin-5-yl] ethanone WO 2013/037415 PCT/EP2011/066061 56 Ri/ [min] Cm.Starting (C No. Product Chemical Name (LC (Mth' Comp. Meth.) [M+H*] H 1-[3-(3-Chloro N N Nphenyl)-1,4,6,7 3-chloro- N / erhdo 0.94 N tetrahydro 3f (A) benzoyl (4) chloride 0 275.08 I c]pyridin-5-yl] CI ethanone H 1-[3-(2-Fluoro-5 N 2-Fluoro N Nmethoxy -5- N / phenyl)-1,4,6,7- 2.97 3g (A) methoxy- tetrahydro- (2) benzoyl F / pyrazolo[4,3- 290.15 chloride 0 c]pyridin-5-yl] ethanone H 1-[3-(3 Ns Methoxy 3- N N / phenyl)-1,4,6,7- 0.99 methoxy 3h (A) tetrahydro- (4) benzoyl 0 pyrazolo[4,3- 272.5 chloride 0 1 c]pyridin-5-yl] ethanone H N 1-[3-(4-Fluoro-3 4-Fluoro /N methoxy -3- phenyl)-1,4,6,7- 1.02 3i (A) methoxy- 0 tetrahydro- (4) benzoyl 0 pyrazolo[4,3- 290.2 chloride F c]pyridin-5-yl] ethanone WO 2013/037415 PCT/EP2011/066061 57 Ri/ [min] Cm.Starting (C No. Product Chemical Name (LC (Mth' Comp. Meth.) [M+H*] H N 5-(5-Acetyl N 4,5,6,7 4-Fluoro- N /N 3-cyano- tetrahydro-1 H- 1.01 3j (A) benzoyl 0 pyrazolo[4,3- (4) chloride CN c]pyridin-3-yl)-2- 285.1 fluoro F benzonitrile H 1-[3-(3-Fluoro N 3-Fluoro- N /N phenyl)-1,4,6,7- 1.47 tetrahydro 3k (A) benzoyl pyrazolo[4,3- (9) chloride O/ 260.16 c]pyridin-5-yl] IF -ethanone H 1-[3-(4 N Trifluoromethyl 4- N N / phenyl)-1,4 1.00 3( t l-oo 0,6,7-tetrahydro 31 (A) methyl- 0 przl[3- (4) benzoyl pyr 309.9 chloride
    CF
    3 din-5-yl] ethanone WO 2013/037415 PCT/EP2011/066061 58 Ri/ [min] Cm.Starting (C No. Product Chemical Name (LC (Mth' Comp. Meth.) [M+H*] H 1-[3-(4-Bromo N 4-Bromo- pyridin-2-yl) N pyridine- N / 1,4,6,7- 0.91 3n (B) 2- tetrahydro- (1) o N carbonyl pyrazolo[4,3- 321.09 chloride c]pyridin-5-yl] Br ethanone H 1-[3-(2-Bromo N S Npyridin-4-yl) 2-B rom o-N N N 1,4,6,7- 0.81 iso 30 (B) io tetrahydro- (1) nicotinoyl O chloride pyrazolo[4,3- 321.06 N c]pyridin-5-yl] Br ethanone H 1-[3-(5-Bromo N pyridin-3-yl) 5-Bromo- N/ N 1,4,6,7- 0.96 3p (B) nicotinoyl tetrahydro- (4) 0 chloride pyrazolo[4,3- 321.12 N c]pyridin-5-yl] Br ethanone WO 2013/037415 PCT/EP2011/066061 59 Ri/ [min] Cm.Starting(LC No. Product Chemical Name (LC (Mth' Comp. Meth.) [M+H*] N 1-(3-m-Tolyl 3-Methyl- N/ 1,4,6,7- 0.92 3q (A) benzoyl tetrahydro- (1) chloride py [, 256.18 c]pyridin-5-yl) ethanone H 1-[3-(6-Methyl 6-Methyl- N pyridin-2-yl) N pyridine- N / 1,4,6,7- 0.74 3r (B) 2- tetrahydro- (1) carbonyl N / pyrazolo[4,3- 257.11 chloride c]pyridin-5-yl] ethanone H 1-[3-(6-Bromo 6-Bromo- NN pyridin-2-yl) pyridine N N 1,4,6,7- 1.06 3s (A) -2- tetrahydro- (4) carbonyl N / pyrazolo[4,3- 321.1 chloride c]pyridin-5-yl] Br ethanone H 1-[3-(4-Methyl 4-Methyl- N 4 -M et h yI N p y rid in -2 -y l) pyridine N nd N /1,4,6,7 3t (B) -2- t (nd) carbonyl N / nd 'N pyrazolo[4,3 chloride c]pyridin-5-yl]- WO 2013/037415 PCT/EP2011/066061 60 Ri/ [min] Cm.Starting(LC No. Product Chemical Name (LC (Mth' Comp. Meth.) [M+H*] ethanone 6- H 6- N 1-[3-(6-Meth Methoxy- N N oxy-pyridin-2 N0. pyridine yl)- 1,4,6,7-tetra 3u (A) (1) -2- 0 hydro-pyrazolo N 273.15 carbonyl [4,3-c]pyridin-5 chloride yl]-ethanone 6-Chloro H 1-[3-(6-Chloro N -5- N 5-methoxy N methoxy- N N pyridin-2-yl)- 1.02 3v (A) pyridine 1,4,6,7-tetra- (4) -2- N hydro-pyrazolo 307.1 carbonyl CI [4,3-c]pyridin-5 chloride yl]-ethanone H 1-[3-(3-Methyl 3-Methyl- N I N pyridin-2-yl) pyridine Nnd 3w pri N / 1,4,6,7-tetra -2- (nd) (B) hydro-pyrazolo carbonyl N / y nd chloride [4,3-c]pyridin-5 yl]-ethanone 4- 1-[3-(4 Methoxy- N /N Methoxy- 0.55 pyridine pyridin-2-yl) -2- 0 1,4,6,7-tetra carbonyl N / hydro-pyrazolo 273.16 chloride [4,3-c]pyridin-5- WO 2013/037415 PCT/EP2011/066061 61 Ri/ [min] Cm.Starting (C No. Product Chemical Name (LC (Mth' Comp. Meth.) [M+H*] yl]-ethanone H 1-(3-Thiophen Thio- N N 2-yl-1,4,6,7 N 30.94 phene-2- N tetrahydro carbonyl pyrazolo[4,3 caOoyl/ 248.08 chloride / c]pyridin-5-yl) ethanone H 1-[3-(5-Chloro 5-Chloro- N N thiophen-2-yl) 1,4,6,7-tetra 3z (A) phene-2- (4) o s hydro-pyrazolo carbonyl 282.02 chrbnylor[4,3-c]pyridin-5 chloride CI yl]-ethanone H 1-(3-Thiophen Thio- N 3-yl-1,4,6,7 N 0.93 3aa phene-3- N / tetrahydro (4) (A) carbonyl pyrazolo[4,3 0 248.05 chloride c]pyridin-5-yl) S ethanone 8-Acetyl-8-aza-bicyclo[3.2.1 ]octan-3-one (4a) 0
    N
    WO 2013/037415 PCT/EP2011/066061 62 According to Scheme 2, Step 1: A suspension of nortropinone hydrochloride (1 g, 6.187 mmol) in acetic anhydride was stirred at 70C for 3h. Water was added, the mixture was boiled for 30 min and cooled down to room temperature. CH 2 Cl 2 and 1 N aqueous NaOH was added until 5 pH 9 was reached. The mixture was extracted 2 times with CH 2 Cl 2 , the combined organic layers were dried over Na 2
    SO
    4 , filtrated and the solution was evaporated to dryness to give 0.7 g of 8-Acetyl-8-aza-bicyclo[3.2.1]octan-3-one (4a). Ri = 1.76 min (LC-method 2). Detected mass: 168.24 [M+H*] 10 1-(3-Phenyl-4,5, 11 -triaza-tricyclo[6.2. 1.0*2,6*]undeca-2(6),3-dien-1 1 -yl)-ethanone (5a) H N N /N N According to Scheme 2, Steps 2+3: To a mixture of 8-Acetyl-8-aza-bicyclo[3.2.1]octan-3-one (4a) (350 mg, 2.1 mmol) in 15 dry tetrahydrofuran at 0C was added 1 N lithium hexamethyldisilazide (2.2 ml, 2.2 mmol) and after 5 min the mixture was cooled to -78C . To a solution of 3-cyanobenzoic acid (323 mg, 2.2 mmol) and N-methyl-morpholine (232 mg, 2.3 mmol) in tetrahydrofuran was added isobutylchloroformate (300 mg, 2.2 mmol). The mixture was stirred for 5 min at 250C, filtrated and washed with dry 20 tetrahydrofuran. This solution was added dropwise to the -780C mixture above and the mixture was then allowed to warm to 250C for 1 h. Solvents were evaporated,
    CH
    2 Cl 2 and water were added, the organic layer was dried over Na 2
    SO
    4 , filtrated and the solution was evaporated to dryness, redissolved in ethanol (10 ml). Hydrazine hydrate (245 mg, 3.14 mmol) was added and the solution was stirred for 25 30 min. Solvents were evaporated and the crude product was purified by silica gel chromatography (dichloromethane/methanol 100/0 to 70/30) to give 45 mg of 1-(3 Phenyl-4,5, 11 -triaza-tricyclo[6.2.1.0*2,6*]undeca-2(6),3-dien-1 1 -yl)-ethanone (5a).
    WO 2013/037415 PCT/EP2011/066061 63 Ri = 1.01 min (LC-method 4). Detected mass: 293.18 [M+H*] 1-[3-(4-Fluoro-phenyl)-4,5,11-triaza-tricyclo[6.2.1.0*2,6*]undeca-2(6),3-dien-1 1-yl] ethanone (5b) H N N" /N 5 F 1-[3-(4-Fluoro-phenyl)-4,5, 11 -triaza-tricyclo[6.2. 1. 0*2,6*]undeca-2(6),3-dien-1 1-yl] ethanone (5b) was obtained by following a similar reaction as used for synthesis of (5a). Ri = 1.06 min (LC-method 4). Detected mass: 286.18 [M+H*] 10 3-[5-Acetyl-1 -(2,4-d ifluoro-benzyl)-4,5,6,7-tetrahydro-1 H-pyrazolo[4,3-c]pyridin-3-yl] benzonitrile (6a) N F NF No 0 N According to Scheme 3: 15 A mixture of 3-(5-Acetyl-4,5,6,7-tetrahydro-1 H-pyrazolo[4,3-c]pyridin-3-yl) benzonitrile (3a) (0.48 g, 1.8 mmol), 2,4-difluorobenzyl bromide (0.41 g, 1.99 mmol) and K 2 C0 3 (498 mg, 3.6 mmol) in 14 ml CH 3 CN was stirred at 80'C for 16 h. A second portion of 2,4-difluorobenzyl bromide (0.41 g, 1.99 mmol) was added and the mixture was stirred for additional 7h. Water was added, the mixture was WO 2013/037415 PCT/EP2011/066061 64 extracted 3 times with ethyl acetate, the combined organic layers were dried over MgSO 4 , filtrated and the solution was evaporated to dryness. The crude product was crystallized from 10 ml 2-propanol and dried in vacuo to give 0.364 g of 3-[5 Acetyl-1 -(2,4-difluoro-benzyl)-4,5,6,7-tetrahydro-1 H-pyrazolo[4,3-c]pyridin-3-yl] 5 benzonitrile (6a). Ri= 1.62 min (LC method 7). Detected mass: 393.15 [M+H*]. The examples in the following table were obtained according to Scheme 4 by following a similar reaction as used for synthesis of (6a). The corresponding 10 halogenides used (Hal-CH 2 -X, particularly the corresponding bromides or chlorides) are obvious to the man skilled in the art and were commercially available. Reaction conditions varied slightly by reaction time (1-3 days), temperature (50-80'C). Products were routinely purified by reverse phase HPLC (CH 3 CN / water gradient with 0,1 % trifluoroacetic acid). 15 Ri/ [min] Comp. SC Product Chemical Name (LC No. Method) [M+H*] a / Cl 1-[1 -(6-Chloro N pyridin-3-ylmethyl) N /N 3-(3-trifluorom ethyl- 1.26 phenyl)-1 4,6,7 0b 3d / F tetrahydro- 4) 435.09 F pyrazolo[4,3 F c]pyridin-5-yl] ethanone WO 2013/037415 PCT/EP2011/066061 65 Ri/ [min] Comp. SC Product Chemical Name (LC No. Method) [M+H*] -N 1-[1-(4-Chloro / pyridin-3-ylmethyl) N 3-(3-trifluorom ethyl N / N Cl phenyl)-1,4,6,7 oc /d tetrahydro- 4 F pyrazolo[4,3 F c]pyridin-5-yl] F ethanone N _ 1-[1 -(3-Methyl pyridin-2-ylmethyl) N 3-(3-trifluoromethyl N / phenyl)-1,4,6,7 6d 3d (2) od 3d F'Y tetrahydro IF pyrazolo[4,3 F c]pyridin-5-yl] F ethanone N 1-[1 -Benzyl-3-(4 N fluoro-phenyl)- 2.29 6e b 'Y N3 1,4,6,7-tetrahydro- (5 6e 3b ,, y(15) pyrazolo[4,3 0 c]pyridin-5-yl] ethanone
    F
    WO 2013/037415 PCT/EP2011/066061 66 Ri/ [min] Comp. SC Product Chemical Name (LC No. Method) [M+H*] F 1-[1-(2,4-Difluoro N, benzyl)-3-(4-fluoro N phenyl)-1,4,6,7- 2.35 6f 3b tetrahydro- (12) pyrazolo[4,3- 386.02 c]pyridin-5-yl] F ethanone 1-[1 -(4-Fluoro N / / F benzyl)-3-(6 N trifluoromethyl- 1.31 6g 3c pyridin-2-yl) o N 1,4,6,7-tetrahydro F pyrazolo[4,3 F c]pyridin-5-yl] ethanone F F 1-[1-(2,4-Difluoro N benzyl)-3-(4 N N trifluoromethyl- 2.02 pyridin-2-yl) 6h 3m O N (9) 1,4,6,7-tetrahydro F pyrazolo[4,3 F c]pyridin-5-yl] F ethanone WO 2013/037415 PCT/EP2011/066061 67 Ri/ [min] Comp. SC Product Chemical Name (LC No. Method) [M+H*] F 1-[1 -(2,4-Difluoro F benzyl)-3-(6 NN trifluoromethyl- 1.3 N / pyridin-2-yl) 6i 3c(4 oi 3 N1,4,6,7-tetrahydro O N 437.15 F pyrazolo[4,3 F F c]pyridin-5-yl] ethanone F 1-[3-(4-Bromo F N pyridin-2-yl)-1-(2,4 N difluoro-benzyl)- 1.2 6j 3n 1,4,6,7-tetrahydro- (1) o N pyrazolo[4,3- 447.1 c]pyridin-5-yl] Br ethanone F 1-[3-(2-Bromo F pyridin-4-yl)-1-(2,4 N difluoro-benzyl)- 1.12 6k 3o N 1,4,6,7-tetrahydro- (1) pyrazolo[4,3- 447.14 0 c]pyridin-5-yl] Br N ethanone WO 2013/037415 PCT/EP2011/066061 68 Ri/ [min] Comp. SC Product Chemical Name (LC No. Method) [M+H*] F 1-[3-(5-Bromo N F pyridin-3-yl)-1-(2,4 N N difluoro-benzyl)- 1.24 6m 3p 1,4,6,7-tetrahydro- (4) o pyrazolo[4,3- 447.2 N c]pyridin-5-yl] Br ethanone F ' ::r 3-[11 -Acetyl-5-(2,4 N difluoro-benzyl) N 4,5,11-triaza 6n 5a N (4) tricyclo[6.2.1.02,6] 419.21 / undeca-2(6),3-dien N 3-yl]-benzonitrile N F 1-[5-(2,4-Difluoro N F benzyl)-3-(4-fluoro N / phenyl)-4,5,11- 1.26 6o 5b 0 triaza-tricyclo (4) [6.2.1.02,6]undeca- 412.17 2(6),3-dien-1 1-yl] F ethanone WO 2013/037415 PCT/EP2011/066061 69 Ri/ [min] Comp. SC Product Chemical Name (LC No. Method) [M+H*] 1-[1-(6-Chloro N C pyridin-3-ylmethyl) N 3-m-tolyl-1,4,6,7- 1.2 6p 3q tetrahydro- (4) o pyrazolo[4,3- 381.12 c]pyridin-5-yl] ethanone 1-[1 -(4-Methoxy N pyridin-2-ylmethyl) N O 3-(3-trifluorom ethyl Nq 3d I phenyl)-1,4,6,7- 325 6q 3d (2) o F tetrahydro- 431.3 F pyrazolo[4,3 F c]pyridin-5-yl] ethanone N 1-[1 -(4-Chloro N pyridin-3-ylmethyl) NO /N Cl 3-m-tolyl-1,4,6,7- 1.16 6r 3q tetrahydro- (4) 0 pyrazolo[4,3- 381.11 c]pyridin-5-yl] ethanone WO 2013/037415 PCT/EP2011/066061 70 Ri/ [min] Comp. SC Product Chemical Name (LC No. Method) [M+H*] N- 1-[1 -(3-Methoxy / pyridin-2-ylmethyl) N 3-(3-trifluoromethyl 6 N phenyl)-1,4,6,7- (2) Os 3d Y tetrahydro- 43. F pyrazolo[4,3 F c]pyridin-5-yl] F ethanone N_ 1-[3-(3-Chloro phenyl)-1 -(3 N methyl-pyridin-2- 1.1 fN ylmethyl)-1,4,6,7 6t 3f (1) o / tetrahydro- 381.12 pyrazolo[4,3 CI c]pyridin-5-yl] ethanone 1-[1-[1-(4-Fluoro F phenyl)-ethyl]-3-(6 N trifluoromethyl- 1.35 N / pyridin-2-yl) 6u 3c(4 O N 1,4,6,7-tetrahydro- 433.14 F pyrazolo[4,3 F F c]pyridin-5-yl] ethanone WO 2013/037415 PCT/EP2011/066061 71 Ri/ [min] Comp. SC Product Chemical Name (LC No. Method) [M+H*] F 1-[1 -(2,4-Difluoro F benzyl)-3-(6 N, methyl-pyridin-2-yl)- 3.15 N 6v 3r N 1,4,6,7-tetrahydro- (2) pyrazolo[4,3- 383.23 O N Nc]pyridin-5-yl] ethanone F 1-[3-(6-Bromo F pyridin-2-yl)-1-(2,4 N difluoro-benzyl)- 1.3 N 6w 3s N 1,4,6,7-tetrahydro- (4) O pyrazolo[4,3- 447.17 r c]pyridin-5-yl] ethanone F 1-[1-(2,4-Difluoro F benzyl)-3-(4 N methyl-pyridin-2-yl)- 0.97 6x 3t N 1,4,6,7-tetrahydro- (1) o N pyrazolo[4,3- 383.2 c]pyridin-5-yl] ethanone WO 2013/037415 PCT/EP2011/066061 72 Ri/ [min] Comp. SC Product Chemical Name (LC No. Method) [M+H*] F 1-[1-(2,4-Difluoro F benzyl)-3-(6 N methoxy-pyridin-2 1.15 N yl)-1,4,6,7 tetrahydro- (1 399.19 oN pyrazolo[4,3 o c]pyridin-5-yl] ethanone F 1-[3-(6-Chloro-5 F methoxy-pyridin-2 N yl)-1-(2,4-difluoro / benzyl)-1,4,6,7 6z 3v (4) o N tetrahydro 433.11 CI pyrazolo[4,3 c]pyridin-5-yl] / ethanone F 1-[1 -(2,4-Difluoro F benzyl)-3-(3 N N m ethyl -pyrid in-2-yl)- 1.14 6ab 3w N 1,4,6,7-tetrahydro- (4) pyrazolo[4,3- 383.1 O N c]pyridin-5-yl] ethanone WO 2013/037415 PCT/EP2011/066061 73 Ri/ [min] Comp. SC Product Chemical Name (LC No. Method) [M+H*] F 1-[1-(2,4-Difluoro F benzyl)-3-(4 N methoxy-pyridin-2 NN yl)1,46,7 6ac 3x N2) tetrahydro ON 399.26 pyrazolo[4,3 c]pyridin-5-yl] ethanone / S 1-[1 -(2-Methyl N N thiazol-4-ylmethyl) N N 3-(3-trifluorom ethyl- 1.23 phenyl)-1,4,6,7 6ad 3d O(4) 6ad 3d 0 tetrahydro- 4 F pyrazolo[4,3 F F c]pyridin-5-yl] ethanone 1-[1-Thiazol-2 N N ylmethyl-3-(3 N N trifluoromethyl- 1.2 phenyl)-1,4,6,7 6ae 3d O(4) 6ae 3d 0 / tetrahydro- 4 F pyrazolo[4,3 c]pyridin-5-yl] F IF ethanone WO 2013/037415 PCT/EP2011/066061 74 Ri/ [min] Comp. SC Product Chemical Name (LC No. Method) [M+H*] F 1-[1 -(2,4-Difluoro F benzyl)-3-thiophen N, 2-yl-1,4,6,7- 1.22 N 6af 3y N tetrahydro- (4) pyrazolo[4,3- 374.07 o S c]pyridin-5-yl] ethanone s CI 1-[1 -(5-Chloro N thiophen-2 N /N ylmethyl)-3-m-tolyl- 1.3 6ag 3q 1,4,6,7-tetrahydro- (4) o pyrazolo[4,3- 386.08 c]pyridin-5-yl] ethanone s CI 1-[1-(5-Chloro thiophen-2 NN ylmethyl)-3-(3 N N trifluoromethyl- 1.35 6ah 3d phenyl)-1,4,6,7- (4) tetrahydro- 440.07 F pyrazolo[4,3 F F c]pyridin-5-yl] ethanone WO 2013/037415 PCT/EP2011/066061 75 Ri/ [min] Comp. SC Product Chemical Name (LC No. Method) [M+H*] 3-[5-Acetyl-1 -(5 N, chloro-thiophen-2 N N ylmethyl)-4,5,6,7- 1.17 6ai 3a tetrahydro-1 H- (1) o pyrazolo[4,3- 397.03 c]pyridin-3-yl] N benzonitrile S CI 1-[3-(3-Chloro phenyl)-1 -(5-chloro N/ thiophen-2 N 1.25 N / ylmethyl)-1,4,6,7 6aj 3f (1) oaj 3f tetrahydro- 460 pyrazolo[4,3 CI c]pyridin-5-yl] ethanone F 1-[3-(5-Chloro F thiophen-2-yl)-1 N (2,4-difluoro 1.31 N benzyl)-1,4,6,7 6ak 3z N (4) tetrahydro- 480 408.01 0 S pyrazolo[4,3 Cl c]pyridin-5-yl] ethanone WO 2013/037415 PCT/EP2011/066061 76 Ri/ [min] Comp. SC Product Chemical Name (LC No. Method) [M+H*] F 1-[1 -(2,4-Difluoro F benzyl)-3-thiophen N 3-yl-1,4,6,7- 1.21 6al 3aa N N tetrahydro- (4) pyrazolo[4,3- 374.06 c]pyridin-5-yl] S ethanone 4-[5-Acetyl-3-(3 CN trifluoromethyl N phenyl)-4,5,6,7 1 N 4.52 N / tetrahydro pyrazolo[4,3- 2) F c]pyridin-1 F F ylmethyl] benzonitrile 3-{5-Acetyl-1 -[1 -(4 F N /fluoro-phenyl) N ethyl]-4,5,6,7- 1.29 6an 3a N tetrahydro-1 H- (4) o pyrazolo[4,3- 389.2 N c]pyridin-3-yl} benzonitrile WO 2013/037415 PCT/EP2011/066061 77 Ri/ [min] Comp. SC Product Chemical Name (LC No. Method) [M+H*] 1 -[1 -[Cyclopropyl F (4-fluoro-phenyl) N, methyl]-3-(4-fluoro N 45 N / phenyl)-1,4,6,7- (2) 6ao 3b(2 oao 3b tetrahydro- 408.34 pyrazolo[4,3 c]pyridin-5-yl] F ethanone F 1-[1-(2,4-Difluoro N ~ / F benzyl)-3-(3 1 N trifluoromethoxy- 1.23 N 3e phenyl)-1,4,6,7 6ap 3e(4 O tetrahydro- 452.13 pyrazolo[4,3 F c]pyridin-5-yl] F F ethanone WO 2013/037415 PCT/EP2011/066061 78 Ri/ [min] Comp. SC Product Chemical Name (LC No. Method) [M+H*] F 1-[1 -(2,6-Difluoro N benzyl)-3-(4-fluoro phenyl)-1,4,6,7- 2.31 /NN 6aq 3b N tetrahydro- (12) o /pyrazolo[4,3- 386.03 c]pyridin-5-yl] ethanone F 1 -{3-(4-Fluoro F N phenyl)-1-[1-(4 N fluoro-phenyl) N / 3.65 ethyl]-1,4,6,7 6ar 3b (8) o tetrahydro- 382.25 pyrazolo[4,3 F c]pyridin-5-yl} ethanone 1-[3-(4-Fluoro N / / CF 3 phenyl)-1 -(4 N trifluoromethyl N / 2.5 6as 3b benzyl)-1,4,6,7- (12) 0 tetrahydro- 418.11 pyrazolo[4,3 F c]pyridin-5-yl] ethanone WO 2013/037415 PCT/EP2011/066061 79 Ri/ [min] Comp. SC Product Chemical Name (LC No. Method) [M+H*] F 1-[1-(2,4-Difluoro F benzyl)-3-(3 N N methoxy-phenyl)- 1.61 6at 3h N 1,4,6,7-tetrahydro- (7) o pyrazolo[4,3- 398.13 c]pyridin-5-yl] ethanone 1-[3-(4-Fluoro N phenyl)-1 -(3 N F trifluoromethyl- 2.49 F F benzyl)-1,4,6,7- (12) 6av 3b (2 o tetrahydro- 418.02 pyrazolo[4,3 F c]pyridin-5-yl] ethanone F 1-[1-[1-(4-Fluoro N phenyl)-ethyl]-3-(3 N N trifluoromethoxy- 1.25 phenyl)-1,4,6,7 6aw 3e e(4) 6aw 3e / tetrahydro- 447.74 0 pyrazolo[4,3 F c]pyridin-5-yl] F ethanone WO 2013/037415 PCT/EP2011/066061 80 Ri/ [min] Comp. SC Product Chemical Name (LC No. Method) [M+H*] F 1-[1-(2,4-Difluoro N, benzyl)-3-(4-fluoro N N F 3-methoxy-phenyl)- 1.26 6ax 3i 1,4,6,7-tetrahydro- (4) pyrazolo[4,3- 416.22 c]pyridin-5-yl] F ethanone F -- 3-[5-Acetyl-1 -(2,5 N / difluoro-benzyl)- 1.13 N N4,5,6,7-tetrahydro SN1H-pyrazolo[4,3- 313 393.13 c]pyridin-3-yl] benzonitrile N F 1-[1-(2,4-Difluoro N benzyl)-3-m-tolyl- 1.16 N/ 1,4,6,7-tetrahydro 6az 3q pyrazolo[4,3 0 382.3 c]pyridin-5-yl] ethanone WO 2013/037415 PCT/EP2011/066061 81 Ri/ [min] Comp. SC Product Chemical Name (LC No. Method) [M+H*] 1-[3-(3-Chloro F N phenyl)-1 -(4-fluoro N 2-methyl-benzyl)- 1.24 6ba 3f N 1,4,6,7-tetrahydro- (1) o pyrazolo[4,3- 398.12 CI c]pyridin-5-yl] ethanone 1-[1 -(2-Fluoro N / benzyl)-3-m-tolyl- 1.26 /N F 1,4,6,7-tetrahydro pyrazolo[4,3- 34 . o c]pyridin-5-yl] ethanone O 1-[1 -(2-Methoxy benzyl)-3-(3 trifluoromethyl- 4.73 phenyl)-1,4,6,7 6bc 3d N (2) N tetrahydro 430.32 pyrazolo[4,3 I F c]pyridin-5-yl] F ethanone
    IF
    WO 2013/037415 PCT/EP2011/066061 82 Ri/ [min] Comp. SC Product Chemical Name (LC No. Method) [M+H*] 1-[3-(3-Chloro phenyl)-1 -(3 methoxy-benzyl)- 1.19 N 0 6bd 3f N / 1,4,6,7-tetrahydro- (1) 1 pyrazolo[4,3- 396.08 c]pyridin-5-yl] CI ethanone N / F (+)-1-{3-(4-Fluoro N phenyl)-1 -[1 -(4 N fluoro-phenyl) 4.79 ethyl]-1,4,6,7 6be 3b O (11) tetrahydro- 382.23 pyrazolo[4,3 F c]pyridin-5-yl} (+)-Isomer ethanone N ~ / F (-)-1-{3-(4-Fluoro phenyl)-1 -[1 -(4 NN 6bf 3b 0 / ethyl]-1,4,6,7- (11) tetrahydro- 382.23 pyrazolo[4,3 F c]pyridin-5-yl} (-)-Isomer ethanone WO 2013/037415 PCT/EP2011/066061 83 Ri/ [min] Comp. SC Product Chemical Name (LC No. Method) [M+H*] CI F 1 -[1 -(4-Chloro-3 fluoro-benzyl)-3-(4 fluoro-phenyl)- 2.47 6bg 3b 0 N N 1,4,6,7-tetrahydro- (12) pyrazolo[4,3- 402.00 c]pyridin-5-yl] ethanone F F F 1-[1-(2,4-Difluoro benzyl)-3-(2-fluoro N 5-methoxy-phenyl)- 1.13 6bh 3g 0 N N 1,4,6,7-tetrahydro- (4) F pyrazolo[4,3- 416.12 c]pyridin-5-yl] 0 ethanone WO 2013/037415 PCT/EP2011/066061 84 Ri/ [min] Comp. SC Product Chemical Name (LC No. Method) [M+H*] F F 5-[5-Acetyl-1 -(2,4 N difluoro-benzyl)- 1.26 6bi 3j 0 N N 4,5,6,7-tetrahydro 1 H-pyrazolo[4,3- 411.19 c]pyridin-3-yl]-2 fluoro-benzonitrile N F F F 1-[1 -(2,4-Difluoro benzyl)-3-(3-fluoro N phenyl)-1,4,6,7- 3.45 6bj 3k N tetrahydro- (13) pyrazolo[4,3- 386.18 c]pyridin-5-yl] ethanone
    F
    WO 2013/037415 PCT/EP2011/066061 85 Ri/ [min] Comp. SC Product Chemical Name (LC No. Method) [M+H*] IF IF 1-[1 -(2,4-Difluoro N benzyl)-3-(4 trifluoromethyl- 1.2 0 N N phenyl)-1,4,6,7- (1) 6bk 31(1 tetrahydro- 435.88 pyrazolo[4,3 c]pyridin-5-yl] ethanone F F F CI 1-[1-[1-(4-Chloro N phenyl)-propyl]-3 N (4-fluoro-phenyl)- 3.81 6b1 3b "Y / 1,4,6,7-tetrahydro- (8) pyrazolo[4,3 c]pyridin-5-yl] F ethanone, Enantiomer 1 enantiomer 1 WO 2013/037415 PCT/EP2011/066061 86 Ri/ [min] Comp. SC Product Chemical Name (LC No. Method) [M+H*] Cl 1-[1-[1-(4-Chloro N phenyl)-propyl]-3 N (4-fluoro-phenyl) 3.81 6bm 3b "Y / 1,4,6,7-tetrahydro- (8) pyrazolo[4,3 c]pyridin-5-yl] F ethanone, Enantiomer 2 enantiomer 2 F 1-[1 -(2-Fluoro-4 methyl-benzyl)-3 N (3-trifluoromethyl 1.35 6bn 3d N / N phenyl)-1,4,6,7 / tetrahydro- 432.13 F pyrazolo[4,3 F c]pyridin-5-yl] F ethanone 1 -(2,4-D ifluoro-benzyl)-3-(4-fluoro-phenyl)-6-methyl-4,5,6,7-tetrahydro-1
    H
    pyrazolo[4,3-c]pyridine, trifluoroacetate salt (7a) WO 2013/037415 PCT/EP2011/066061 87 F N NIF HN / F O F FOH FF According to Scheme 4: To a solution of 1 N lithium hexamethyldisilazide in dry tetrahydrofuran (4.69 ml, 4.69 mmol) at -780C was added a solution of N-tert-butoxycarbonyl-4-piperidone 5 (1.0 g, 4.69 mmol) in dry diethyl ether (9 ml) dropwise and the mixture was stirred at -780C for 30 min. A solution of 4-fluorobenzoyl chloride (743 mg, 4.69 mmol) in dry diethyl ether was added. The mixture was allowed to warm to 250C overnight. Water was added, the solution was extracted 3 times with CH 2 C1 2 , the combined organic layers were washed once with brine, dried over Na 2
    SO
    4 , filtrated and the solution 10 was evaporated to dryness, redissolved in ethanol (25 ml) and tetrahydrofuran (11 ml), (2,4-Difluoro-benzyl)-hydrazine (731 mg, 4.62 mmol) was added and the mixture was stirred for 10 min at 250C. The mixture was poured on 1 N aqueous NaOH, extracted 3 times with ethyl acetate, the combined organic layers were washed with brine, dried over Na 2
    SO
    4 , filtrated and the solution was evaporated to 15 dryness. The residue was dissolved in 4N HCI/dioxane (3 ml, 12 mmol) and stirred for 2 days. Solvents were evaporated and the crude product was purified by reverse phase HPLC (CH 3 CN / water gradient with 0,1 % trifluoroacetic acid) to give 257 mg of 1 -(2,4-D ifluoro-benzyl)-3-(4-fluoro-phenyl)-6-methyl-4,5,6,7-tetrahydro-1 H pyrazolo[4,3-c]pyridine, trifluoroacetate salt (7a). 20 Ri = 1.05 min (LC-method 4). Detected mass: 358.24 [M+H*] 1 -Benzyl-3-(4-fluoro-phenyl)-4,5,6,7-tetrahydro-1 H-pyrazolo[4,3-c]pyridine, hydrochloride (7b) WO 2013/037415 PCT/EP2011/066061 88 N HN /N H N H Cl F According to Scheme 5: A mixture of 1 -[1 -Benzyl-3-(4-fluoro-phenyl)-1,4,6,7-tetrahydro-pyrazolo[4,3 c]pyridin-5-yl]-ethanone (6e) (6.9 g, 20 mmol), ethanol (73ml) and 1ON aqueous HCI 5 (137 ml) was stirred at 800C for 2h and then overnight at room temperature. The mixture was concentrated in vacuo and the product was filtrated off and washed with a small amount of cold water to give 4.87 g of 1 -Benzyl-3-(4-fluoro-phenyl) 4,5,6,7-tetrahydro-1 H-pyrazolo[4,3-c]pyridine; hydrochloride (7b). Ri = 1.80 min (LC-method 12). Detected mass: 308.17 [M+H*] 10 The examples in the following table were obtained according to Scheme 5 by following a similar reaction as used for synthesis of (7b). Reaction conditions varied slightly by reaction time (2 h -3 days), concentration of the aqueous HCI (2-1 0M) and work-up procedure (sometimes after evaporation of solvents the residue was 15 purified by reverse phase HPLC (CH 3 CN / water gradient with 0,1 % trifluoroacetic acid). The free amine was easily obtained by adding aqueous NaHCO3 and extracting with 3 times CH 2 Cl 2 , combining organic layers, drying over Na 2
    SO
    4 , filtrating off and evaporating solvents of the filtrate to dryness.
    WO 2013/037415 PCT/EP2011/066061 89 Ri/ [min] Comp. SC Product Chemical Name (LC No. Method) [M+H*] F 3-[1-(2,4-Difluoro N benzyl)-4,5,6,7- 0.96 7 N F tetrahydro-1
    H
    7c 6a HN pyrazolo[4,3- (4) 351.33 c]pyridin-3-yl] benzonitrile N F 1-(2,4-Difluoro N N F benzyl)-3-(4-fluoro- 1.07 7d 6f HN / phenyl)-4,5,6,7 tetrahydro-1 H 344.19 pyrazolo[4,3 c]pyridine F F 3-(4-Fluoro phenyl)-1-[1-(4 N fluoro-phenyl) N2.01 7 b HN / / ethyl]-4,5,6,7 tetrahydro-1 H- 3) 340.1 pyrazolo[4,3 c]pyridine F (enantiomer 1) WO 2013/037415 PCT/EP2011/066061 90 Ri/ [min] Comp. SC Product Chemical Name (LC No. Method) [M+H*] F 3-(4-Fluoro N phenyl)-1 -[1 -(4 N fluoro-phenyl)- 2.01 HN / ethyl]-4,5,6,7 7f 6bf(3 tetrahydro-1 H- 3) pyrazolo[4,3 c]pyridine F (enantiomer 2) 3-[1 -(2,4-Difluoro-benzyl)-5-(3-methyl-oxetane-3-carbonyl)-4,5,6,7-tetrahydro-1 H pyrazolo[4,3-c]pyridin-3-yl]-benzonitrile (8a) r F 0 N N N F 5 9N According to Scheme 6, method A: To a 1 O 0 C cold solution of 3-[1-(2,4-Difluoro-benzyl)-4,5,6,7-tetrahydro-1 H pyrazolo[4,3-c]pyridin-3-yl]-benzonitrile, trifluoroacetate (7c) (0.055 g, 0.118 mmol) in N,N-dimethylformamide (2 ml) was added triethylamine (18 [1i, 0.13 mmol), 1 10 hydroxybenzotriazole (17 mg, 0.124 mmol), 3-methyl-3-oxetane carboxylic acid (13.8 mg) and finally 1 -ethyl-3-(3-dimethylam inopropyl)carbodiim ide hydrochloride WO 2013/037415 PCT/EP2011/066061 91 (24 mg, 0.124 mmol). The mixture was allowed to warm to 250C and stirred for 16 h and purified by reverse phase HPLC (CH3CN / water gradient with 0,1 % trifluoroacetic acid) to give 38 mg of 3-[1 -(2,4-D ifluoro-benzyl)-5-(3-methyl-oxetane 3-carbonyl)-4,5,6,7-tetrahydro-1 H-pyrazolo[4,3-c]pyridin-3-yl]-benzonitrile (8a). 5 Ri = 1.23 min (LC-method 4). Detected mass: 449.27 [M+H*] 3-[1-(2,4-Difluoro-benzyl)-5-isobutyryl-4,5,6,7-tetrahydro-1 H-pyrazolo[4,3-c]pyridin 3-yl]-benzonitrile (8b) F N N N F 0O -N 10 According to Scheme 6, method B: A mixture of 3-[1-(2,4-Difluoro-benzyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin 3-yl]-benzonitrile (7c) (0.057 g, 0.163 mmol), K 2 C0 3 (45 mg, 0.327 mmol) and isobutyryl chloride (21 mg, 0.196 mmol) in dry CH 3 CN (1.5 ml) was stirred at 600C for 1 h. Water was added, the solution was extracted 3 times with CH 2 Cl 2 , the 15 combined organic layers were washed once with brine, dried over Na 2
    SO
    4 , filtrated and the residue was purified by reverse phase HPLC (CH 3 CN / water gradient with 0,1 % trifluoroacetic acid) to give 48 mg of 3-[1-(2,4-Difluoro-benzyl)-5-isobutyryl 4,5,6,7-tetrahydro-1 H-pyrazolo[4,3-c]pyridin-3-yl]-benzonitrile (8b). Ri = 1.18 min (LC-method 1). Detected mass: 421.29 [M+H*] 20 3-[5-Cyclopropanecarbonyl-1 -(2,4-d ifluoro-benzyl)-4,5,6,7-tetrahydro-1 H pyrazolo[4,3-c]pyridin-3-yl]-benzonitrile (8c) WO 2013/037415 PCT/EP2011/066061 92 F N N N F 0O -N According to Scheme 6, method C: To a 0C cold mixture of 3-[1-(2,4-Difluoro-benzyl)-4,5,6,7-tetrahydro-1 H pyrazolo[4,3-c]pyridin-3-yl]-benzonitrile, hydrochloride salt (7c) (0.050 g, 0.129 5 mmol), NaHCO 3 (44 mg, 0.517 mmol), water (2 ml) and ethyl acetate (2 ml) was added cyclopropanecarbonyl chloride (13.5 mg, 0.129 mmol) and the mixture was stirred at 250C for 16 h. Water was added, the solution was extracted 2 times with ethyl acetate, the combined organic layers were washed once with brine, dried over MgSO4, filtrated and purified by reverse phase HPLC (CH 3 CN / water gradient with 10 0,1 % trifluoroacetic acid) to give 21 mg of 3-[5-Cyclopropanecarbonyl-1-(2,4 difluoro-benzyl)-4,5,6,7-tetrahydro-1 H-pyrazolo[4,3-c]pyridin-3-yl]-benzonitrile (8c). Ri = 4.14 min (LC-method 13). Detected mass: 419.18 [M+H*] 3-[5-(2-tert-Butoxy-acetyl)-1 -(2,4-d ifluoro-benzyl)-4,5,6,7-tetrahydro-1 H 15 pyrazolo[4,3-c]pyridin-3-yl]-benzonitrile (8d) F N N N F 0 -N According to Scheme 6, method D: To a OC cold mixture of 3-[1-(2,4-Difluoro-benzyl)-4,5,6,7-tetrahydro-1 H pyrazolo[4,3-c]pyridin-3-yl]-benzonitrile (7c) (0.4 g, 1.142 mmol) and 2-tert- WO 2013/037415 PCT/EP2011/066061 93 butoxyacetic acid (196 mg, 1.485 mmol) was added N,N-diisopropylethylamine (0.59 g, 4.57 mmol) and TOTU (0-(Cyano(ethoxycarbonyl)methylenamino)-1,1,3,3 tetramethyluronium tetrafluoroborate, 562 mg, 1.71 mmol) and the mixture was stirred at 250C for 1 h. The crude product was purified by reverse phase HPLC 5 (CH 3 CN / water gradient with 0,1 % trifluoroacetic acid) to give 120 mg of 3-[5-(2 tert-Butoxy-acetyl)-1 -(2,4-d ifluoro-benzyl)-4,5,6,7-tetrahydro-1 H-pyrazolo[4,3 c]pyridin-3-yl]-benzonitrile (8d). Ri = 1.34 min (LC-method 4). Detected mass: 465.3 [M+H*] 10 3-[1 -(2,4-Difluoro-benzyl)-5-(3-methyl-3H-imidazole-4-carbonyl)-4,5,6,7-tetrahydro 1 H-pyrazolo[4,3-c]pyridin-3-yl]-benzonitrile (8w) F N N NN N F -N According to Scheme 6, method E: 15 A mixture of 3-[1-(2,4-Difluoro-benzyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin 3-yl]-benzonitrile (7c) (0.04 g, 0.114 mmol), 3-Methyl-3H-imidazole-4-carbonyl chloride (0.083 g, 0.457 mmol) and triethylamine (138 mg, 1.37 mmol) in CH 2 Cl 2 was stirred at 250C for 16 h. The crude product was purified by reverse phase HPLC (CH3CN / water gradient with 0,1 % trifluoroacetic acid) to give 43 mg of 3-[1-(2,4 20 Difluoro-benzyl)-5-(3-methyl-3H-imidazole-4-carbonyl)-4,5,6,7-tetrahydro-1 H pyrazolo[4,3-c]pyridin-3-yl]-benzonitrile (8w). Ri = 3.53 min (LC-method 2). Detected mass: 459.24 [M+H*] WO 2013/037415 PCT/EP2011/066061 94 1-[1 -(2,4-D ifluoro-benzyl)-3-(4-fl uoro-phenyl)-6-methyl-1, 4,6,7-tetrahydro pyrazolo[4,3-c]pyridin-5-yl]-ethanone (8z) F N N / F 0 F According to Scheme 6, method F: 5 A mixture of 1-(2,4-Difluoro-benzyl)-3-(4-fluoro-phenyl)-6-methyl-4,5,6,7-tetrahydro 1 H-pyrazolo[4,3-c]pyridine (7a) (0.53 g, 1.35 mmol), acetic anhydride (5.5 ml) and pyridine (5.5 ml) was stirred at 250C for 16 h. The mixture was poured on 50 mI water, extracted with 150 ml ethyl acetate , the combined organic layers were washed with 3 times 0,5 N NaOH (50 ml) and once with brine, dried over MgSO 4 , 10 filtrated and evaporated to dryness. The crude product was silica gel chromatography (eluting with heptane / ethyl acetate) to give 156 mg of 1-[1 -(2,4 D ifluoro-benzyl)-3-(4-fluoro-phenyl)-6-methyl-1, 4,6,7-tetrahydro-pyrazolo[4,3 c]pyridin-5-yl]-ethanone (8z). Ri = 1.3 min (LC-method 4). Detected mass: 400.22 [M+H*] 15 The examples in the following table were obtained according to Scheme 6 by following one of the methods described for the synthesis of 8a-8c (Method (A) according to 8a, Method (B) and Method (C) according to 8c). The acylating reagents are obvious to the man skilled in the art and therefore not mentioned.
    WO 2013/037415 PCT/EP2011/066061 95 Ri/ [min] Comp. SC Product Chemical Name (LC No. (M) Method) [M+H*] F F 3-[1-(2,4-Difluoro / benzyl)-5-(3 N methanesulfonyl | N 3.93 7c 0 N /Nbenzoyl)-4, 5,6,7 8e (13) (A) tetrahydro-1 H 533.16 -N pyrazolo[4,3 c]pyridin-3-yl] benzonitrile [1-Benzyl-3-(4 fluoro-phenyl) N 1,4,6,7 N3.49 7b 0 N tetrahydro 8f(8 (C) pyrazolo[4,3 c]pyridin-5-yl]-(4- 430.1 fluoro-phenyl) F F methanone [1 -Benzyl-3-(4 O / fluoro-phenyl) N 1,4,6,7 N3.44 7b 0 N tetrahydro (C) pyrazolo[4,3 c]pyridin-5-yl]-(4- 442.13 methoxy-phenyl) 0 F methanone WO 2013/037415 PCT/EP2011/066061 96 Ri/ [min] Comp. SC Product Chemical Name
    (LC
    No. (M) Method) [M+H*] [1-Benzyl-3-(4 fluoro-phenyl) N 1,4,6,7 N 3.45 7b O N N tetrahydro (C) pyrazolo[4,3- 412.1 c]pyridin-5-yl] phenyl F methanone F 3-[5-Cyclobutane carbonyl-1-(2,4 N difluoro-benzyl) 8i 7c O N N 4,5,6,7- 1. (B) tetrahydro-1 H- (1) 433.28 pyrazolo[4,3 N c]pyridin-3-yl] benzonitrile 3-[5 F Cyclopentane / carbonyl-1-(2,4 7c N F difluoro-benzyl)- 1.23 8j 0 N / 4,5,6,7- (1) (B) tetrahydro-1 H- 447.23 pyrazolo[4,3 c]pyridin-3-yl] benzonitrile WO 2013/037415 PCT/EP2011/066061 97 Ri/ [min] Comp. SC Product Chemical Name
    (LC
    No. (M) Method) [M+H*] F F 3-[1-(2,4-Difluoro / benzyl)-5-(4 NN methanesulfonyl 7c 0 N / benzoyl)-4,5,6,7 8k (3 (A) tetrahydro-1 H- 53 533.15 pyrazolo[4,3 'N c]pyridin-3-yl] O=S=O benzonitrile F 3-[1-(2,4-Difluoro benzyl)-5-(tetra N hydro-pyran-4 NF 1.23 7c O N / carbonyl)-4,5,6,7 81(4 (C) tetrahydro-1 H 463.29 pyrazolo[4,3 N c]pyridin-3-yl] benzonitrile 3-[1-(2,4-Difluoro F benzyl)-5 / (tetrahydro-furan N F 3-carbonyl)- 1.23 8m O N 4,5,6,7- (4) (C) tetrahydro-1 H- 449.25 pyrazolo[4,3 N 0 -c]pyridin-3-yl] benzonitrile WO 2013/037415 PCT/EP2011/066061 98 Ri/ [min] Comp. SC Product Chemical Name
    (LC
    No. (M) Method) [M+H*] F 3-[1-(2,4-Difluoro benzyl)-5-(2 N methoxy-acetyl) 7c N F 4,5,6,7 8n 0 N (4 (B) tetrahydro-1 H- (4) 423.18 0 /pyrazolo[4,3 N c]pyridin-3-yl] benzonitrile 3-[1-(2,4-Difluoro F benzyl)-5-(2,2 /dimethyl N F propionyl)- 1.36 8o Oc N / 4,5,6,7- (4) (B) tetrahydro-1H- 435.31 pyrazolo[4,3 c]pyridin-3-yl] benzonitrile F 3-[1-(2,4-Difluoro /benzyl)-5 7c NN F propionyl-4,5,6,7- 1.28 8p 0 N / tetrahydro-1 H- (4) (B) pyrazolo[4,3- 407.27 c]pyridin-3-yl] benzonitrile WO 2013/037415 PCT/EP2011/066061 99 Ri/ [min] Comp. SC Product Chemical Name
    (LC
    No. (M) Method) [M+H*] 3-[1-(2,4-Difluoro F benzyl)-5-((S)-2 /hydroxy N 7c N N F propionyl)- 1.18 8q 0 N 4,5,6,7- (4) H tetrahydro-1 H- 423.25 pyrazolo[4,3 c]pyridin-3-yl] benzonitrile 1-[1-Benzyl-3-(4 N fluoro-phenyl) 7b 0 N /N 1,4,6,7- 3.47 8r tetrahydro- (8) (C) pyrazolo[4,3- 426.12 c]pyridin-5-yl]-2 F phenyl-ethanone F 3-[5-Butyryl-1 /(2,4-difluoro 7c N F benzyl)-4,5,6,7- 1.18 7c N 8s 0 N / tetrahydro-1 H- (1) (C) pyrazolo[4,3- 421.28 c]pyridin-3-yl] benzonitrile WO 2013/037415 PCT/EP2011/066061 100 Ri/ [min] Comp. SC Product Chemical Name (LC No. (M) Method) [M+H*] F 3-[1-(2,4-Difluoro benzyl)-5 N F (pyridine-2- 4.07 7c N N carbonyl)-4,5,6,7 (C) tetrahydro-1 H- (1 456.17 N pyrazolo[4,3 -- N c]pyridin-3-yl] benzonitrile 3-[1-(2,4-Difluoro F benzyl)-5-(3 N ~ / fluoro-pyridine-4 7c / N F carbonyl)-4,5,6,7 8u O4N4(2 (A) tetrahydro-1 H- (2) 474.19 F pyrazolo[4,3 N c]pyridin-3-yl] benzonitrile 3-[1-(2,4-Difluoro F benzyl)-5 N (pyrimidine-4- 1.19 7c | N F carbonyl)-4,5,6,7 8vN O1N1(4 (A) tetrahydro-1 H- 4) 457.31 N pyrazolo[4,3 N c]pyridin-3-yl] N benzonitrile WO 2013/037415 PCT/EP2011/066061 101 Ri/ [min] Comp. SC Product Chemical Name (LC No. (M) Method) [M+H*] 3-[1-(2,4-Difluoro F benzyl)-5-(1 methyl-1 H N pyrazole-3- 4.49 8x 7c -N carbonyl)-4,5,6,7- (2) (E) N tetrahydro-1 H- 459.24 CN pyrazolo[4,3 c]pyridin-3-yl] benzonitrile F F 3-(3-Cyano phenyl)-1-(2,4 difluoro-benzyl) N 1,4,6,7- 1.35 7c 8y /B O NN tetrahydro- (4) (B) pyrazolo[4,3- 423.2 /N c]pyridine-5 carboxylic acid ethyl ester 3-(4-Fluoro-phenyl)-1 -[(R)-1 -(4-fluoro-phenyl)-ethyl]-5-methanesulfonyl-4,5,6,7 tetrahydro-1 H-pyrazolo[4,3-c]pyridine, enantiomer 1 (9a) WO 2013/037415 PCT/EP2011/066061 102 F N 0 N /N xS 0 F enantiomer 1 According to Scheme 7: To a mixture of 3-(4-Fluoro-phenyl)-1 -[1 -(4-fluoro-phenyl)-ethyl]-4,5,6,7-tetrahydro 1H-pyrazolo[4,3-c]pyridine (enantiomer 1) (7e) (0.120 g, 0.353 mmol) and 5 triethylamine (0.135 ml, 1.06 mmol) in CH 2 Cl 2 at 0C was added methanesulfonyl chloride (49 mg, 0.424 mmol) and the mixture was stirred at 250C for 16 h. The crude product was purified by reverse phase HPLC (CH 3 CN / water gradient with 0,1 % trifluoroacetic acid) to give 96 mg of 3-(4-Fluoro-phenyl)-1 -[(R)-1 -(4-fluoro phenyl)-ethyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-1 H-pyrazolo[4,3-c]pyridine (9a). 10 Ri = 3.58 min (LC-method 8). Detected mass: 418.09 [M+H*] 3-(4-Fluoro-phenyl)-1 -[(R)-1 -(4-fluoro-phenyl)-ethyl]-5-methanesulfonyl-4,5,6,7 tetrahydro-1 H-pyrazolo[4,3-c]pyridine, enantiomer 2 (9b) F N 0 N /N S 0 F enantiomer 2 WO 2013/037415 PCT/EP2011/066061 103 3-(4-Fluoro-phenyl)-1 -[(R)-1 -(4-fluoro-phenyl)-ethyl]-5-methanesulfonyl-4,5,6,7 tetrahydro-1 H-pyrazolo[4,3-c]pyridine, enantiomer 2 (9b) was obtained starting from 3-(4-Fluoro-phenyl)-1 -[1 -(4-fluoro-phenyl)-ethyl]-4,5,6,7-tetrahydro-1 H-pyrazolo[4,3 c]pyridine (enantiomer 2) (7f) by following a similar reaction as used for synthesis of 5 (9a). Ri = 3.58 min (LC-method 8). Detected mass: 418.09 [M+H*] 3-(3-Cyano-phenyl)-1 -(2,4-difluoro-benzyl)-1,4,6,7-tetrahydro-pyrazolo[4,3 c]pyridine-5-carboxylic acid isopropylamide (11 a) F N H N F N N 0 10 N According to Scheme 8: To a mixture of 3-[1 -(2,4-Difluoro-benzyl)-4,5,6,7-tetrahydro-1 H-pyrazolo[4,3 c]pyridin-3-yl]-benzonitrile (7c) (0.060 g, 0.171 mmol) and triethylamine (138 mg, 1.37 mmol) at 00C was added isopropylisocyanate (17.5 mg, 0.21 mmol) and the 15 mixture was stirred at room temperature for 16 h. The crude product was purified by reverse phase HPLC (CH 3 CN / water gradient with 0,1 % trifluoroacetic) to give 19 mg of 3-(3-Cyano-phenyl)-1-(2,4-difluoro-benzy)-1,4,6,7-tetrahydro-pyrazolo[4,3 c]pyridine-5-carboxylic acid isopropylamide (11 a). Ri = 1.16 min (LC-method 1). Detected mass: 436.25 [M+H*] 20 The examples in the following table were obtained according to Scheme 9 by following a similar reaction as used for synthesis of (11 a).
    WO 2013/037415 PCT/EP2011/066061 104 Ri/ [min] Comp. SC Product Chemical Name (LC No. Method) [M+H*] F 3-(4-Fluoro phenyl)-1-[1-(4 N fluoro-phenyl) H N ethyl]-1,4,6,7 N N / 3.45 tetrahydro- (8) 11b 7e 0 pyrazolo[4,3- 417 411.17 c]pyridine-5 F carboxylic acid ethylamide, enantiomer 1 enantiomer 1 F 3-(4-Fluoro phenyl)-1-[1-(4 N" fluoro-phenyl) N H N ethyl]-1,4,6,7 lic -r 0 z tetrahydro- (8) 11c 7f 0 pyrazolo[4,3- 416 411.16 c]pyridine-5 F carboxylic acid enantiomer 2 ethylamide, enantiomer 2 WO 2013/037415 PCT/EP2011/066061 105 Ri/ [min] Comp. SC Product Chemical Name (LC No. Method) [M+H*] F 3-(4-Fluoro phenyl)-1-[1-(4 fluoro-phenyl) N H N ethyl]-1,4,6,7 lit 7e tetrahydro- (13 11f 7e 0 pyrazolo[4,3- 43 439.15 c]pyridine-5 F carboxylic acid enantiomer 1 tert-butylamide, enantiomer 1 F 3-(3-Cyano phenyl)-1-(2,4 difluoro-benzyl) N F 1,4,6,7- 1.14 11h 7c NH N N tetrahydro- (1) pyrazolo[4,3- 422.21 c]pyridine-5 N carboxylic acid ethylamide 3-(3-Cyano-phenyl)-1 -(2,4-difluoro-benzyl)-1,4,6,7-tetrahydro-pyrazolo[4,3 c]pyridine-5-carboxylic acid methylamide (12a) WO 2013/037415 PCT/EP2011/066061 106 H N I F N H N F N N 0N -N According to Scheme 9: To a mixture of 3-[1 -(2,4-Difluoro-benzyl)-4,5,6,7-tetrahydro-1 H-pyrazolo[4,3 c]pyridin-3-yl]-benzonitrile (7c) (0.060 g, 0.171 mmol) and triethylamine (60 mg, 0.60 5 mmol) in CH 2
    CI
    2 at OC was added para-nitrophenylchloroformate (38 mg, 0.188 mmol) and the mixture was stirred at OC for 45 min. 2 M methylamine in tetrahydrofuran (2ml, 4 mmol) was added and the mixture was stirred for 3 days at room temperature. The crude product was purified by reverse phase HPLC (CH 3 CN / water gradient with 0,1 % trifluoroacetic) to give 3.4 mg of 3-(3-Cyano-phenyl)-1 10 (2,4-difluoro-benzyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid methylamide (12a). Ri = 1.11 min (LC-method 1). Detected mass: 408.15 [M+H*] The examples in the following table were obtained according to Scheme 10 by 15 following a similar reaction as used for synthesis of (12a), but at a reaction temperature of 800C.
    WO 2013/037415 PCT/EP2011/066061 107 Ri/ [min] Cm. SC Product Chemical Name (Method) No. [M+H*] F {3-(4-Fluoro -( phenyl)-1 -[1 -(4 N fluoro-phenyl) eN N /N ethyl]-1,4,6,7- 3.74 12b 7e tetrahydro-pyr- (13) azolo[4,3-c]pyridin- 453.11 5-yl}-morpholin-4 F yl-methanone, enantiomer 1 enantiomer 1 {3-(4-Fluoro F phenyl)-1 -[1 -(4 HO fluoro-phenyl) N N ethyl]-1,4,6,7 N<D N N tetrahydro- 3.37 12c 7e y pyrazolo[4,3- (13) c]pyridin-5-yl}-((S)- 453.11 3-hydroxy F pyrrolidin-1-yl) enantiomer 1 methanone, enantiomer 1 F 3-(3-Cyano phenyl)-1-(2,4 difluoro-benzyl)- 1.16 N F 12d 7c N 1,4,6,7-tetrahydro- (1) Ny N pyrazolo[4,3- 422.2 / c]pyridine-5 N carboxylic acid WO 2013/037415 PCT/EP2011/066061 108 Ri/ [min] Cm. SC Product Chemical Name (Method) No. [M+H*] dimethylamide 3-(3-Cyano F phenyl)-1-(2,4 difluoro-benzyl) N F 1,4,6,7-tetrahydro- 1.34 12e 7c HO N N N pyrazolo[4,3- (14) o /c]pyridine-5- 452.1 CN carboxylic acid (2 hydroxy-ethyl) methyl-amide 2-[5-Acetyl-1 -(2,4-difluoro-benzyl)-4,5,6,7-tetrahydro-1 H-pyrazolo[4,3-c]pyridin-3-yl] isonicotinonitrile (13a) F N F N N" o N N 5 According to Scheme 10: To a solution of Zn(CN) 2 (39 mg, 0.335 mmol) and tetrakis(triphenylphosphine)palladium(0) (19 mg, 0.016 mmol) in dry N,N dimethylformamide (0.6 ml) at 150 0 C was slowly added a solution of 1-[3-(4-Bromo pyridin-2-yl)-1 -(2,4-difluoro-benzyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl] 10 ethanone (6j) (0.15 g, 0.335 mmol) in dry N,N-dimethylformamide (1 ml). The mixture was stirred at 150 0 C for 3 h and then at 25 0 C for 16 h. The mixture was diluted with methyl-tert-butylether, filtrated over Celite, washed with water, dried WO 2013/037415 PCT/EP2011/066061 109 over Na 2
    SO
    4 , filtrated and evaporated to dryness. The residue was suspended in methanol, and the solid was filtrated off to give 67 mg of 2-[5-Acetyl-1 -(2,4-difluoro benzyl)-4,5,6,7-tetrahydro-1 H-pyrazolo[4,3-c]pyridin-3-yl]-isonicotinonitrile (1 3a). Ri = 1.11 min (LC-method 1). Detected mass: 394.22 [M+H*] 5 The examples in the following table were obtained according to Scheme 11 by following a similar reaction as described for the synthesis of 13a. Sometimes the products were purified by reverse phase HPLC (CH 3 CN / water gradient with 0,1 % trifluoroacetic acid). Ri/ [min] Comp SC Product Chemical Name (LC No. Method) [M+H*] F 6-[5-Acetyl-1 -(2,4 F difluoro-benzyl) N 4,5,6,7 N 11 N tetrahydro-1 H 13b 6w(1 /3b 6w pyrazolo[4,3- (1) N c]pyridin-3-yl]- 394.22 pyridine-2 N carbonitrile 10 3-[1-(2,4-Difluoro-benzyl)-5-(2-hydroxy-acetyl)-4,5,6,7-tetrahydro-1 H-pyrazolo[4,3 c]pyridin-3-yl]-benzonitrile (14a) WO 2013/037415 PCT/EP2011/066061 110 F N F N N /'N HO NK OO 0 N A solution of 3-[5-(2-tert-Butoxy-acetyl)-1 -(2,4-d ifluoro-benzyl)-4,5,6,7-tetrahydro 1H-pyrazolo[4,3-c]pyridin-3-yl]-benzonitrile (8d) (90 mg , 0.193 mmol) and 5 trifluoroacetic acid (221 mg, 1.94 mmol) in CH 2 Cl 2 was stirred at 250C for 1 day. Solvents were evaporated and the residue purified by reverse phase HPLC (CH 3 CN / water gradient with 0,1 % trifluoroacetic acid) to give 48 mg of 3-[1-(2,4-Difluoro benzyl)-5-(2-hydroxy-acetyl)-4,5,6,7-tetrahydro-1 H-pyrazolo[4,3-c]pyridin-3-yl] benzonitrile (14a). 10 Ri = 1.19 min (method 4). Detected mass: 409.21 [M+H*] The following LC methods were used to analyze the exemplary embodiments: Following abbreviations are used: FA: formic acid 15 TFA: trifluoroacetic acid ACN: acetonitrile LC method 1: Stationary phase: Waters UPLC BEH C18 2,1*50 mm; 1.7p 20 Gradient: H 2 0+0.05% FA : ACN+0.035%FA 95:5 (0min) to 5:95(1.1min) to 5:95(1.7min) to 95:5 (1.9min) to 95:5 (2min) Flow: 0.9 mL/min, 550C 25 LC method 2: WO 2013/037415 PCT/EP2011/066061 111 Stationary phase: Waters XBridge C18 4.6*50 mm; 2,5p Gradient: H 2 0+0.1%FA: AcN+0.1%FA 97:3 (0min) to 40:60 (3.5 min) to 2:98(4min) to 2:98(5min) to 97:3 (5.2min) to 97:3 (6.5m in); 5 Flow: 1.3 mL/min LC method 3: Stationary phase: WatersXBridgeCl8,4,6*50; 2,5p Gradient: H 2 0+0.05%TFA: ACN+0.05%TFA 95:5(0min) to 10 95:5(0.2 min) to 5:95(2,4min) to 5:95(3,2min) to 95:5(3,3min) to 95:5(4,0min) Flow: 1.7 mL/min, 40'C LC method 4: 15 Stationary phase: Waters UPLC BEH C18 2,1*50 mm; 1.7p Gradient: H 2 0+0.1%FA: ACN+0.08%FA 95:5 (0min) to 5:95(1.1min) to 5:95(1.7min) to 95:5 (1.8min) to 95:5 (2min) Flow: 0.9 mL/min, 55'C 20 LC method 5: Stationary phase: WatersXBridgeCl8,4,6*50, 2,5p Gradient: H 2 0+0.05%TFA: ACN+0.05%TFA 95:5(0min) to 95:5(0.2 min) to 5:95(2,4min) to 5:95(3,5min) to 25 95:5(3,6min) to 95:5(4,5min) Flow: 1.7 mL/min, 50'C LC method 6: Stationary phase: WatersXBridgeCl8,4,6*50, 2,5p 30 Gradient: H 2 0+0.05%TFA: ACN+0.05%TFA 95:5(0min) to 5:95(2,6 min) to 5:95(3,0min) to 95:5(3,1min), to 95:5(4.0min) WO 2013/037415 PCT/EP2011/066061 112 Flow: 1.7 mL/min, 400C LC method 7: Stationary phase: Merck Chromolith FastGrad. RP-18e, 50x2mm 5 Gradient: H 2 0+0.05% TFA : ACN+0.05% TFA 98:2(0 min) to 98:2(0.2 min) to 2:98(2.4 min) to 2:98(3.2 min) to 98:2(3.3 min) to 98:2(4 min) Flow: 2 mL/min, 500C 10 LC method 8: Stationary phase: WatersXBridgeCl 8,4,6*50,2,5p Gradient: H 2 0+0.05%TFA : ACN+0.05%TFA 95:5(0min) to 95:5(0.3min) to 5:95(3.5 min) to 5:95(4min) Flow: 1.3ml/min, 400C 15 LC method 9: Stationary phase: Waters UPLC BEH C18 2,1*50 mm; 1.7p Gradient: H20+0.05%FA : ACN+0.035%FA 98:2 (Gmin) to 5:95(2min) to 5:95(2.6min) to 95:5 (2.7min) to 95:5 20 (3min) Flow: 0.9 ml/min 550 LC method 10: Stationary phase: 0
    .
    2 pl1 0 X2 0 LunaC1 8, 3p 25 Gradient: 0 min 93%H 2 0 (0.05%TFA)-1.0min- 95%ACN; 95%ACN to 1.45min; 7%ACN 1.50min Flow: 1 ml/min 550C LC method 11: 30 Stationary phase: Waters XBridge C18 4.6*50 mm; 2.5p WO 2013/037415 PCT/EP2011/066061 113 Gradient: H 2 0+0.1%FA : ACN+0.08%FA 97:3 (0min) to 40:60 (3.5 min) to 2:98(4min) to 2:98(5min) to 97:3 (5.2min) to 97:3 (6.5m in) Flow: 1.3 ml, 45 C 5 LC method 12: Stationary phase: YMC JSphere33*2, 4p Gradient: H 2 0+0.05%FA : ACN+0.05%FA 95:5(0min) to 95:5(0.5min) to 5:95(3.5 min) to 5:95(4min) 10 Flow: 1.3 ml/min, r.t. LC method 13: Stationary phase: YMC-Pack JSphere H80 33*2. Gradient: H 2 0+0.05%TFA : CH 3 0H+0.05%TFA 98:2(1 min) to 15 5:95(5.0min) to 5:95(6.25min) Flow: 1.0 ml/min, r.t. LC method 14: Stationary phase: YMC-JSphere-ODS-H80 (20 x 2 1 4 [t) 20 Gradient: Omin 96 % H 2 0 (0.05%TFA) to 95 % CH 3 CN (2.4min) to 4 % CH 3 CN (2.45 min) Flow: 1.0 ml/min, 300C LC method 15: 25 Stationary phase: YMC JSphere33*2,4p. Gradient: (AcN+0.05% TFA) : H20+0.05% TFA; 5:95(Omin)to5:95(0.5min)to95:5(3.5min)to95:5(4min) Flow: 1.3 ml/min 30 WO 2013/037415 PCT/EP2011/066061 114 Determination of the activity on the TASK-1 channel in Xenopus oocytes Human TASK-1 channels were expressed in Xenopus oocytes. For this purpose, oocytes were isolated from Xenopus laevis and defoliculated. Subsequently, TASK 5 1-encoding RNA synthesized in vitro was injected into oocytes. After two days of TASK-1 protein expression, TASK-1 currents were measured by two-microelectrode voltage clamp. Data were acquired and analyzed using a TEC-10 cx amplifier (NPI Electronic, Tamm, Germany) connected to an ITC-16 interface (Instrutech Corp., Long Island, USA) and Pulse software (HEKA Elektronik, Lambrecht, Germany). 10 Oocytes were clamped to -90 mV and TASK-1 mediated currents were measured during 500 ms voltage pulses to 40 mV. Oocytes were continuously superfused with ND96 buffer containing: NaCI 96 mM, KCI 2 mM, CaCl 2 1.8 mM, MgCl 2 1 mM, HEPES 5 mM (pH adjusted to 7.4 with NaOH). All experiments were performed at room temperature. 15 Test substances were consecutively added to the bath solution at rising concentrations. Compound effects were calculated as the percentage inhibition of TASK-1 control current before compound application. IC 50 values were obtained by fitting the data to the general dose-response equation. 20 The following products/compounds were tested in said assay by using the respective form (salt or free base) obtained as in the examples described above and the following activities were measured (IC50 values or inhibition (in %) at 5 pM). Example Inhibition (%) IC50 (pM) No. at 5 pM 6a 0.095 6ab 76% 6ac 80% 6ad 86% 6ae 84% WO 2013/037415 PCT/EP2011/066061 115 Example Inhibition (%) IC50 (pM) No. at 5 pM 6af 72% 6ag 75% 6ah 53% 6ai 79% 6aj 76% 6ak 0.27 6al 75% 6am 0.114 6an 0.187 6ao 0.258 6ap 0.285 6aq 0.359 6ar 0.552 6as 0.659 6at 0.72 6av 0.911 6aw 0.947 6ax 0.975 6ay 86% 6az 89% 6b 0.172 6ba 81% 6bb 82% 6bc 70% 6bd <10 6be 0.5 6bf 0.5 6bg 0.398 6bh <10 WO 2013/037415 PCT/EP2011/066061 116 Example Inhibition (%) IC50 (pM) No. at 5 pM 6bi 1.645 6bj 1.16 6bk 1.15 6bl 0.966 6bm 0.251 6bn 81% 6c 0.215 6d 0.422 6f 0.598 6g 0.0995 6h 0.19 6i 0.216 6j <10 6k 78% 6m 2.441 6n 0.091 6o <10 6p 88% 6q 70% 6r 79% 6s 83% 6t 62% 6u 89% 6v 73% 6w <10 6x 82% 6y 86% 6z 75% 8a 0.276 WO 2013/037415 PCT/EP2011/066061 117 Example Inhibition (%) IC50 (pM) No. at 5 pM 8b 0.019 8c 0.047 8d 75% 8e 1.625 8f 1.28 8g 3.264 8h 2.399 8i 0.064 8j 0.722 8k 0.906 81 0.585 8m 0.89 8n 80% 8o 0.131 8p 0.53 8q 0.756 8r 1.138 8s <10 8t 0.246 8u 0.416 8v 0.864 8w 1.149 8x 1.878 8y 77% 8z 0.511 9a 0.54 9b 0.611 11a 76% 11b 1.52 WO 2013/037415 PCT/EP2011/066061 118 Example Inhibition (%) IC50 (pM) No. at 5 pM 11c 1.167 lif 58% 11h 91 % 12a 0.38 12b 0.511 12c 0.734 12d 74% 12e 65% 13a 0.422 13b 0.462 14a <10 Investigation of the refractory period and the left-atrial vulnerability in the pig 5 The compounds were tested for prolongation of the refractory period and antiarrhythmic activity on the atrium of the anesthetized pig as described in the literature (Knobloch et al. 2002. Naunyn-Schmiedberg's Arch. Pharmacol. 366; 482 487). Here the anti-arrhythmic action relates to the inhibition of the occurrence of episodes of arrhythmias which are induced by a prematurely placed extra-stimulus 10 (S2) in the left atrium (= left-atrial vulnerability). The refractory period values are stated in percent of the basal values 15 minutes after injection. Mean values for the refractory periods are shown from three rates (150, 200 and 250/min). The inhibitory values for the inhibition of episodes of arrhythmias refer to 3 measurements (3 timepoints) before administration vs. 3 measurements during the first hour after 15 administration of the compounds. The action of 3-[5-Acetyl-1 -(2,4-difluoro-benzyl)-4,5,6,7-tetrahydro-1 H-pyrazolo[4,3 c]pyridin-3-yl]-benzonitrile (6a) on the refractory period of the left atrium and antiarrhythmic activity in the anesthetized pig after a bolus administration of 1 mg/kg WO 2013/037415 PCT/EP2011/066061 119 is shown in table 1. From the results shown in table 1, it is seen that it was possible to prevent 61% of the induced arrhythmias. Table 1 Mean value % increase in the refractory period 14% % inhibition of the arrhythmias 61% Number of animals n = 3 5
    权利要求:
    Claims (19)
    [1] 1. A compound of the formula I R2 X R3 N R1 1 ~- 5 R4 A wherein A = (C 6 -C 1 o)-aryl or a five- or six-membered heteroaryl, comprising 1-3 10 heteroatoms selected from the group N, 0 and S, wherein aryl and heteroaryl are optionally substituted with 1-3 rests selected independently from F, Cl, Br, CN, (C1-C 6 )-alkyl-, (C1-C 6 )-alkyl-0 and (C1-C 6 )-alkyl-S-, wherein one or more hydrogen atoms of the alkyl moieties may be 15 replaced by fluorine; X = (C 6 -C 1 o)-aryl or a five- or six-membered heteroaryl, comprising 1-3 heteroatoms selected from the group N, 0 and S, wherein aryl and heteroaryl are optionally substituted with 1-3 rests 20 selected independently from F, Cl, Br, CN, (C 1 -C 6 )-alkyl-, (C 1 -C 6 )-alkyl-O-, (C 1 -C 6 )-alkyl-S-, (C 1 -C 6 )-alkyl-O-C(O)- and (C 1 -C 6 )-alkyl-SO 2 -, wherein one or more hydrogen atoms of the alkyl moieties may be replaced by fluorine; 25 R1 = R5-C(=0)- or (C 1 -C 6 )-alkyl-SO 2 -; R2 = H, (C 1 -C 6 )-alkyl-, (C 3 -C 6 )-cycloalkyl-; WO 2013/037415 PCT/EP2011/066061 121 R3 = H, (C 1 -C 4 )-alkyl-; R4 = H, (C 1 -C 4 )-alkyl-; 5 or wherein R3 and R4 together form a (C
    [2] 2 -C 3 )-alkylene bridge; R5 = H, (C1-C 6 )-alkyl-, (C
    [3] 3 -C 6 )-cycloalkyl-, (C1-C 6 )-alkyl-O-, (C1-C 6 )-alkyl-S-, (C1 C 6 )-alkyl-O-(C 1 -C 6 )-alkyl-, HO-(C1-C 6 )-alkyl-, (C 3 -C 6 )-cycloalkyl-(C 1 -C 6 )-alkyl-, 10 (C 6 -C 1 o)-aryl-, (C 6 -C 1 o)-aryl-(C 1 -C 6 )-alkyl-, R7R6N-, heteroaryl, heteroaryl (C1-C 6 )-alkyl-, aliphatic heterocycle, wherein one or more hydrogen atoms of the alkyl moieties may be replaced by fluorine, and wherein the aliphatic heterocycle is selected from the group of 15 morpholinyl, piperidinyl, pyrrolidinyl and 4 to 7 membered aliphatic heterocycles comprising an oxygen atom, and wherein the aliphatic heterocycle may be optionally substituted with 1 to 3 substituents independently selected from the group of F, OH, (C1-C6) alkyl-O- and (C 1 -C 6 )-alkyl-, and 20 wherein the heteroaryl residues are five- or six-membered ring systems, comprising 1-3 heteroatoms selected from the group N, 0 and S, and wherein aryl and heteroaryl are optionally substituted with 1-3 rests selected independently from F, Cl, Br, CF 3 , (C 1 -C 6 )-alkyl-, (C 1 -C 6 )-alkyl-O-, 25 CN, (C 1 -C 2 )-alkyl-SO 2 -; R6 = H, (C 1 -C 6 )-alkyl-, (C 3 -C 6 )-cycloalkyl-, wherein one hydrogen atom of the alkyl group may be replaced by an OH or (C 1 -C 6 )-alkyl-0- residue, and 30 wherein one or more hydrogen atoms of the alkyl group may be replaced by fluorine; WO 2013/037415 PCT/EP2011/066061 122 R7 = H, (C1-C 6 )-alkyl-; wherein one or more hydrogen atoms of the alkyl group may be replaced by fluorine, 5 and/or of a stereoisomeric form of the compound of the formula I and/or mixtures of these forms, and/or their pharmaceutically acceptable salts, and with the proviso if R5 is methyl and R2, R3 and R4 are equal to H and A is equal to
    [4] 4-fluoro-phenyl, the residue X is not phenyl, 4-fluoro-phenyl, 4-chloro-phenyl, 4 10 methyl-phenyl, 4-methoxy-phenyl, 4-acetoxyphenyl, 2-chloro-phenyl, 3,4 dichlorophenyl, and with the proviso if R5 is methyl and R2, R3 and R4 are equal to H and X is a phenyl residue, the residue A is not phenyl, 4-fluoro-phenyl, 4-chloro-phenyl, 4-methyl phenyl, 4-ethyloxy-phenyl, 3-trifluoromethyl-phenyl, 2-thiophenyl or 4 15 methylthiophenyl, and with the proviso if R5 is methyl and R2 is methyl and R3 and R4 are equal to H and A is equal to 4-fluoro-phenyl, the residue X is not phenyl. 2. A compound according to claim 1, wherein 20 A = phenyl or a five- or six-membered heteroaryl selected from the group consisting of pyridine-2-yl, pyridine-3-yl, pyridine-4-yl, thiophen-2-yl or thiophen-3-yl, wherein phenyl and heteroaryl are optionally substituted with 1-3 rests selected independently from F, Cl, Br, CN, (C1-C 6 )-alkyl-, (C1-C 6 )-alkyl-0 25 and (C1-C 6 )-alkyl-S-, wherein one or more hydrogen atoms of the alkyl moieties may be replaced by fluorine; X = a five- or six-membered heteroaryl, comprising 1-3 heteroatoms selected 30 from the group N, 0 and S, WO 2013/037415 PCT/EP2011/066061 123 wherein the heteroaryl group is optionally substituted with 1-3 residues selected independently from F, Cl, Br, CN, (C1-C 6 )-alkyl-, (C1-C 6 )-alkyl-0 and (C1-C 6 )-alkyl-S-, (C1-C 6 )-alkyl-O-C(O)- and (C 1 -C 6 )-alkyl-SO 2 -, wherein one or more hydrogen atoms of the alkyl moieties may be 5 replaced by fluorine. R1 = R5-C(=O)- or (C 1 -C 6 )-alkyl-SO 2 -; R2 = H, (C 1 -C 4 )-alkyl-, (C 3 -C 6 )-cycloalkyl-; 10 R3 = H, (C1-C 2 )-alkyl-; R4 = H, (C1-C 2 )-alkyl-; 15 or wherein R3 and R4 together form a (C 2 -C 3 )-alkylene bridge; R5 = H, (C1-C 6 )-alkyl-, (C 3 -C 6 )-cycloalkyl-, (C1-C 6 )-alkyl-O-, (C1-C 6 )-alkyl-S-, (C1 C 6 )-alkyl-O-(C 1 -C 6 )-alkyl-, HO-(C1-C 6 )-alkyl-, (C 3 -C 6 )-cycloalkyl-(C 1 -C 6 )-alkyl-, (C 6 -C 1 o)-aryl-, (C 6 -C1o)-aryl-(C1-C 6 )-alkyl-, R7R6N-, heteroaryl, heteroaryl 20 (C1-C 6 )-alkyl-, aliphatic heterocycle, wherein one or more hydrogen atoms of the alkyl moieties may be replaced by fluorine, and wherein the aliphatic heterocycle is selected from the group of morpholinyl, piperidinyl, pyrrolidinyl and 4 to 7 membered aliphatic 25 heterocycles comprising an oxygen atom, and wherein the aliphatic heterocycle may be optionally substituted with 1 to 3 substituents independently selected from the group of F, OH, (C1-C6) alkyl-O- and (C 1 -C 6 )-alkyl-, and wherein the heteroaryl residues are five- or six-membered ring 30 systems, comprising 1-3 heteroatoms selected from the group N, 0 and S, and WO 2013/037415 PCT/EP2011/066061 124 wherein aryl and heteroaryl are optionally substituted with 1-3 rests selected independently from F, Cl, Br, CF 3 , (C 1 -C 6 )-alkyl-, (C 1 -C 6 )-alkyl-O-, CN, (C 1 -C 2 )-alkyl-SO 2 -; 5 R6 = H, (C 1 -C 6 )-alkyl-, (C 3 -C 6 )-cycloalkyl-, wherein one hydrogen atom of the alkyl group may be replaced by an OH- or (C 1 -C 6 )-alkyl-0- residue, and wherein one or more hydrogen atoms of the alkyl group may be replaced by fluorine; 10 R7 = H, (C 1 -C 6 )-alkyl-; wherein one or more hydrogen atoms of the alkyl group may be replaced by fluorine, 15 and/or of a stereoisomeric form of the compound of the formula I and/or mixtures of these forms, and/or their pharmaceutically acceptable salts. 3. A compound according to claim 1 or 2, wherein A= phenyl, 20 wherein the phenyl residue is optionally substituted with 1-3 rests selected independently from F, CI, Br, CN, (C 1 -C 4 )-alkyl-, (C 1 -C 4 )-alkyl-O- and (C1 C4)-alkyl-S-, wherein one or more hydrogen atoms of the alkyl moieties may be replaced by fluorine; 25 X = a five- or six-membered heteroaryl, selected from the group consisting of pyridine-2-yl, pyridine-3-yl, pyridine-4-yl, thiophen-2-yl, thiophen-3-yl, thiazol 2-yl, thiazol-4-yl, thiazol-5-yl, wherein the heteroaryl group is optionally substituted with 1-3 residues 30 selected independently from F, CI, Br, CN, (C 1 -C 6 )-alkyl-, (C 1 -C 6 )-alkyl-0 and (C 1 -C 6 )-alkyl-S-, (C 1 -C 6 )-alkyl-O-C(O)- and (C 1 -C 6 )-alkyl-SO 2 -, WO 2013/037415 PCT/EP2011/066061 125 wherein one or more hydrogen atoms of the alkyl moieties may be replaced by fluorine; R1 = R5-C(=O)- or (C 1 -C 2 )-alkyl-SO 2 -; 5 R2 = H, (C1-C 2 )-alkyl-, cyclopropyl-; R3 = H, methyl-; 10 R4 = H, methyl-; or wherein R3 and R4 together form an ethylene bridge; and wherein 15 R5 = H, (C1-C 4 )-alkyl-, (C 3 -C 6 )-cycloalkyl-, (C1-C 2 )-alkyl-O-, (C1-C 2 )-alkyl-S-, (C1 C 4 )-alkyl-0-methyl-, HO-(C1-C 2 )-alkyl-, (C 3 -C 6 )-cycloalkyl-(C 1 -C 2 )-alkyl-, phenyl, phenyl-(C1-C 2 )-alkyl-, R7R6N-, heteroaryl, heteroaryl-(C 1 -C 4 )-alkyl-, aliphatic heterocycle, wherein one or more hydrogen atoms of the alkyl moieties may be 20 replaced by fluorine, and wherein the aliphatic heterocycle is selected from the group of morpholinyl, piperidinyl, pyrrolidinyl, oxetanyl, tetrahydrofuranyl, and tetrahydropyranyl, and wherein the aliphatic heterocycle may be optionally substituted with 1 25 or 2 substituents independently selected from the group of F, OH, (C1-C2) alkyl-O- and (C1-C 4 )-alkyl-, and wherein the phenyl residue is optionally substituted with 1-3 rests selected independently from F, Cl, Br, CF 3 , (C 1 -C 4 )-alkyl-, (C 1 -C 4 )-alkyl-O-, CN, (C 1 -C 2 )-alkyl-SO 2 30 wherein the heteroaryl residues are selected from the group consisting of pyridine-2-yl, pyridine-3-yl, pyridine-4-yl, thiophen-2-yl, thiophen-3-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol- WO 2013/037415 PCT/EP2011/066061 126
    [5] 5-yl, pyrazol-3-yl, pyrazol-4-yl, imidazol-2-yl, imidazol-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyridazin-3-yl, pyridazin-4-yl, pyrazin-2-yl and pyrazin-3-yl, and wherein the heteroaryl residues are optionally substituted with 1 or 2 5 rests selected independently from F, Cl, Br, CF3, (C1-C 4 )-alkyl-, (C1-C 4 )-alkyl 0-, CN, (C 1 -C 2 )-alkyl-SO 2 -, R6 = H, (C1-C 4 )-alkyl-, cyclopropyl, wherein one hydrogen atom of the alkyl group may be replaced by an 10 OH, methoxy or ethoxy residue; and R7 = H, methyl-, ethyl; and/or of a stereoisomeric form of the compound of the formula I and/or mixtures of 15 these forms, and/or their pharmaceutically acceptable salts. 4. A compound according to any one of claims 1 to 3, wherein A = phenyl, wherein the phenyl residue is optionally substituted with 1 or 2 rests 20 selected independently from F, Cl, Br, CN, (C1-C 4 )-alkyl-, CF 3 , CF 2 H, CFH 2 , methoxy, ethoxy, OCF 3 , and (C 1 -C 2 )-alkyl-S-; X = a five- or six-membered heteroaryl, selected from the group consisting of pyridine-2-yl, pyridine-3-yl, pyridine-4-yl, thiophen-2-yl, thiophen-3-yl, thiazol 25 2-yl, thiazol-4-yl, thiazol-5-yl, wherein these residues are optionally substituted with 1 or 2 residues selected independently from F, Cl, Br, CN, (C 1 -C 4 )-alkyl-, CF 3 , CF 2 H, CFH 2 , methoxy, ethoxy, OCF 3 , (C 1 -C 2 )-alkyl-S-, (C 1 -C 2 )-alkyl-O-C(O)- and methyl-SO 2 -; 30 WO 2013/037415 PCT/EP2011/066061 127 R1 = R5-C(=O)- or (C 1 -C 2 )-alkyl-SO 2 -; R2 = H, methyl, ethyl, cyclopropyl; 5 R3 and R4 = H, and R5 = methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert.-butyl, cyclopropyl or cyclobutyl; 10 and/or of a stereoisomeric form of the compound of the formula I and/or mixtures of these forms, and/or their pharmaceutically acceptable salts. 5. A compound according to any one of claims 1, wherein A = a five- or six-membered heteroaryl, comprising 1-3 heteroatoms selected 15 from the group N, 0 and S, wherein the heteroaryl is substituted with 1-3 residues selected independently from F, Cl, Br, CN, (C1-C 6 )-alkyl-, (C1-C 6 )-alkyl-0- and (C1 Cs)-alkyl-S-, wherein one or more hydrogen atoms of the alkyl moieties may be 20 replaced by fluorine; X = phenyl, thiophen-2-yl or thiophen-3-yl, wherein these residues are optionally substituted with 1-3 rests selected independently from F, Cl, Br, CN, (C 1 -C 6 )-alkyl-, (C 1 -C 6 )-alkyl-0- and (C1 25 C 6 )-alkyl-S-, (C 1 -C 6 )-alkyl-O-C(O)- and (C 1 -C 6 )-alkyl-SO 2 -, wherein one or more hydrogen atoms of the alkyl moieties may be replaced by fluorine; R1 = R5-C(=0)- or (C 1 -C 6 )-alkyl-SO 2 -; 30 WO 2013/037415 PCT/EP2011/066061 128 R2 = H, (C 1 -C 6 )-alkyl-, (C 3 -C 6 )-cycloalkyl-; R3 = H, (C 1 -C 4 )-alkyl-; 5 R4 = H, (C1-C 4 )-alkyl-; or wherein R3 and R4 together form a (C 2 -C 3 )-alkylene bridge; R5 = H, (C1-C 6 )-alkyl-, (C 3 -C 6 )-cycloalkyl-, (C1-C 6 )-alkyl-O-, (C1-C 6 )-alkyl-S-, (C1 10 C 6 )-alkyl-O-(C 1 -C 6 )-alkyl-, HO-(C1-C 6 )-alkyl-, (C 3 -C 6 )-cycloalkyl-(C 1 -C 6 )-alkyl-, (C 6 -C 1 o)-aryl-, (C 6 -C1o)-aryl-(C1-C 6 )-alkyl-, R7R6N-, heteroaryl, heteroaryl (C1-C 6 )-alkyl-, aliphatic heterocycle, wherein one or more hydrogen atoms of the alkyl moieties may be replaced by fluorine, and 15 wherein the aliphatic heterocycle is selected from the group of morpholinyl, piperidinyl, pyrrolidinyl and 4 to 7 membered aliphatic heterocycles comprising an oxygen atom, and wherein the aliphatic heterocycle may be optionally substituted with 1 to 3 substituents selected from the group of F, OH, (C1-C 6 )-alkyl-0- and (C1 20 C 6 )-alkyl-, and wherein the heteroaryl residues are five- or six-membered ring systems, comprising 1-3 heteroatoms selected from the group N, 0 and S, and wherein aryl and heteroaryl are optionally substituted with 1-3 rests 25 selected independently from F, Cl, Br, CF 3 , (C 1 -C 6 )-alkyl-, (C 1 -C 6 )-alkyl-O-, CN, (C 1 -C 2 )-alkyl-SO 2 -; R6 = H, (C 1 -C 6 )-alkyl-, (C 3 -C 6 )-cycloalkyl-, wherein one hydrogen atom of the alkyl group may be replaced by an 30 OH- or (C 1 -C 6 )-alkyl-0- residue, and wherein one or more hydrogen atoms of the alkyl group may be replaced by fluorine; WO 2013/037415 PCT/EP2011/066061 129 R7 = H, (C1-C 6 )-alkyl-; wherein one or more hydrogen atoms of the alkyl group may be replaced by fluorine, 5 and/or of a stereoisomeric form of the compound of the formula I and/or mixtures of these forms, and/or their pharmaceutically acceptable salts, with the proviso that A is not 4-methylthiophenyl if in compounds of formula I R5 is methyl and R2, R3 and R4 are hydrogen and X is phenyl. 10
    [6] 6. A compound according to claim 5, wherein A = 2-pyridyl, 3-pyridyl or 4-pyridyl, wherein the pyridyl residues are substituted with 1 or 2 residues selected independently from F, Cl, Br, CN, (C1-C 4 )-alkyl-, CF 3 , CF 2 H, CFH 2 , 15 methoxy, ethoxy, OCF 3 , and (C 1 -C 2 )-alkyl-S-; X = phenyl, thiophen-2-yl or thiophen-3-yl, wherein these residues are substituted with 1 or 2 residues selected independently from F, Cl, Br, CN, (C 1 -C 4 )-alkyl-, CF 3 , CF 2 H, CFH 2 , 20 methoxy, ethoxy, OCF 3 , (C 1 -C 2 )-alkyl-S-, (C 1 -C 2 )-alkyl-O-C(O)- and methyl-SO 2 -; R1 = R5-C(=O)- or (C 1 -C 2 )-alkyl-SO 2 -; 25 R2 = H, methyl, ethyl, cyclopropyl; R3 and R4 = H; and R5 = H, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert.-butyl 30 or wherein R5 = cyclopropyl, cyclobutyl, cyclopentyl or (C 3 -C 6 )-cycloalkyl-(C 1 -C 2 )-alkyl-; WO 2013/037415 PCT/EP2011/066061 130 or wherein R5 = (C1-C 2 )-alkyl-O-, (C1-C 2 )-alkyl-S-, or OCF 3 , or wherein R5 = (C1-C 4 )-alkyl-0-methyl-, HO-(C1-C 2 )-alkyl-, 5 or wherein R5 = phenyl or phenylmethyl-, wherein the phenyl residues are optionally substituted with 1-3 rests selected independently from F, Cl, Br, CF 3 , (C 1 -C 2 )-alkyl-, (C 1 -C 2 )-alkyl-O-, CN, methyl-SO 2 -; 10 or wherein, R5 = R7R6N-, wherein R6 = H, (C 1 -C 4 )-alkyl-, cyclopropyl, wherein one hydrogen atom of the alkyl group may be replaced by an OH, methoxy or ethoxy residue; and 15 R7 = H, methyl-, ethyl; or wherein R5 = heteroaryl, heteroaryl-(C 1 -C 6 )-alkyl-, wherein the heteroaryl residues are selected from the group consisting of pyridine-2-yl, pyridine-3-yl, pyridine-4-yl, thiophen-2-yl, thiophen-3-yl, 20 thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol 5-yl, pyrazol-3-yl, pyrazol-4-yl, imidazol-2-yl, imidazol-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyridazin-3-yl, pyridazin-4-yl, pyrazin-2-yl and payrazin-3-yl, and wherein the heteroaryl residues are optionally substituted with 1 or 2 25 rests selected independently from F, CI, Br, CF 3 , (C 1 -C 4 )-alkyl-, (C 1 -C 4 )-alkyl 0-, CN, (C 1 -C 2 )-alkyl-SO 2 -, or wherein R5 = an aliphatic heterocycle, wherein the aliphatic heterocycle is selected from the group of 30 morpholinyl, piperidinyl, pyrrolidinyl, oxetanyl and tetrahydrofuranyl, tetrahydropyranyl, and WO 2013/037415 PCT/EP2011/066061 131 wherein the aliphatic heterocycle may be optionally substituted with 1 or 2 substituents independently selected from the group of F, OH, (C1-C2) alkyl-O- and (C1-C 4 )-alkyl-; 5 and/or of a stereoisomeric form of the compound of the formula I and/or mixtures of these forms, and/or their pharmaceutically acceptable salts.
    [7] 7. A compound according to claim 1, wherein 10 A is equal to phenyl, wherein the phenyl residue is optionally substituted with 1-3 residues selected independently from F, Cl, Br, CN, (C1-C 4 )-alkyl-, (C1-C 4 )-alkyl-O and (C1-C 4 )-alkyl-S-, wherein one or more hydrogen atoms of the alkyl moieties may be 15 replaced by fluorine, and X is equal to phenyl, wherein the phenyl group is optionally substituted with 1, 2 or 3 residues selected independently from F, Cl, Br, CN, (C1-C 4 )-alkyl-, (C1-C 4 )-alkyl-O-, 20 (C1-C 4 )-alkyl-S-, (C1-C 4 )-alkyl-O-C(O)- and (C 1 -C 4 )-alkyl-SO 2 -, wherein one or more hydrogen atoms of the alkyl moieties may be replaced by fluorine, and R1 = R5-C(=O)- or (C 1 -C 6 )-alkyl-SO 2 -; 25 R2 = H, (C 1 -C 6 )-alkyl-, (C 3 -C 6 )-cycloalkyl-; R3 = H, (C 1 -C 4 )-alkyl-; 30 R4 = H, (C 1 -C 4 )-alkyl-; or wherein R3 and R4 together form a (C 2 -C 3 )-alkylene bridge; WO 2013/037415 PCT/EP2011/066061 132 R5 = H, (C1-C 6 )-alkyl-, (C 3 -C 6 )-cycloalkyl-, (C1-C 6 )-alkyl-O-, (C1-C 6 )-alkyl-S-, (C1 C 6 )-alkyl-O-(C 1 -C 6 )-alkyl-, HO-(C1-C 6 )-alkyl-, (C 3 -C 6 )-cycloalkyl-(C 1 -C 6 )-alkyl-, (C 6 -C 1 o)-aryl-, (C 6 -C 1 o)-aryl-(C 1 -C 6 )-alkyl-, R7R6N-, heteroaryl, heteroaryl 5 (C1-C 6 )-alkyl-, aliphatic heterocycle, wherein one or more hydrogen atoms of the alkyl moieties may be replaced by fluorine, and wherein the aliphatic heterocycle is selected from the group of morpholinyl, piperidinyl, pyrrolidinyl and 4 to 7 membered aliphatic 10 heterocycles comprising an oxygen atom, and wherein the aliphatic heterocycle may be optionally substituted with 1 to 3 substituents selected from the group of F, OH, (C1-C 6 )-alkyl-0- and (C1 C 6 )-alkyl-, and wherein the heteroaryl residues are five- or six-membered ring 15 systems, comprising 1-3 heteroatoms selected from the group N, 0 and S, and wherein aryl and heteroaryl are optionally substituted with 1-3 rests selected independently from F, Cl, Br, CF 3 , (C 1 -C 6 )-alkyl-, (C 1 -C 6 )-alkyl-O-, CN, (C 1 -C 2 )-alkyl-SO 2 -; 20 R6 = H, (C 1 -C 6 )-alkyl-, (C 3 -C 6 )-cycloalkyl-, wherein one hydrogen atom of the alkyl group may be replaced by an OH- or (C 1 -C 6 )-alkyl-0- residue, and wherein one or more hydrogen atoms of the alkyl group may be 25 replaced by fluorine; R7 = H, (C 1 -C 6 )-alkyl-; wherein one or more hydrogen atoms of the alkyl group may be replaced by fluorine, 30 with the proviso if R5 is methyl and R2, R3 and R4 are equal to H and A is equal to 4-fluoro-phenyl, the residue X is not phenyl, 4-fluoro-phenyl, 4-chloro-phenyl, 4- WO 2013/037415 PCT/EP2011/066061 133 methyl-phenyl, 4-methoxy-phenyl, 4-acetoxyphenyl, 2-chloro-phenyl, 3,4 dichlorophenyl, and with the proviso if R5 is methyl and R2, R3 and R4 are equal to H and X is a phenyl residue, the residue A is not phenyl, 4-fluoro-phenyl, 4-chloro-phenyl, 4-methyl 5 phenyl, 4-ethyloxy-phenyl, or 3-trifluoromethyl-phenyl, and with the proviso if R5 is methyl and R2 is methyl and R3 and R4 are equal to H and A is equal to 4-fluoro-phenyl, the residue X is not phenyl.
    [8] 8. A compound according to claim 7, wherein 10 A= phenyl, wherein the phenyl residue is substituted with 1 or 2 residues selected independently from F, Cl, Br, CN, (C1-C 4 )-alkyl-, CF 3 , CF 2 H, CFH 2 , methoxy, ethoxy, OCF 3 and (C 1 -C 2 )-alkyl-S-; 15 X= phenyl, wherein the phenyl residue is substituted with 1 or 2 residues selected independently from F, Cl, Br, CN, (C 1 -C 4 )-alkyl-, CF 3 , CF 2 H, CFH 2 , methoxy, ethoxy, OCF 3 , (C 1 -C 2 )-alkyl-S-, (C 1 -C 2 )-alkyl-O-C(O)- and 20 methyl-SO 2 -, R1 = R5-C(=O)- or methyl-SO 2 -, R2 = H, (C1-C 2 )-alkyl-, cyclopropyl-; 25 R3 = H, methyl-; R4 = H, methyl-; 30 or wherein R3 and R4 together form an ethylene bridge; and wherein WO 2013/037415 PCT/EP2011/066061 134 R5 is equal to a heteroaryl or heteroaryl-(C1-C 6 )-alkyl-, wherein the heteroaryl residues are selected from the group consisting of pyridine-2-yl, pyridine-3-yl, pyridine-4-yl, thiophen-2-yl, thiophen-3-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, pyrazol-3-yl, pyrazol-4-yl, imidazol 5 2-yl, imidazol-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyridazin-3-yl, pyridazin-4-yl, pyrazin-2-yl and pyrazin-3-yl, and wherein these residues are optionally substituted with 1 or 2 residues selected independently from F, Cl, Br, CF 3 , methyl, ethyl, methoxy, ethoxy, CN, methyl-SO 2 -, 10 or wherein R5 is equal to H or wherein R5 is equal to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or (C 3 -C 6 )-cycloalkyl (C1-C 2 )-alkyl-, 15 or wherein R5 is equal to (C 1 -C 2 )-alkyl-O- or (C 1 -C 2 )-alkyl-S-, or wherein R5 is equal to (C 1 -C 4 )-alkyl-0-methyl-, HO-(C 1 -C 2 )-alkyl-, or wherein 20 R5 is equal to phenyl- or phenylmethyl-, wherein the phenyl residues are optionally substituted with 1-3 residues selected independently from F, CI, Br, CF 3 , (C 1 -C 2 )-alkyl-, (C1-C2) alkyl-O-, CN, methyl-SO 2 -, and wherein one or more hydrogen atoms of the alkyl moieties may be 25 replaced by fluorine; or wherein R5 is equal to R7R6N-, wherein R6 = H, (C 1 -C 4 )-alkyl-, cyclopropyl-, wherein one hydrogen atom of the alkyl group may be replaced by a hydroxy, methoxy or ethoxy residue, and 30 R7 = H, methyl-, ethyl-; or wherein R5 is equal to an aliphatic heterocycle, WO 2013/037415 PCT/EP2011/066061 135 wherein the aliphatic heterocycle is selected from the group of oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, morpholinyl, piperidinyl, pyrrolidinyl, and wherein the aliphatic heterocycle may be optionally substituted with 1 5 or 2 substituents selected from the group of F, OH, (C1-C 2 )-alkyl-O- and (C1 C 4 )-alkyl-, and wherein one or more hydrogen atoms of the alkyl groups may be replaced by fluorine; and/or of a stereoisomeric form of the compound of the formula I and/or mixtures of 10 these forms, and/or their pharmaceutically acceptable salts.
    [9] 9. A compound according to claim 7, wherein A = phenyl, 15 wherein the phenyl residue is substituted with 1 or 2 residues selected independently from F, Cl, Br, CN, (C1-C 4 )-alkyl-, CF 3 , CF 2 H, CFH 2 , methoxy, ethoxy, OCF 3 and (C 1 -C 2 )-alkyl-S-; X = phenyl, 20 wherein the phenyl residue is substituted with 1 or 2 residues selected independently from F, Cl, Br, CN, (C 1 -C 4 )-alkyl-, CF 3 , CF 2 H, CFH 2 , methoxy, ethoxy, OCF 3 , (C 1 -C 2 )-alkyl-S-, (C 1 -C 2 )-alkyl-O-C(O)- and methyl-SO 2 -, 25 R1 = R5-C(=O)-; R2 = H, (C 1 -C 2 )-alkyl-, cyclopropyl-; R3 = H, methyl-; 30 R4 = H, methyl-; WO 2013/037415 PCT/EP2011/066061 136 or wherein R3 and R4 together form an ethylene bridge; and wherein R5 is equal to (C 2 -C 4 )-alkyl, 5 or wherein R5 is equal to methyl, with the proviso if R5 is methyl and R2, R3 and R4 are equal to H and A is equal to 4-fluoro-phenyl, the residue X is not phenyl, 4-fluoro-phenyl, 4 chloro-phenyl, 4-methyl-phenyl, 4-methoxy-phenyl, 4-acetoxyphenyl, 2 10 chloro-phenyl, 3,4-dichlorophenyl; and/or of a stereoisomeric form of the compound of the formula I and/or mixtures of these forms, and/or their pharmaceutically acceptable salts. 15
    [10] 10. A compound according to claim 1, wherein A = (C 6 -C 1 o)-aryl or a five- or six-membered heteroaryl, comprising 1-3 heteroatoms selected from the group N, 0 and S, wherein aryl and heteroaryl are optionally substituted with 1-3 rests 20 selected independently from F, Cl, Br, CN, (C1-C 6 )-alkyl-, (C1-C 6 )-alkyl-0 and (C1-C 6 )-alkyl-S-, wherein one or more hydrogen atoms of the alkyl moieties may be replaced by fluorine; 25 X = (C 6 -C 1 o)-aryl or a five- or six-membered heteroaryl, comprising 1-3 heteroatoms selected from the group N, 0 and S, wherein aryl and heteroaryl are optionally substituted with 1-3 rests selected independently from F, Cl, Br, CN, (C 1 -C 6 )-alkyl-, (C 1 -C 6 )-alkyl-0 and (C 1 -C 6 )-alkyl-S-, (C 1 -C 6 )-alkyl-O-C(O)- and (C 1 -C 6 )-alkyl-SO 2 -, 30 wherein one or more hydrogen atoms of the alkyl moieties may be replaced by fluorine; WO 2013/037415 PCT/EP2011/066061 137 R1 = R5-C(=O)- or (C 1 -C 6 )-alkyl-SO 2 -; R2 = H, (C 1 -C 6 )-alkyl-, (C 3 -C 6 )-cycloalkyl-; 5 R3 = H, (C1-C 4 )-alkyl-; R4 = H, (C 1 -C 4 )-alkyl-; or wherein R3 and R4 together form a (C 2 -C 3 )-alkylene bridge; 10 and wherein R5 is equal to a heteroaryl or heteroaryl-(C1-C 6 )-alkyl-, wherein the heteroaryl residues are five- or six-membered ring systems, comprising 1-3 heteroatoms selected from the group N, 0 and S, and 15 wherein the heteroaryl residues are optionally substituted with 1-3 residues selected independently from F, Cl, Br, CF 3 , (C 1 -C 6 )-alkyl-, (C 1 -C 6 )-alkyl-O-, CN, (C 1 -C 2 )-alkyl-SO 2 -, wherein one or more hydrogen atoms of the alkyl moieties may be replaced by fluorine, 20 with the proviso if in compounds of formula I A is a 3-cyanophenyl residue and X a 2,4-difluorophenyl residue R5 is not pyrimidin-4-yl, pyridine-2-yl, 1 methyl-pyrazol-3-yl or 1-methyl-imidazol-2-yl, or wherein R5 is methyl, with the proviso if in compounds of formula I R2, R3 and R4 are hydrogen 25 and X is a 2,4-difluorophenyl residue A is not pyridine-3-yl, 2-fluoro-phenyl, 3 fluoro-phenyl, 4-fluorophenyl, 3-cyano-phenyl, 3-methoxy-phenyl, 3 trifluormethoxy-phenyl, 2-fluoro-5-methoxy-phenyl, and with the proviso if in compounds of formula I R2, R3 and R4 are hydrogen and X is a 3-cyanophenyl residue A is not a 4-fluorophenyl residue, and 30 with the proviso if in compounds of formula I R3 is methyl, R2 and R4 are hydrogen and X is a 2,4-difluoro-phenyl residue A is not a 4-fluoro-phenyl, and WO 2013/037415 PCT/EP2011/066061 138 with the proviso if in compounds of formula I R2, R3 and R4 are hydrogen and X is phenyl A is not phenyl, 3-trifluoromethyl-phenyl, 4-fluoro-phenyl, 4 chloro-phenyl, 4-methyl-phenyl, 4-ethyloxy-phenyl, 4-acetoxyphenyl, 4 methyl-thiophenyl, 2-thiophenyl, and 5 with the proviso if in compounds of formula I R2, R3 and R4 are hydrogen and A is 4-fluoro-phenyl X is not phenyl, 2-chloro-phenyl, 3,4-dichloro-phenyl, 4-chloro-phenyl, 4-fluoro-phenyl, 4-methyl-phenyl, 4-methoxy-phenyl, 4 ethyloxy-phenyl, and with the proviso if R5 is methyl and R2 is methyl, and R3 and R4 are equal to 10 H and A is equal to 4-fluoro-phenyl, the residue X is not phenyl, and or wherein R5 is equal to H, (C 2 -C 6 )-alkyl, CF 3 , CF 2 H, CFH 2 , wherein one or more hydrogen atoms of the alkyl residue may be replaced by fluorine; 15 or wherein R5 is equal to (C 3 -C 6 )-cycloalkyl or (C 3 -C 6 )-cycloalkyl-(C 1 -C 4 )-alkyl-, with the proviso if in compounds of formula I A is a 3-cyanophenyl residue and X a 2,4-difluorophenyl residue R5 is not cyclopropyl, or wherein 20 R5 is equal to (C1-C 4 )-alkyl-O- or (C1-C 4 )-alkyl-S-, wherein one or more hydrogen atoms of the alkyl moieties may be replaced by fluorine; or wherein R5 is equal to (C 1 -C 4 )-alkyl-O-(C 1 -C 2 )-alkyl-, HO-(C 1 -C 4 )-alkyl-, 25 or wherein R5 is equal to phenyl-, phenyl-(C 1 -C 4 )-alkyl-, wherein the phenyl residues are optionally substituted with 1-3 residues selected independently from F, Cl, Br, CF 3 , (C 1 -C 6 )-alkyl-, (C1-C) alkyl-O-, CN, (C 1 -C 2 )-alkyl-SO 2 -, and 30 wherein one or more hydrogen atoms of the alkyl moieties may be replaced by fluorine, WO 2013/037415 PCT/EP2011/066061 139 with the proviso if in compounds of formula I A is a 3-cyanophenyl residue and X a 2,4-difluorophenyl residue R5 is not 3-methylsulfonyl-phenyl or 4 methylsulfonyl-phenyl; or wherein 5 R5 is equal to R7R6N-, wherein R6 = H, (C1-C 4 )-alkyl-, cyclopropyl-, wherein one hydrogen atom of the alkyl group may be replaced by an OH, methoxy or ethoxy residue and R7 = H, (C1-C 2 )-alkyl-, or wherein 10 R5 is equal to an aliphatic heterocycle, wherein the aliphatic heterocycle is selected from the group of oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, morpholinyl, piperidinyl, pyrrolidinyl, and wherein the aliphatic heterocycle may be optionally substituted with 1 15 or 2 substituents selected from the group of F, OH, (C1-C 4 )-alkyl-O- and (C1 C 4 )-alkyl-, and wherein one or more hydrogen atoms of the alkyl groups may be replaced by fluorine, with the proviso if in compounds of formula I A is a 3-cyanophenyl residue 20 and X a 2,4-difluorophenyl residue R5 is not 3-methyl-oxetan-3-yl, tetrahydrofuran-3-yl, tetrahydropyran-4-yl or 1-methyl-piperidin-4-yl.
    [11] 11. A compound according to claim 10, wherein 25 A = phenyl, pyridine-2-yl, pyridine-3-yl, pyridine-4-yl, thiophen-2-yl or thiophen-3 yl, wherein these residues are optionally substituted with 1 or 2 residues selected independently from F, Cl, Br, CN, (C 1 -C 4 )-alkyl-, CF 3 , CF 2 H, CFH 2 , methoxy, ethoxy, OCF 3 and (C 1 -C 2 )-alkyl-S-; 30 X= phenyl, WO 2013/037415 PCT/EP2011/066061 140 wherein the phenyl residue is substituted with 1 or 2 residues selected independently from F, Cl, Br, CN, (C1-C 4 )-alkyl-, CF 3 , CF 2 H, CFH 2 , methoxy, ethoxy, OCF 3 , (C 1 -C 2 )-alkyl-S-, (C 1 -C 2 )-alkyl-O-C(O)- and methyl-SO 2 -, 5 or pyridine-2-yl, pyridine-3-yl, pyridine-4-yl, thiophen-2-yl, thiophen-3-yl, thiazol 2-yl, thiazol-4-yl, thiazol-5-yl, wherein these residues are optionally substituted with 1 or 2 residues selected independently from F, CI, Br, CN, (C 1 -C 4 )-alkyl-, CF 3 , CF 2 H, 10 CFH 2 , methoxy, ethoxy, OCF 3 , (C 1 -C 2 )-alkyl-S-, (C 1 -C 2 )-alkyl-O-C(O)- and methyl-SO 2 -; R1 = R5-C(=O)- or (C1-C 2 )-alkyl-SO 2 -; 15 R2 = H, (C1-C 2 )-alkyl-, cyclopropyl-; R3 = H, (C1-C 2 )-alkyl-; R4 = H, (C1-C 2 )-alkyl-; 20 or wherein R3 and R4 together form an ethylene bridge; and wherein R5 is equal to a heteroaryl or heteroaryl-(C 1 -C 6 )-alkyl-, wherein the heteroaryl 25 residues are selected from the group consisting of pyridine-2-yl, pyridine-3-yl, pyridine-4-yl, thiophen-2-yl, thiophen-3-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, pyrazol-3-yl, pyrazol-4-yl, imidazol 2-yl, imidazol-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyridazin-3-yl, pyridazin-4-yl, pyrazin-2-yl and payrazin-3-yl, and 30 wherein these residues are optionally substituted with 1 or 2 residues selected independently from F, CI, Br, CF 3 , methyl, ethyl, methoxy, ethoxy, CN, methyl-SO 2 -, WO 2013/037415 PCT/EP2011/066061 141 with the proviso if in compounds of formula I A is a 3-cyanophenyl residue and X a 2,4-difluorophenyl residue R5 is not pyrimidin-4-yl, pyridine-2-yl, 1-methyl pyrazol-3-yl or 1 -methyl-imidazol-2-yl, or wherein R5 is methyl, 5 with the proviso if in compounds of formula I R2, R3 and R4 are hydrogen and X is a 2,4-difluorophenyl residue A is not pyridine-3-yl, 2-fluoro-phenyl, 3-fluoro phenyl, 4-fluorophenyl, 3-cyano-phenyl, 3-methoxy-phenyl, 3-trifluormethoxy phenyl, 2-fluoro-5-methoxy-phenyl, and with the proviso if in compounds of formula I R2, R3 and R4 are hydrogen and X 10 is a 3-cyanophenyl residue A is not a 4-fluorophenyl residue, and with the proviso if in compounds of formula I R3 is methyl, R2 and R4 are hydrogen and X is a 2,4-difluoro-phenyl residue A is not a 4-fluoro-phenyl, and with the proviso if in compounds of formula I R2, R3 and R4 are hydrogen and X is phenyl A is not phenyl, 3-trifluoromethyl-phenyl, 4-fluoro-phenyl, 4-chloro 15 phenyl, 4-methyl-phenyl, 4-ethoxy-phenyl, 2-thiophenyl, 4-methylthiophenyl, and with the proviso if in compounds of formula I R2, R3 and R4 are hydrogen and A is 4-fluoro-phenyl X is not 2-chloro-phenyl, 3,4-dichloro-phenyl, 4-chloro-phenyl, 4-fluoro-phenyl, 4-methyl-phenyl, 4-methoxy-phenyl, 4-ethoxy-phenyl or 4 acetoxyphenyl, and 20 or wherein R5 is equal to H, (C 2 -C 4 )-alkyl, CF 3 ; or wherein R5 is equal to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or (C 3 -C 6 )-cycloalkyl (C1-C 2 )-alkyl-, 25 with the proviso if in compounds of formula I A is a 3-cyanophenyl residue and X a 2,4-difluorophenyl residue R5 is not cyclopropyl, or wherein R5 is equal to (C 1 -C 2 )-alkyl-O- or (C 1 -C 2 )-alkyl-S-, wherein one or more hydrogen atoms of the alkyl moieties may be 30 replaced by fluorine; or wherein R5 is equal to (C 1 -C 4 )-alkyl-0-methyl-, HO-(C 1 -C 2 )-alkyl-, WO 2013/037415 PCT/EP2011/066061 142 wherein one or more hydrogen atoms of the alkyl moieties may be replaced by fluorine; or wherein R5 is equal to phenyl-, phenyl-(C1-C 2 )-alkyl-, 5 wherein the phenyl residues are optionally substituted with 1-3 residues selected independently from F, Cl, Br, CF 3 , (C 1 -C 2 )-alkyl-, (C1-C2) alkyl-O-, CN, methyl-SO 2 -, and wherein one or more hydrogen atoms of the alkyl moieties may be replaced by fluorine, 10 with the proviso if in compounds of formula I A is a 3-cyanophenyl residue and X a 2,4-difluorophenyl residue R5 is not 3-methylsulfonyl-phenyl or 4 methylsulfonyl-phenyl; or wherein R5 is equal to R7R6N-, wherein 15 R6 = H, (C 1 -C 4 )-alkyl-, cyclopropyl-, wherein one hydrogen atom of the alkyl group may be replaced by a hydroxy, methoxy or ethoxy residue and R7 = H, methyl-, ethyl or wherein R5 is equal to an aliphatic heterocycle, 20 wherein the aliphatic heterocycle is selected from the group of oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, morpholinyl, piperidinyl, pyrrolidinyl, and wherein the aliphatic heterocycle may be optionally substituted with 1 or 2 substituents selected from the group of F, OH, (C1-C 2 )-alkyl-O- and (C1 25 C 4 )-alkyl-, and wherein one or more hydrogen atoms of the alkyl groups may be replaced by fluorine, with the proviso if in compounds of formula I A is a 3-cyanophenyl residue and X a 2,4-difluorophenyl residue R5 is not 3-methyl-oxetan-3-yl, 30 tetrahydrofuran-3-yl, tetrahydropyran-4-yl or 1-methyl-piperidin-4-yl, WO 2013/037415 PCT/EP2011/066061 143 and/or of a stereoisomeric form of the compound of the formula I and/or mixtures of these forms, and/or their pharmaceutically acceptable salts.
    [12] 12. A compound according to claim 10, wherein 5 A is equal to phenyl, wherein the phenyl residue is optionally substituted with 1, 2 or 3 residues selected independently from F, Cl, Br, CN, (C1-C 4 )-alkyl-, (C1-C 4 )-alkyl-O and (C1-C 4 )-alkyl-S-, 10 wherein one or more hydrogen atoms of the alkyl moieties may be replaced by fluorine, and X is equal to phenyl, wherein the phenyl group is optionally substituted with 1, 2 or 3 residues 15 selected independently from F, Cl, Br, CN, (C1-C 4 )-alkyl-, (C1-C 4 )-alkyl-O-, (C1-C 4 )-alkyl-S-, (C1-C 4 )-alkyl-O-C(O)- and (C 1 -C 4 )-alkyl-SO 2 -, wherein one or more hydrogen atoms of the alkyl moieties may be replaced by fluorine, and 20 R1 = R5-C(=O)- or (C 1 -C 6 )-alkyl-SO 2 -; R2 = H, (C 1 -C 6 )-alkyl-, (C 3 -C 6 )-cycloalkyl-; R3 = H, (C 1 -C 4 )-alkyl-; 25 R4 = H, (C 1 -C 4 )-alkyl-; or wherein R3 and R4 together form a (C 2 -C 3 )-alkylene bridge; 30 and wherein WO 2013/037415 PCT/EP2011/066061 144 R5 is equal to a heteroaryl or heteroaryl-(C1-C 6 )-alkyl-, wherein the heteroaryl residues are five- or six-membered ring systems, comprising 1-3 heteroatoms selected from the group N, 0 and S, and wherein the heteroaryl residues are optionally substituted with 1-3 residues 5 selected independently from F, Cl, Br, CF 3 , (C 1 -C 6 )-alkyl-, (C 1 -C 6 )-alkyl-O-, CN, (C 1 -C 2 )-alkyl-SO 2 -, wherein one or more hydrogen atoms of the alkyl moieties may be replaced by fluorine, with the proviso if in compounds of formula I A is a 3-cyanophenyl residue 10 and X a 2,4-difluorophenyl residue R5 is not pyrimidin-4-yl, pyridine-2-yl, 1 methyl-pyrazol-3-yl or 1-methyl-imidazol-2-yl, or wherein R5 is methyl, with the proviso if in compounds of formula I R2, R3 and R4 are hydrogen and X is a 2,4-difluorophenyl residue A is not pyridine-3-yl, 2-fluoro-phenyl, 3 15 fluoro-phenyl, 4-fluorophenyl, 3-cyano-phenyl, 3-methoxy-phenyl, 3 trifluormethoxy-phenyl, 2-fluoro-5-methoxy-phenyl, and with the proviso if in compounds of formula I R2, R3 and R4 are hydrogen and X is a 3-cyanophenyl residue A is not a 4-fluorophenyl residue, and with the proviso if in compounds of formula I R3 is methyl, R2 and R4 are 20 hydrogen and X is a 2,4-difluoro-phenyl residue A is not a 4-fluoro-phenyl, and with the proviso if in compounds of formula I R2, R3 and R4 are hydrogen and X is phenyl A is not phenyl, 3-trifluoromethyl-phenyl, 4-fluoro-phenyl, 4 chloro-phenyl, 4-methyl-phenyl, 4-ethyloxy-phenyl, 4-methyl-thiophenyl, 2 25 thiophenyl, and with the proviso if in compounds of formula I R2, R3 and R4 are hydrogen and A is 4-fluoro-phenyl X is not phenyl, 2-chloro-phenyl, 3,4-dichloro-phenyl, 4-chloro-phenyl, 4-fluoro-phenyl, 4-methyl-phenyl, 4-methoxy-phenyl, 4 ethyloxy-phenyl, 4-acetoxyphenyl, and 30 with the proviso if R5 is methyl and R2 is methyl, and R3 and R4 are equal to H and A is equal to 4-fluoro-phenyl, the residue X is not phenyl, and or wherein WO 2013/037415 PCT/EP2011/066061 145 R5 is equal to H, (C 2 -C 6 )-alkyl, CF 3 , CF 2 H, CFH 2 , wherein one or more hydrogen atoms of the alkyl residue may be replaced by fluorine; or wherein 5 R5 is equal to (C 3 -C 6 )-cycloalkyl or (C 3 -C 6 )-cycloalkyl-(C 1 -C 4 )-alkyl-, with the proviso if in compounds of formula I A is a 3-cyanophenyl residue and X a 2,4-difluorophenyl residue R5 is not cyclopropyl, or wherein R5 is equal to (C1-C 4 )-alkyl-O- or (C1-C 4 )-alkyl-S-, 10 wherein one or more hydrogen atoms of the alkyl moieties may be replaced by fluorine; or wherein R5 is equal to (C 1 -C 4 )-alkyl-O-(C 1 -C 2 )-alkyl-, HO-(C 1 -C 4 )-alkyl-, or wherein 15 R5 is equal to phenyl-, phenyl-(C 1 -C 4 )-alkyl-, wherein the phenyl residues are optionally substituted with 1-3 residues selected independently from F, Cl, Br, CF 3 , (C 1 -C 6 )-alkyl-, (C1-C) alkyl-O-, CN, (C 1 -C 2 )-alkyl-SO 2 -, and wherein one or more hydrogen atoms of the alkyl moieties may be 20 replaced by fluorine, with the proviso if in compounds of formula I A is a 3-cyanophenyl residue and X a 2,4-difluorophenyl residue R5 is not 3-methylsulfonyl-phenyl, 4 methylsulfonyl-phenyl; or wherein 25 R5 is equal to R7R6N-, wherein R6 = H, (C 1 -C 4 )-alkyl-, cyclopropyl-, wherein one hydrogen atom of the alkyl group may be replaced by an OH, methoxy or ethoxy residue and R7 = H, (C 1 -C 2 )-alkyl-, or wherein 30 R5 is equal to an aliphatic heterocycle, WO 2013/037415 PCT/EP2011/066061 146 wherein the aliphatic heterocycle is selected from the group of oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, morpholinyl, piperidinyl, pyrrolidinyl, and wherein the aliphatic heterocycle may be optionally substituted with 1 5 or 2 substituents selected from the group of F, OH, (C1-C 4 )-alkyl-O- and (C1 C 4 )-alkyl-, and wherein one or more hydrogen atoms of the alkyl groups may be replaced by fluorine, with the proviso if in compounds of formula I A is a 3-cyanophenyl residue 10 and X a 2,4-difluorophenyl residue R5 is not 3-methyl-oxetan-3-yl, tetrahydrofuran-3-yl, tetrahydropyran-4-yl or 1-methyl-piperidin-4-yl. R6 = H, (C1-C 6 )-alkyl-, (C 3 -C 6 )-cycloalkyl-, wherein one hydrogen atom of the alkyl group may be replaced by an 15 OH- or (C1-C 6 )-alkyl-0- residue, and wherein one or more hydrogen atoms of the alkyl group may be replaced by fluorine; R7 = H, (C1-C 6 )-alkyl-; 20 wherein one or more hydrogen atoms of the alkyl group may be replaced by fluorine.
    [13] 13. A compound according to claim 12, wherein 25 A = phenyl, wherein the phenyl residue is substituted with 1 or 2 residues selected independently from F, Cl, Br, CN, (C 1 -C 4 )-alkyl-, CF 3 , CF 2 H, CFH 2 , methoxy, ethoxy, OCF 3 and (C 1 -C 2 )-alkyl-S-; 30 X = phenyl, wherein the phenyl residue is substituted with 1 or 2 residues selected independently from F, Cl, Br, CN, (C 1 -C 4 )-alkyl-, CF 3 , CF 2 H, CFH 2 , WO 2013/037415 PCT/EP2011/066061 147 methoxy, ethoxy, OCF 3 , (C 1 -C 2 )-alkyl-S-, (C 1 -C 2 )-alkyl-O-C(O)- and methyl-SO 2 -, R1 = R5-C(=O)- or methyl-SO 2 -, 5 R2 = H, (C1-C 2 )-alkyl-, cyclopropyl-; R3 = H, methyl-; 10 R4 = H, methyl-; or wherein R3 and R4 together form an ethylene bridge; and wherein 15 R5 is equal to a heteroaryl or heteroaryl-(C1-C 6 )-alkyl-, wherein the heteroaryl residues are selected from the group consisting of pyridine-2-yl, pyridine-3-yl, pyridine-4-yl, thiophen-2-yl, thiophen-3-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, pyrazol-3-yl, pyrazol-4-yl, imidazol 2-yl, imidazol-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyridazin-3-yl, 20 pyridazin-4-yl, pyrazin-2-yl and payrazin-3-yl, and wherein these residues are optionally substituted with 1 or 2 residues selected independently from F, Cl, Br, CF 3 , methyl, ethyl, methoxy, ethoxy, CN, methyl-SO 2 -, with the proviso if in compounds of formula I A is a 3-cyanophenyl residue and X 25 a 2,4-difluorophenyl residue R5 is not pyrimidin-4-yl, pyridine-2-yl, 1-methyl pyrazol-3-yl or 1 -methyl-imidazol-2-yl, or wherein R5 is methyl, with the proviso if in compounds of formula I R2, R3 and R4 are hydrogen and X is a 2,4-difluorophenyl residue A is not pyridine-3-yl, 2-fluoro-phenyl, 3-fluoro 30 phenyl, 4-fluorophenyl, 3-cyano-phenyl, 3-methoxy-phenyl, 3-trifluormethoxy phenyl, 2-fluoro-5-methoxy-phenyl, and WO 2013/037415 PCT/EP2011/066061 148 with the proviso if in compounds of formula I R2, R3 and R4 are hydrogen and X is a 3-cyanophenyl residue A is not a 4-fluorophenyl residue, and with the proviso if in compounds of formula I R3 is methyl, R2 and R4 are hydrogen and X is a 2,4-difluoro-phenyl residue A is not a 4-fluoro-phenyl, and 5 with the proviso if in compounds of formula I R2, R3 and R4 are hydrogen and A is 4-fluoro-phenyl X is not 2-chloro-phenyl, 3,4-dichloro-phenyl, 4-chloro-phenyl, 4-fluoro-phenyl, 4-methyl-phenyl, 4-methoxy-phenyl, 4-ethoxy-phenyl or 4 acetoxyphenyl, and or wherein 10 R5 is equal to H, (C 2 -C 4 )-alkyl, CF 3 ; or wherein R5 is equal to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or (C 3 -C 6 )-cycloalkyl (C1-C 2 )-alkyl-, with the proviso if in compounds of formula I A is a 3-cyanophenyl residue 15 and X a 2,4-difluorophenyl residue R5 is not cyclopropyl, or wherein R5 is equal to (C 1 -C 2 )-alkyl-O- or (C 1 -C 2 )-alkyl-S-, wherein one or more hydrogen atoms of the alkyl moieties may be replaced by fluorine; 20 or wherein R5 is equal to (C 1 -C 4 )-alkyl-0-methyl-, HO-(C 1 -C 2 )-alkyl-, wherein one or more hydrogen atoms of the alkyl moieties may be replaced by fluorine; or wherein 25 R5 is equal to phenyl-, phenyl-(C 1 -C 2 )-alkyl-, wherein the phenyl residues are optionally substituted with 1-3 residues selected independently from F, Cl, Br, CF 3 , (C 1 -C 2 )-alkyl-, (C1-C2) alkyl-O-, CN, methyl-SO 2 -, and wherein one or more hydrogen atoms of the alkyl moieties may be 30 replaced by fluorine, WO 2013/037415 PCT/EP2011/066061 149 with the proviso if in compounds of formula I A is a 3-cyanophenyl residue and X a 2,4-difluorophenyl residue R5 is not 3-methylsulfonyl-phenyl, 4-methylsulfonyl phenyl; or wherein 5 R5 is equal to R7R6N-, wherein R6 = H, (C1-C 4 )-alkyl-, cyclopropyl-, wherein one hydrogen atom of the alkyl group may be replaced by a hydroxy, methoxy or ethoxy residue and R7 = H, methyl-, ethyl or wherein 10 R5 is equal to an aliphatic heterocycle, wherein the aliphatic heterocycle is selected from the group of oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, morpholinyl, piperidinyl, pyrrolidinyl, and wherein the aliphatic heterocycle may be optionally substituted with 1 15 or 2 substituents selected from the group of F, OH, (C1-C 2 )-alkyl-O- and (C1 C 4 )-alkyl-, and wherein one or more hydrogen atoms of the alkyl groups may be replaced by fluorine, with the proviso if in compounds of formula I A is a 3-cyanophenyl residue 20 and X a 2,4-difluorophenyl residue R5 is not 3-methyl-oxetan-3-yl, tetrahydrofuran-3-yl, tetrahydropyran-4-yl or 1-methyl-piperidin-4-yl, and/or of a stereoisomeric form of the compound of the formula I and/or mixtures of these forms, and/or their pharmaceutically acceptable salts. 25
    [14] 14. A compound according to claim 10, wherein A= phenyl, wherein the phenyl residue is substituted with 1 or 2 residues selected 30 independently from F, Cl, Br, CN, (C 1 -C 4 )-alkyl-, CF 3 , CF 2 H, CFH 2 , methoxy, ethoxy, OCF 3 and (C 1 -C 2 )-alkyl-S-; WO 2013/037415 PCT/EP2011/066061 150 X= phenyl, wherein the phenyl residue is substituted with 1 or 2 residues selected independently from F, Cl, Br, CN, (C 1 -C 4 )-alkyl-, CF 3 , CF 2 H, CFH 2 , methoxy, ethoxy, OCF 3 , (C 1 -C 2 )-alkyl-S-, (C 1 -C 2 )-alkyl-O-C(O)- and 5 methyl-SO 2 -, R1 = R5-C(=O)-; R2 = H, (C 1 -C 2 )-alkyl-, cyclopropyl-; 10 R3 = H, methyl-; R4 = H, methyl-; 15 or wherein R3 and R4 together form an ethylene bridge; and wherein R5 is equal to (C 2 -C 4 )-alkyl; 20 and/or of a stereoisomeric form of the compound of the formula I and/or mixtures of these forms, and/or their pharmaceutically acceptable salts.
    [15] 15. A compound according to claim 1 selected from the group consisting of 3-(3 Cyano-phenyl)-1-(2,4-difluoro-benzyl)-1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5 25 carboxylic acid isopropylamide; 3-(4-Fluoro-phenyl)-1 -[(S)-1 -(4-fluoro-phenyl)-ethyl] 1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid ethylamide; 3-(4-Fluoro phenyl)-1-[(R)-1-(4-fluoro-phenyl)-ethyl]-1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5 carboxylic acid ethylam ide; 3-(4-Fluoro-phenyl)-1 -[(S)-1 -(4-fluoro-phenyl)-ethyl] 1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butylamide; 3-(3 30 Cyano-phenyl)-1-(2,4-difluoro-benzyl)-1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5 carboxylic acid ethylamide; 3-(3-Cyano-phenyl)-1 -(2,4-difluoro-benzyl)-1 4,6,7 tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid methylamide; {3-(4-Fluoro- WO 2013/037415 PCT/EP2011/066061 151 phenyl)-1 -[(S)-1 -(4-fluoro-phenyl)-ethyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5 yl}-morpholin-4-yl-methanone; {3-(4-Fluoro-phenyl)-1-[(S)-1-(4-fluoro-phenyl)-ethyl] 1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-((S)-3-hydroxy-pyrrolidin-1 -yl) methanone; 3-(3-Cyano-phenyl)-1 -(2,4-difluoro-benzyl)-1 4,6,7-tetrahydro 5 pyrazolo[4,3-c]pyridine-5-carboxylic acid dimethylamide; 3-(3-Cyano-phenyl)-1 -(2,4 difluoro-benzyl)-1 4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid (2 hydroxy-ethyl)-methyl-amide; 2-[5-Acetyl-1-(2,4-difluoro-benzyl)-4,5,6,7-tetrahydro 1 H-pyrazolo[4,3-c]pyridin-3-yl]-isonicotinonitrile; 6-[5-Acetyl-1 -(2,4-difluoro-benzyl) 4,5,6,7-tetrahydro-1 H-pyrazolo[4,3-c]pyridin-3-yl]-pyridine-2-carbonitrile; 3-[1-(2,4 10 Difluoro-benzyl)-5-(2-hydroxy-acetyl)-4,5,6,7-tetrahydro-1 H-pyrazolo[4,3-c]pyridin-3 yl]-benzonitrile; 3-[5-Acetyl-1 -(2,4-difluoro-benzyl)-4,5,6,7-tetrahydro-1 H pyrazolo[4,3-c]pyridin-3-yl]-benzonitrile; 1 -[1 -(2,4-Difluoro-benzyl)-3-(3-methyl pyridin-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone; 1-[1-(2,4 Difluoro-benzyl)-3-(4-methoxy-pyridin-2-yl)-1 4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin 15 5-yl]-ethanone; 1 -[1 -(2-Methyl-thiazol-4-ylmethyl)-3-(3-trifluoromethyl-phenyl) 1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone; 1-[1-Thiazol-2-ylmethyl-3 (3-trifluoromethyl-phenyl)-1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone; 1-[1 -(2,4-Difluoro-benzyl)-3-thiophen-2-yl-1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin 5-yl]-ethanone; 1-[1-(5-Chloro-thiophen-2-ylmethyl)-3-m-tolyl-1,4,6,7-tetrahydro 20 pyrazolo[4,3-c]pyridin-5-yl]-ethanone; 1-[1-(5-Chloro-thiophen-2-ylmethyl)-3-(3 trifluoromethyl-phenyl)-1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone; 3-[5-Acetyl-1 -(5-chloro-thiophen-2-ylmethyl)-4,5,6,7-tetrahydro-1 H-pyrazolo[4,3 c]pyridin-3-yl]-benzonitrile; 1-[3-(3-Chloro-phenyl)-1-(5-chloro-thiophen-2-ylmethyl) 1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone; 1-[3-(5-Chloro-thiophen-2 25 yl)-1 -(2,4-difluoro-benzyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone; 1-[1 -(2,4-Difluoro-benzyl)-3-thiophen-3-yl-1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin 5-yl]-ethanone; 4-[5-Acetyl-3-(3-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro pyrazolo[4,3-c]pyridin-1-ylmethyl]-benzonitrile; 3-{5-Acetyl-1-[1-(4-fluoro-phenyl) ethyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-benzonitrile; 1-[1 30 [Cyclopropyl-(4-fluoro-phenyl)-methyl]-3-(4-fluoro-phenyl)-1 4,6,7-tetrahydro pyrazolo[4,3-c]pyridin-5-yl]-ethanone; 1-[1-(2,4-Difluoro-benzyl)-3-(3 trifluoromethoxy-phenyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone; 1- WO 2013/037415 PCT/EP2011/066061 152 [1 -(2,6-Difluoro-benzyl)-3-(4-fluoro-phenyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin 5-yl]-ethanone; 1-{3-(4-Fluoro-phenyl)-1-[1-(4-fluoro-phenyl)-ethyl]-1,4,6,7 tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-ethanone; 1-[3-(4-Fluoro-phenyl)-1-(4 trifluoromethyl-benzyl)-1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone; 1-[1 5 (2,4-Difluoro-benzyl)-3-(3-methoxy-phenyl)-1 4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin 5-yl]-ethanone; 1-[3-(4-Fluoro-phenyl)-1-(3-trifluoromethyl-benzyl)-1,4,6,7 tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone; 1-[1-[1-(4-Fluoro-phenyl)-ethyl]-3 (3-trifluoromethoxy-phenyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone; 1-[1 -(2,4-Difluoro-benzyl)-3-(4-fluoro-3-methoxy-phenyl)-1 4,6,7-tetrahydro 10 pyrazolo[4,3-c]pyridin-5-yl]-ethanone; 3-[5-Acetyl-1-(2,5-difluoro-benzyl)-4,5,6,7 tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-benzonitrile; 1-[1-(2,4-Difluoro-benzyl)-3 m-tolyl-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone; 1-[1-(6-Chloro pyridin-3-ylmethyl)-3-(3-trifluoromethyl-phenyl)-1 ,4,6,7-tetrahydro-pyrazolo[4,3 c]pyridin-5-yl]-ethanone; 1-[3-(3-Chloro-phenyl)-1-(4-fluoro-2-methyl-benzyl)-1,4,6,7 15 tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone; 1-[1-(2-Fluoro-benzyl)-3-m-tolyl 1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone; 1-[1-(2-Methoxy-benzyl)-3 (3-trifluoromethyl-phenyl)-1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone; 1-[3-(3-Chloro-phenyl)-1 -(3-methoxy-benzyl)-1 4,6,7-tetrahydro-pyrazolo[4,3 c]pyridin-5-yl]-ethanone; 1-[1-(4-Chloro-3-fluoro-benzyl)-3-(4-fluoro-phenyl)-1,4,6,7 20 tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone; 1-[1-(2,4-Difluoro-benzyl)-3-(2 fluoro-5-methoxy-phenyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone; 5-[5-Acetyl-1 -(2,4-difluoro-benzyl)-4,5,6,7-tetrahydro-1 H-pyrazolo[4,3-c]pyridin-3-yl] 2-fluoro-benzonitrile; 1-[1-(2,4-Difluoro-benzyl)-3-(3-fluoro-phenyl)-1,4,6,7 tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone; 1-[1-(2,4-Difluoro-benzyl)-3-(4 25 trifluoromethyl-phenyl)-1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone; 1 -[1 -[(R)-1 -(4-Chloro-phenyl)-propyl]-3-(4-fluoro-phenyl)-1 4,6,7-tetrahydro pyrazolo[4,3-c]pyridin-5-yl]-ethanone; 1-[1-[(S)-1-(4-Chloro-phenyl)-propyl]-3-(4 fluoro-phenyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone; 1-[1-(2 F Iuoro-4-methyl-benzyl)-3-(3-trifluorom ethyl-phenyl)-1 4,6,7-tetrahydro-pyrazolo[4,3 30 c]pyridin-5-yl]-ethanone; 1 -[1 -(4-Chloro-pyridin-3-ylmethyl)-3-(3-trifluoromethyl phenyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone; 1-[1-(3-Methyl pyridin-2-ylmethyl)-3-(3-trifluoromethyl-phenyl)-1 ,4,6,7-tetrahydro-pyrazolo[4,3- WO 2013/037415 PCT/EP2011/066061 153 c]pyridin-5-yl]-ethanone; 1-[1-(2,4-Difluoro-benzyl)-3-(4-fluoro-phenyl)-1,4,6,7 tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone; 1-[1-(4-Fluoro-benzyl)-3-(6 trifluoromethyl-pyridin-2-yl)-1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone; 1-[1 -(2,4-Difluoro-benzyl)-3-(4-trifluoromethyl-pyridin-2-yl)-1 4,6,7-tetrahydro 5 pyrazolo[4,3-c]pyridin-5-yl]-ethanone; 1 -[1 -(2 ,4-D ifluoro-benzyl)-3-(6-trifluorom ethyl pyridin-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone; 1-[3-(4-Bromo pyridin-2-yl)-1-(2,4-difluoro-benzyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl] ethanone; 1-[3-(2-Bromo-pyridin-4-yl)-1-(2,4-difluoro-benzyl)-1,4,6,7-tetrahydro pyrazolo[4,3-c]pyridin-5-yl]-ethanone; 1-[3-(5-Bromo-pyridin-3-yl)-1-(2,4-difluoro 10 benzyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone; 3-[11 -Acetyl-5-(2,4 difluoro-benzyl)-4,5, 11 -triaza-tricyclo[6.2.1.02,6]undeca-2(6),3-dien-3-yl] benzonitrile; 1-[5-(2,4-Difluoro-benzyl)-3-(4-fluoro-phenyl)-4,5,11-triaza tricyclo[6.2.1.02,6]undeca-2(6),3-dien-11-yl]-ethanone; 1-[1-(6-Chloro-pyridin-3 ylmethyl)-3-m-tolyl-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone; 1-[1-(4 15 Methoxy-pyridin-2-ylmethyl)-3-(3-trifluoromethyl-phenyl)-1 4,6,7-tetrahydro pyrazolo[4,3-c]pyridin-5-yl]-ethanone; 1-[1-(4-Chloro-pyridin-3-ylmethyl)-3-m-tolyl 1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone; 1-[1-(3-Methoxy-pyridin-2 ylmethyl)-3-(3-trifluoromethyl-phenyl)-1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl] ethanone; 1 -[3-(3-Chloro-phenyl)-1 -(3-methyl-pyridin-2-ylmethyl)-1,4,6,7-tetrahydro 20 pyrazolo[4,3-c]pyridin-5-yl]-ethanone; 1-[1-[1-(4-Fluoro-phenyl)-ethyl]-3-(6 trifluoromethyl-pyridin-2-yl)-1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone; 1-[1 -(2,4-Difluoro-benzyl)-3-(6-methyl-pyridin-2-yl)-1 ,4,6,7-tetrahydro-pyrazolo[4,3 c]pyridin-5-yl]-ethanone; 1-[3-(6-Bromo-pyridin-2-yl)-1-(2,4-difluoro-benzyl)-1,4,6,7 tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone; 1-[1-(2,4-Difluoro-benzyl)-3-(4 25 methyl-pyridin-2-yl)-1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone; 1-[1 (2,4-Difluoro-benzyl)-3-(6-methoxy-pyridin-2-yl)-1 4,6,7-tetrahydro-pyrazolo[4,3 c]pyridin-5-yl]-ethanone; 1-[3-(6-Chloro-5-methoxy-pyridin-2-yl)-1-(2,4-difluoro benzyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone; 3-[1-(2,4-Difluoro benzyl)-5-(3-methyl-oxetane-3-carbonyl)-4, 5,6, 7-tetrahydro-1 H-pyrazolo[4,3 30 c]pyridin-3-yl]-benzonitrile; 3-[1-(2,4-Difluoro-benzyl)-5-isobutyryl-4,5,6,7-tetrahydro 1 H-pyrazolo[4,3-c]pyridin-3-yl]-benzonitrile; 3-[5-Cyclopropanecarbonyl-1 -(2,4 difluoro-benzyl)-4,5,6,7-tetrahydro-1 H-pyrazolo[4,3-c]pyridin-3-yl]-benzonitrile; 3-[5- WO 2013/037415 PCT/EP2011/066061 154 (2-tert-Butoxy-acetyl)-1 -(2,4-d ifluoro-benzyl)-4,5,6,7-tetrahydro-1 H-pyrazolo[4,3 c]pyridin-3-yl]-benzonitrile; 3-[1-(2,4-Difluoro-benzyl)-5-(3-methanesulfonyl-benzoyl) 4,5,6,7-tetrahydro-1 H-pyrazolo[4,3-c]pyridin-3-yl]-benzonitrile; [1 -Benzyl-3-(4-fluoro phenyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-(4-fluoro-phenyl)-methanone; 5 [1 -Benzyl-3-(4-fluoro-phenyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-(4 methoxy-phenyl)-methanone; [1 -Benzyl-3-(4-fluoro-phenyl)-1 4,6,7-tetrahydro pyrazolo[4,3-c]pyridin-5-yl]-phenyl-methanone; 3-[5-Cyclobutanecarbonyl-1-(2,4 difluoro-benzyl)-4,5,6,7-tetrahydro-1 H-pyrazolo[4,3-c]pyridin-3-yl]-benzonitrile; 3-[5 Cyclopentanecarbonyl-1 -(2,4-difluoro-benzyl)-4,5,6,7-tetrahydro-1 H-pyrazolo[4,3 10 c]pyridin-3-yl]-benzonitrile; 3-[1-(2,4-Difluoro-benzyl)-5-(4-methanesulfonyl-benzoyl) 4,5,6,7-tetrahydro-1 H-pyrazolo[4,3-c]pyridin-3-yl]-benzonitrile; 3-[1-(2,4-Difluoro benzyl)-5-(tetrahydro-pyran-4-carbonyl)-4,5,6,7-tetrahydro-1 H-pyrazolo[4,3 c]pyridin-3-yl]-benzonitrile; 3-[1-(2,4-Difluoro-benzyl)-5-(tetrahydro-furan-3 carbonyl)-4,5,6,7-tetrahydro-1 H-pyrazolo[4,3-c]pyridin-3-yl]-benzonitrile; 3-[1-(2,4 15 Difluoro-benzyl)-5-(2-methoxy-acetyl)-4,5,6,7-tetrahydro-1 H-pyrazolo[4,3-c]pyridin 3-yl]-benzonitrile; 3-[1-(2,4-Difluoro-benzyl)-5-(2,2-dimethyl-propionyl)-4,5,6,7 tetrahydro-1 H-pyrazolo[4,3-c]pyridin-3-yl]-benzonitrile; 3-[1-(2,4-Difluoro-benzyl)-5 propionyl-4,5,6,7-tetrahydro-1 H-pyrazolo[4,3-c]pyridin-3-yl]-benzonitrile; 3-[1-(2,4 Difluoro-benzyl)-5-((S)-2-hydroxy-propionyl)-4,5,6,7-tetrahydro-1 H-pyrazolo[4,3 20 c]pyridin-3-yl]-benzonitrile; 1-[1-Benzyl-3-(4-fluoro-phenyl)-1,4,6,7-tetrahydro pyrazolo[4,3-c]pyridin-5-yl]-2-phenyl-ethanone; 3-[5-Butyryl-1-(2,4-difluoro-benzyl) 4,5,6,7-tetrahydro-1 H-pyrazolo[4,3-c]pyridin-3-yl]-benzonitrile; 3-[1-(2,4-Difluoro benzyl)-5-(pyridine-2-carbonyl)-4,5,6,7-tetrahydro-1 H-pyrazolo[4,3-c]pyridin-3-yl] benzonitrile; compound with trifluoro-acetic acid; 3-[1-(2,4-Difluoro-benzyl)-5-(3 25 fluoro-pyridine-4-carbonyl)-4,5,6,7-tetrahydro-1 H-pyrazolo[4,3-c]pyridin-3-yl] benzonitrile; compound with trifluoro-acetic acid; 3-[1-(2,4-Difluoro-benzyl)-5 (pyrimidine-4-carbonyl)-4,5,6,7-tetrahydro-1 H-pyrazolo[4,3-c]pyridin-3-yl] benzonitrile; 3-[1-(2,4-Difluoro-benzyl)-5-(3-methyl-3H-imidazole-4-carbonyl) 4,5,6,7-tetrahydro-1 H-pyrazolo[4,3-c]pyridin-3-yl]-benzonitrile; 3-[1-(2,4-Difluoro 30 benzyl)-5-(1 -methyl-1 H-pyrazole-3-carbonyl)-4,5,6,7-tetrahydro-1 H-pyrazolo[4,3 c]pyridin-3-yl]-benzonitrile; 3-(3-Cyano-phenyl)-1 -(2,4-difluoro-benzyl)-1 4,6,7 tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid ethyl ester; 1-[1 -(2,4-Difluoro- WO 2013/037415 PCT/EP2011/066061 155 benzyl)-3-(4-fluoro-phenyl)-6-methyl-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl] ethanone; 3-(4-Fluoro-phenyl)-1-[(R)-1-(4-fluoro-phenyl)-ethyl]-5-methanesulfonyl 4,5,6,7-tetrahydro-1 H-pyrazolo[4,3-c]pyridine; 3-(4-Fluoro-phenyl)-1-[(S)-1-(4-fluoro phenyl)-ethyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-1 H-pyrazolo[4,3-c]pyridine; their 5 stereoisomeric and/or their pharmaceutically acceptable salts thereof.
    [16] 16. A medicament comprising a compound of formula I and/or its pharmaceutically acceptable salt according to any one of claims 1 to 15. 10
    [17] 17. A compound of formula I or of a compound according to any one of claims 1 to 15 and/or their pharmaceutically acceptable salts for the treatment or prevention of diseases of TASK-1 channel-mediated diseases R2 X R3 N R1 R4 A 15 wherein A = (C 6 -C1o)-aryl or a five- or six-membered heteroaryl, comprising 1-3 heteroatoms selected from the group N, 0 and S, 20 wherein aryl and heteroaryl are optionally substituted with 1-3 rests selected independently from F, Cl, Br, CN, (C1-C 6 )-alkyl-, (C1-C 6 )-alkyl-0 and (C1-C 6 )-alkyl-S-, wherein one or more hydrogen atoms of the alkyl moieties may be replaced by fluorine; 25 X = (C 6 -C 1 o)-aryl or a five- or six-membered heteroaryl, comprising 1-3 heteroatoms selected from the group N, 0 and S, WO 2013/037415 PCT/EP2011/066061 156 wherein aryl and heteroaryl are optionally substituted with 1-3 rests selected independently from F, Cl, Br, CN, (C1-C 6 )-alkyl-, (C1-C 6 )-alkyl-0 and (C1-C 6 )-alkyl-S-, (C1-C 6 )-alkyl-O-C(O)- and (C 1 -C 6 )-alkyl-SO 2 -, wherein one or more hydrogen atoms of the alkyl moieties may be 5 replaced by fluorine; R1 = R5-C(=O)- or (C 1 -C 6 )-alkyl-SO 2 -; R2 = H, (C 1 -C 6 )-alkyl-, (C 3 -C 6 )-cycloalkyl-; 10 R3 = H, (C1-C 4 )-alkyl-; R4 = H, (C1-C 4 )-alkyl-; 15 or R3, R4 together form a (C 2 -C 3 )-alkylene bridge; R5 = (C1-C 6 )-alkyl-, (C 3 -C 6 )-cycloalkyl-, (C1-C 6 )-alkyl-O-, (C1-C 6 )-alkyl-S-, (C1-C6) alkyl-O-(C1-C 6 )-alkyl-, HO-(C1-C 6 )-alkyl-, (C 3 -C 6 )-cycloalkyl-(C 1 -C 6 )-alkyl-, (C 6 -C 1 o)-aryl-, (C 6 -C 1 o)-aryl-(C 1 -C 6 )-alkyl-, R7R6N-, heteroaryl, heteroaryl 20 (C1-C 6 )-alkyl-, aliphatic heterocycle, wherein the aliphatic heterocycle is selected from the group of morpholinyl, piperidinyl, pyrrolidinyl and 4 to 7 membered aliphatic heterocycles comprising an oxygen atom, and wherein the aliphatic heterocycle may be optionally substituted with 1 25 to 3 substituents selected from the group of F, OH, (C1-C 6 )-alkyl-0- and (C1 C 6 )-alkyl-, and wherein the heteroaryl residues are five- or six-membered ring systems, comprising 1-3 heteroatoms selected from the group N, 0 and S, and 30 wherein aryl and heteroaryl are optionally substituted with 1-3 rests selected independently from F, Cl, Br, CF 3 , (C 1 -C 6 )-alkyl-, (C 1 -C 6 )-alkyl-O-, CN, (C 1 -C 2 )-alkyl-SO 2 -, and WO 2013/037415 PCT/EP2011/066061 157 wherein one or more hydrogen atoms of the alkyl moieties may be replaced by fluorine; R6 = H, (C1-C 6 )-alkyl-, (C 3 -C 6 )-cycloalkyl-, 5 wherein one hydrogen atom of the alkyl group may be replaced by an OH- or (C1-C 6 )-alkyl-0- residue, and wherein one or more hydrogen atoms of the alkyl group may be replaced by fluorine; 10 R7 = H, (C1-C 6 )-alkyl-; wherein one or more hydrogen atoms of the alkyl group may be replaced by fluorine.
    [18] 18. A compound of formula I and/or a pharmaceutically acceptable salt thereof 15 according to any one of claims 1 to 15, a medicament according to claim 16 or a compound according to claim 17 for the treatment or prevention of arrhythmias, particularly atrial trachyarrhythmias, atrial fibrillation and atrial flutter.
    [19] 19. A compound of formula I and/or a pharmaceutically acceptable salt thereof 20 according to any one of claims 1 to 15, a medicament according to claim 16 or a compound according to claim 17 for the treatment or prevention of sleep-related respiratory disorders, central and obstructive sleep apneas, upper airway resistance syndrome, Cheyne-Stokes respiration, snoring, disrupted central respiratory drive, sudden child death, postoperative hypoxia and apnea, muscle-related respiratory 25 disorders, respiratory disorders after long-term mechanical ventilation (weaning), respiratory disorders during adaptation in high mountains, acute and for respiratory disorders, chronic lung disorders with hypoxia and hypercapnia, chronic obstructive pulmonary disease (COPD) and obesity hypoventilation syndrome; or as a respiratory stimulant for the treatment or prevention of respiratory 30 depression associated with anesthesia or procedural sedations for small interventions or for diagnostic purposes, as a respiratory stimulant for the treatment or prevention of respiratory depression by opioids in chronic pain treatment WO 2013/037415 PCT/EP2011/066061 158 particularly in cancer or palliative care or procedural sedations and/or for weaning from longterm mechanical ventilation; or for the treatment or prevention of multiple sclerosis and inflammatory or degenerative disorders of the central nervous system. 5
    类似技术:
    公开号 | 公开日 | 专利标题
    US9598410B2|2017-03-21|Substituted 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-C]pyridines, their use as medicament, and pharmaceutical preparations comprising them
    US10105370B2|2018-10-23|1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof
    DE60132001T2|2008-12-04|PYRIDINE DERIVATIVES WITH IKB KINASE | HEMMENDER EFFECT
    KR20160135283A|2016-11-25|5-substituted indazole-3-carboxamides and preparation and use thereof
    CA2662728C|2015-03-31|Substituted bipyridine derivatives and their use
    WO2013037914A1|2013-03-21|Substituted 4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them
    AU2013214226A1|2014-08-21|Fused pyrroledicarboxamides and their use as pharmaceuticals
    MX2014002968A|2014-07-09|Indanyl-substituted 4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridine s, their use as medicament, and pharmaceutical preparations comprising them.
    DK2755972T3|2016-01-25|INDANYL SUBSTITUTED 4,5,6,7-TETRAHYDRO-1H-PYRAZOLE [4,3-C] PYRIDINES, THEIR USE AS MEDICINE AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE
    KR20170137130A|2017-12-12|Indole derivative
    MXPA06009974A|2007-04-20|2-pyridinyl[7-| pyrazolo[1,5-a]pyrimidin-3-yl]methanones
    同族专利:
    公开号 | 公开日
    SG11201400092VA|2014-07-30|
    HUE028378T2|2016-12-28|
    SI2755973T1|2016-02-29|
    CY1117396T1|2017-04-26|
    EP2755973A1|2014-07-23|
    IL231050A|2016-06-30|
    US20140330009A1|2014-11-06|
    US9598410B2|2017-03-21|
    US9127001B2|2015-09-08|
    US20160060259A1|2016-03-03|
    CN103930421B|2016-06-29|
    PT2755973E|2016-02-16|
    WO2013037415A1|2013-03-21|
    JP5957525B2|2016-07-27|
    KR20140077912A|2014-06-24|
    PL2755973T3|2016-04-29|
    JP2014526479A|2014-10-06|
    ES2559450T3|2016-02-12|
    DK2755973T3|2016-01-25|
    HK1194740A1|2014-10-24|
    HRP20160049T1|2016-02-12|
    AU2011376721B2|2017-06-08|
    IL231050D0|2014-03-31|
    CN103930421A|2014-07-16|
    CA2846366A1|2013-03-21|
    EP2755973B1|2015-11-04|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    DK27383A|1982-02-17|1983-08-18|Lepetit Spa|PROCEDURE FOR PREPARING PYRAZOLE PYRIDINES|
    DE10332685A1|2003-07-18|2005-02-17|Bayer Healthcare Ag|Use of a modulator of specific potassium channels, expressed preferentially in the atrium, for treatment and prevention of arrhythmia, coronary disease and hypertension|
    US7772232B2|2004-04-15|2010-08-10|Bristol-Myers Squibb Company|Quinazolinyl compounds as inhibitors of potassium channel function|
    DE102005028845A1|2005-06-22|2006-12-28|Sanofi-Aventis Deutschland Gmbh|New substituted pyrrolidin-2-ones, piperidin-2-ones and isothiazolidine-1,1-dioxides useful for treating e.g. dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, breast cancer and heart failure|
    DE102005028862A1|2005-06-22|2007-01-11|Sanofi-Aventis Deutschland Gmbh|Substituted heterocycles, their use as medicament and pharmaceutical compositions containing them|
    SG163543A1|2006-04-27|2010-08-30|Sanofi Aventis Deutschland|Inhibitors of the task-1 and task-3 ion channel|
    US20130178475A1|2010-03-17|2013-07-11|Ironwood Pharmaceuticals, Inc.|sGC STIMULATORS|
    US9127001B2|2011-09-16|2015-09-08|Sanofi|Substituted 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them|US9127001B2|2011-09-16|2015-09-08|Sanofi|Substituted 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them|
    US9016191B2|2012-04-20|2015-04-28|Robert S. Krolick|Portable baking oven|
    EP3134406A1|2014-04-24|2017-03-01|Dart NeuroscienceLtd|Substituted 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole and 4,5,6,7-tetrahydro-2h-pyrazolo [4,3-c]pyridine compounds as glyt1 inhibitors|
    US10040759B2|2014-11-05|2018-08-07|Dart NeuroscienceLtd.|Substituted azetidinyl compounds as GlyT1 inhibitors|
    WO2016109663A2|2014-12-30|2016-07-07|Novira Therapeutics, Inc.|Derivatives and methods of treating hepatitis b infections|
    US10414765B2|2015-12-10|2019-09-17|Bayer Pharma Aktiengesellschaft|Substituted perhydropyrrolo[3,4-c]pyrrole derivatives and the use of same|
    CN108290887A|2015-12-10|2018-07-17|拜耳制药股份公司|2- phenyl -3-imidazo [1,2-A] pyridine derivate as TASK-1 and TASK-2 channel blockers for treating relevant respiratory condition of sleeping|
    WO2018227427A1|2017-06-14|2018-12-20|Bayer Aktiengesellschaft|Substituted bridged diazepane derivatives and use thereof|
    CN110719911A|2017-06-14|2020-01-21|拜耳股份公司|Diazabicyclo-substituted imidazopyrimidines and their use for the treatment of respiratory disorders|
    US20200308582A1|2017-10-12|2020-10-01|Universität Heidelberg|Kcnk3-based gene therapy of cardiac arrhythmia|
    法律状态:
    2017-10-05| FGA| Letters patent sealed or granted (standard patent)|
    2019-04-11| MK14| Patent ceased section 143(a) (annual fees not paid) or expired|
    优先权:
    申请号 | 申请日 | 专利标题
    PCT/EP2011/066061|WO2013037415A1|2011-09-16|2011-09-16|Substituted 4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them|
    [返回顶部]